<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for prevention of weight gain in people with schizophrenia - Agarwal, SM - 2022 | Cochrane Library</title> <meta content="Pharmacological interventions for prevention of weight gain in people with schizophrenia - Agarwal, SM - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013337.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for prevention of weight gain in people with schizophrenia - Agarwal, SM - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013337.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013337.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for prevention of weight gain in people with schizophrenia" name="citation_title"/> <meta content="Sri Mahavir Agarwal&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Nicolette Stogios&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Zohra A Ahsan" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Jonathan T Lockwood" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Markus J Duncan" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Hiroyoshi Takeuchi" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Tony Cohn" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Valerie H Taylor" name="citation_author"/> <meta content="Women's College Hospital, University of Toronto" name="citation_author_institution"/> <meta content="Gary Remington" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="Guy E J Faulkner" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Margaret Hahn" name="citation_author"/> <meta content="Centre for Addiction and Mental Health, University of Toronto" name="citation_author_institution"/> <meta content="margaret.hahn@camh.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD013337.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/10/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013337.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013337.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013337.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antipsychotic Agents [adverse effects]; Betahistine [therapeutic use]; Famotidine [therapeutic use]; Fluoxetine [therapeutic use]; *Melatonin [therapeutic use]; *Metformin [therapeutic use]; Nausea [drug therapy]; Nizatidine [therapeutic use]; Ranitidine [therapeutic use]; Reboxetine [therapeutic use]; *Schizophrenia [drug therapy, prevention &amp; control]; Topiramate [therapeutic use]; Weight Gain" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013337.pub2&amp;doi=10.1002/14651858.CD013337.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="urvLIhM4";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013337\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013337\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","pt","ms","ja","hr","fa","fr","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013337.pub2",title:"Pharmacological interventions for prevention of weight gain in people with schizophrenia",firstPublishedDate:"Oct 3, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013337.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013337.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013337.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013337.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013337.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013337.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013337.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013337.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013337.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013337.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7731 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013337.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0272"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0099"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-sec-0255"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/supinfo/CD013337StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/supinfo/CD013337StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for prevention of weight gain in people with schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work."><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0004">Sri Mahavir Agarwal</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work."><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0005">Nicolette Stogios</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0006">Zohra A Ahsan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0007">Jonathan T Lockwood</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0008">Markus J Duncan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0009">Hiroyoshi Takeuchi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0010">Tony Cohn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0011">Valerie H Taylor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0012">Gary Remington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0013">Guy E J Faulkner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information#CD013337-cr-0014"><i class="icon corresponding-author fa fa-envelope"></i>Margaret Hahn</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information/en#CD013337-sec-0285">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 October 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013337.pub2">https://doi.org/10.1002/14651858.CD013337.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013337-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013337-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013337-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013337-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013337-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013337-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013337-abs-0006">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013337-abs-0001" lang="en"> <section id="CD013337-sec-0001"> <h3 class="title" id="CD013337-sec-0001">Background</h3> <p>Antipsychotic‐induced weight gain is an extremely common problem in people with schizophrenia and is associated with increased morbidity and mortality. Adjunctive pharmacological interventions may be necessary to help manage antipsychotic‐induced weight gain. This review splits and updates a previous Cochrane Review that focused on both pharmacological and behavioural approaches to this problem. </p> </section> <section id="CD013337-sec-0002"> <h3 class="title" id="CD013337-sec-0002">Objectives</h3> <p>To determine the effectiveness of pharmacological interventions for preventing antipsychotic‐induced weight gain in people with schizophrenia. </p> </section> <section id="CD013337-sec-0003"> <h3 class="title" id="CD013337-sec-0003">Search methods</h3> <p>The Cochrane Schizophrenia Information Specialist searched Cochrane Schizophrenia's Register of Trials on 10 February 2021. There are no language, date, document type, or publication status limitations for inclusion of records in the register. </p> </section> <section id="CD013337-sec-0004"> <h3 class="title" id="CD013337-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that examined any adjunctive pharmacological intervention for preventing weight gain in people with schizophrenia or schizophrenia‐like illnesses who use antipsychotic medications. </p> </section> <section id="CD013337-sec-0005"> <h3 class="title" id="CD013337-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently extracted data and assessed the quality of included studies. For continuous outcomes, we combined mean differences (MD) in endpoint and change data in the analysis. For dichotomous outcomes, we calculated risk ratios (RR). We assessed risk of bias for included studies and used GRADE to judge certainty of evidence and create summary of findings tables. The primary outcomes for this review were clinically important change in weight, clinically important change in body mass index (BMI), leaving the study early, compliance with treatment, and frequency of nausea. The included studies rarely reported these outcomes, so, post hoc, we added two new outcomes, average endpoint/change in weight and average endpoint/change in BMI. </p> </section> <section id="CD013337-sec-0006"> <h3 class="title" id="CD013337-sec-0006">Main results</h3> <p>Seventeen RCTs, with a total of 1388 participants, met the inclusion criteria for the review. Five studies investigated metformin, three topiramate, three H2 antagonists, three monoamine modulators, and one each investigated monoamine modulators plus betahistine, melatonin and samidorphan. The comparator in all studies was placebo or no treatment (i.e. standard care alone). We synthesised all studies in a quantitative meta‐analysis. Most studies inadequately reported their methods of allocation concealment and blinding of participants and personnel. The resulting risk of bias and often small sample sizes limited the overall certainty of the evidence. Only one reboxetine study reported the primary outcome, number of participants with clinically important change in weight. Fewer people in the treatment condition experienced weight gains of more than 5% and more than 7% of their bodyweight than those in the placebo group (&gt; 5% weight gain RR 0.27, 95% confidence interval (CI) 0.11 to 0.65; 1 study, 43 participants; &gt; 7% weight gain RR 0.24, 95% CI 0.07 to 0.83; 1 study, 43 participants; very low‐certainty evidence). No studies reported the primary outcomes, 'clinically important change in BMI', or 'compliance with treatment'. However, several studies reported 'average endpoint/change in body weight' or 'average endpoint/change in BMI'. </p> <p>Metformin may be effective in preventing weight gain (MD −4.03 kg, 95% CI −5.78 to −2.28; 4 studies, 131 participants; low‐certainty evidence); and BMI increase (MD −1.63 kg/m2, 95% CI −2.96 to −0.29; 5 studies, 227 participants; low‐certainty evidence). Other agents that may be slightly effective in preventing weight gain include H2 antagonists such as nizatidine, famotidine and ranitidine (MD −1.32 kg, 95% CI −2.09 to −0.56; 3 studies, 248 participants; low‐certainty evidence) and monoamine modulators such as reboxetine and fluoxetine (weight: MD −1.89 kg, 95% CI −3.31 to −0.47; 3 studies, 103 participants; low‐certainty evidence; BMI: MD −0.66 kg/m2, 95% CI −1.05 to −0.26; 3 studies, 103 participants; low‐certainty evidence). Topiramate did not appear effective in preventing weight gain (MD −4.82 kg, 95% CI −9.99 to 0.35; 3 studies, 168 participants; very low‐certainty evidence<i>)</i>. For all agents, there was no difference between groups in terms of individuals leaving the study or reports of nausea. However, the results of these outcomes are uncertain given the very low‐certainty evidence. </p> </section> <section id="CD013337-sec-0007"> <h3 class="title" id="CD013337-sec-0007">Authors' conclusions</h3> <p>There is low‐certainty evidence to suggest that metformin may be effective in preventing weight gain. Interpretation of this result and those for other agents, is limited by the small number of studies, small sample size, and short study duration. In future, we need studies that are adequately powered and with longer treatment durations to further evaluate the efficacy and safety of interventions for managing weight gain. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013337-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013337-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013337-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013337-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013337-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013337-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013337-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013337-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013337-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013337-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD013337-abs-0015">Română</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013337-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013337-abs-0002" lang="en"> <h3>How effective are medications given alongside antipsychotics at preventing weight gain in people with schizophrenia? </h3> <p><b>Key messages</b> </p> <p>‐ Metformin may be effective in preventing weight gain caused by antipsychotics.</p> <p>‐ H2 antagonists and monoamine modulators may be slightly effective in preventing weight gain caused by antipsychotics. </p> <p>‐ Future studies should include more people and evaluate them for longer.</p> <p><b>What are antipsychotics?</b> </p> <p>Antipsychotics are medications used to treat symptoms of psychosis, such as hallucinations, delusions and agitation. They are often used to treat people with schizophrenia. Examples of antipsychotics are haloperidol (Haldol), chlorpromazine (Thorazine), olanzapine (Zyprexa) and risperidone (Risperdal). </p> <p><b>Schizophrenia and weight gain</b> </p> <p>People with schizophrenia are twice as likely as the general population to be overweight, perhaps due to a poor diet and an inactive lifestyle. Excess weight can lead to other health conditions, such as heart disease, stroke and diabetes. </p> <p>Unfortunately, an unwanted effect of antipsychotics is weight gain. Sometimes, people with schizophrenia are given medications alongside antipsychotics (‘add‐on’ medications) to prevent this additional weight gain. These add‐on medications may stop people feeling hungry or help them feel full. Usually, they are medications developed for other purposes, such as metformin, which is a medicine to treat diabetes, and fluoxetine, which is an antidepressant. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out whether add‐on medications to prevent weight gain caused by antipsychotics were effective in people with schizophrenia. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that examined any medicine given alongside antipsychotics to prevent weight gain in people with schizophrenia. Study participants could be any age or sex but had to have a diagnosis of schizophrenia or a schizophrenia‐like illness. They had to be chosen at random to receive either the weight‐prevention medicine, or a placebo (a dummy medicine) or no add‐on medicine (standard treatment). </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 17 studies with 1388 people that examined the effects of add‐on medications to prevent weight gain caused by antipsychotics. The add‐on medications were metformin, topiramate, H2 antagonists, monoamine modulators, monoamine modulators plus betahistine, melatonin, and samidorphan. Studies were short, lasting between 6 and 24 weeks. And they were small, with only 63 people on average ‐ the smallest included only 14 people, the largest 561 people. </p> <p>Studies done to date suggest that:</p> <p>‐ metformin may be effective in preventing weight gain and is well‐tolerated compared to standard treatment (5 studies, 232 participants); </p> <p>‐ H2 antagonists, such as nizatidine, famotidine and ranitidine, or monoamine modulators, such as reboxetine and fluoxetine may be potentially effective in preventing weight gain caused by antipsychotics; </p> <p>‐ topiramate is probably not effective in preventing weight gain caused by antipsychotics.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is limited because we found only a small number of studies for each add‐on medication. Studies included few people, and lasted only a short time. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to February 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013337-sec-0272" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013337-sec-0272"></div> <h3 class="title" id="CD013337-sec-0273">Implications for practice</h3> <section id="CD013337-sec-0273"> <section id="CD013337-sec-0274"> <h5 class="title">For people with schizophrenia</h5> <p>An increase in weight during treatment with antipsychotics is a common problem experienced by individuals with schizophrenia. As a preventative strategy, starting metformin treatment along with an antipsychotic may lead to lesser weight gain and may not cause other adverse effects. Evidence about the use of most other adjunctive pharmacological agents is limited by the small number of studies utilising the agents, variability in the studies testing the same agent, and variability in the duration and intensity of the studies using the same interventional agent. Individuals with schizophrenia are advised to seek the support and advice of their clinical team for weight management and appraising the evidence in this review, and collaborate with their physician to decide a mutually acceptable approach to weight gain prevention. We urge individuals with schizophrenia to work with researchers and clinicians to help discover better evidence of the effects of various interventional agents than is currently available. This is very important as people with mental illness are systematically excluded from studies of efficacy of weight‐reducing agents in the general population. </p> </section> <section id="CD013337-sec-0275"> <h5 class="title">For clinicians</h5> <p>The evidence for weight prevention interventions is limited for most of the agents described in this review. Metformin is the only treatment with some evidence to suggest it may be a well‐tolerated and effective agent in preventing weight gain when started together with an antipsychotic. However, it is important to realise that the first strategy in preventing weight gain is to carefully appraise the metabolic risks associated with an antipsychotic agent, although treatment of the mental illness should be prioritised (<a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a>). Thereafter, the patients, their families and their care circles should be informed about the metabolic profiles of the prescribed antipsychotic agents and be given advice regarding maintaining a healthy lifestyle with adequate diet and exercise. In order to keep track of an individual's weight and metabolic profile, baseline and pre‐planned monitoring should be conducted as has been summarised in relevant guidelines. Treatment with weight loss or weight maintenance‐promoting agents, such as metformin, may be considered to prevent weight gain. Furthermore, as far as possible, treatment with an interventional agent should be in addition to lifestyle interventions and not as a substitute for them. </p> </section> <section id="CD013337-sec-0276"> <h5 class="title">For policy makers</h5> <p>The metabolic disturbance and weight gain that is experienced in people with schizophrenia is associated with reduced quality of life, as well as premature morbidity and mortality. In the long term, the impact of increased obesity rates will cause significant economic strain. Only modest reductions in weight gain have been observed with current strategies that aim to prevent weight gain in people with schizophrenia. As most evidence of pharmacological agents for preventing weight gain have been reported in short‐term studies, it is imperative that effectiveness of these interventions is demonstrated in longer‐term studies (longer than six months). At present, metformin emerges as the only agent that may cause few adverse effects and be effective in preventing weight gain when started with an antipsychotic. Important to note is that treatment with any pharmacological agent must always be accompanied by lifestyle interventions. As individuals with schizophrenia frequently contact their mental health service providers, it should be noted that frequent reinforcement may be essential for attaining long‐term adoption of physical activity on a regular basis, as well as dietary modification. Furthermore, professionals who are trained to be sensitive and supportive in regard to the mental health‐specific barriers to dietary modification and physical activity can address these issues in individuals more effectively (<a href="./references#CD013337-bbs2-0241" title="RichardsonCR , FaulknerG , McDevittJ , SkrinarGS , HutchinsonDS , PietteJD . Integrating physical activity into mental health services for persons with serious mental illness. Psychiatric services (Washington, D.C.)2005;56(3):324-31. [PMID: 15746508]">Richardson 2005</a>). The cost‐effectiveness of any of the pharmacological strategies has not been formally established. </p> </section> </section> <h3 class="title" id="CD013337-sec-0277">Implications for research</h3> <section id="CD013337-sec-0277"> <section id="CD013337-sec-0278"> <h5 class="title">General</h5> <p>Data reporting was not consistent among the studies included in this review. In order to improve the quality of comparisons, future studies should follow a standardised method of measuring and reporting outcomes (<a href="./references#CD013337-bbs2-0226" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet2001;357(9263):1191-4.">Moher 2001</a>). </p> </section> <section id="CD013337-sec-0279"> <h5 class="title">Specific</h5> <p>Larger randomised controlled trials of longer treatment durations are required to determine the true effects of these adjunctive pharmacological agents for prevention of weight gain in schizophrenia. The studies that we included in this review were completed over a short time period (up to six months), and therefore limit our ability to determine the long‐term effectiveness of these medications. Moreover, reporting would be more efficient if researchers included baseline and final outcomes, along with their mean differences and standard deviations. Binary outcomes such as the number of participants losing more than 7% of their initial body weight would also be helpful and easier to interpret. </p> <p>As noted in the 'Standard care' section (see <a href="#CD013337-sec-0021">Types of interventions</a>), these studies did not explicitly outline what other components were included in their interventions, beyond the prescribed medications. Behavioural lifestyle interventions should be used in all pharmacological studies and should be a part of all arms of the design. Structured scales should be used for the assessments of side effects and medication tolerability. Studies should aim to use intention‐to‐treat analysis and describe in detail the interventions and characteristic of participants who were randomised into the study as well as those lost to follow‐up along with their outcome. In order to reduce the risk of bias and improve the certainty of the evidence, study authors should clearly describe the generation and concealment of participant allocation. Most of our included studies did not use or describe adequate methods of allocation concealment. Furthermore, the lack of description or usage of adequate allocation techniques may influence the degree of interventional effects. </p> <p>In terms of outcome measures, future studies could add to their study results by including other measures of body mass, in addition to body weight and BMI. For instance, waist circumference may be the single best indicator for cardiovascular risk factors and a good alternative for identifying the need for weight management. </p> <p>For a suggested design, please see <a href="#CD013337-tbl-0005">Table 1</a>. </p> </section> </section> <div class="table" id="CD013337-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design for future studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomisation: random</p> <p>Allocation: concealed</p> <p>Blinding: double‐blind</p> <p>Duration: 12 months</p> <p>Setting: inpatients or outpatients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: patients with schizophrenia, or any schizophrenia‐like illness</p> <p>Gender: male and female</p> <p>Age: mean 30 years, range: 18‐65 (adult population)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological interventions for preventing weight gain including those currently licensed for weight loss, an off‐label therapy, withdrawn from the market, or an isolated nutritive supplement </p> <p>Samidorphan ‐ standalone + combination therapy with olanzapine</p> <p>Pharmacological adjunct plus behavioural intervention versus behavioural intervention alone </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically important change in weight (e.g. binary outcomes such as ≥ 7% weight loss)<br/>Clinically important change in BMI </p> <p>Waist‐to‐hip ratio</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Look at effects of factors such as stage of illness and ethnicity</p> <p>Dose effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>BMI:</b> body mass index </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013337-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013337-sec-0008"></div> <div class="table" id="CD013337-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in weight ranged from 5.88 to 6.87</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.03 kg lower<br/>(5.78 lower to 2.28 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight</b> </p> <p>Average endpoint/change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI ranged from 1.93 to 2.26</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.63 lower<br/>(2.96 lower to 0.29 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.25 to 4.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(14 to 239) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.38<br/>(0.28 to 19.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/>(16 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The total number of participants included in the review is less than the number of participants required for a single, adequately powered study. Also, the confidence interval is extremely wide.<br/><sup>b</sup>We deemed one of the included studies in this outcome to have high risk of bias.<br/><sup>c</sup>Heterogeneity of the results was quite high making interpretation uncertain. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013337-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> H2 antagonists<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with H2 antagonists</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in body weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in body weight ranged from 4.18 to 4.88</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.32 lower<br/>(2.09 lower to 0.56 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight</b>: clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI was 1.82</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.66 lower<br/>(0.99 lower to 0.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.72 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>189<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(247 to 539) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(0.34 to 3.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(23 to 245) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The risk of bias is uncertain for most studies included in this comparison.<br/><sup>b</sup>The total number of participants included in the review is less than the number of participants required for a single, adequately powered study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013337-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> monoamine modulators<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with monoamine modulators</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in body weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in body weight ranged from 4.91 to 5.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.89 lower<br/>(3.31 lower to 0.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in BMI (kg/m<sup>2</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI ranged from 0.86 to 1.12</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.66 lower<br/>(1.05 lower to 0.26 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.56 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>115<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000<br/>(149 to 435) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The total number of participants included in the review is less than the number of participants required for a single, adequately powered study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013337-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> topiramate<br/><b>Comparison:</b> placebo or no treatmentL </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topiramate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in weight was 4.02</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.82 lower<br/>(9.99 lower to 0.35 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in BMI (kg/m<sup>2</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI was 22.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.68 lower<br/>(4.10 lower to 1.26 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/>(0.85 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>132<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000<br/>(322 to 534) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/>(0.26 to 5.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(10 to 830) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The risk of bias is uncertain or high for most studies included in this comparison.<br/><sup>b</sup>The total number of participants included in the review is less than the number of participant required for a single, adequately powered study.<br/><sup>c</sup>The risk of bias is high for most studies included in this comparison. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013337-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013337-sec-0009"></div> <section id="CD013337-sec-0010"> <h3 class="title" id="CD013337-sec-0010">Description of the condition</h3> <section id="CD013337-sec-0011"> <h4 class="title">Schizophrenia and weight gain</h4> <p>Schizophrenia is a complex and severe neuropsychiatric disorder characterised by delusions, hallucinations, disorganised behaviour and progressive cognitive deficits (<a href="./references#CD013337-bbs2-0209" title='KeshavanMS , TandonR , BoutrosNN , NasrallahHA . Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophrenia Research2008;106(2-3):89-107.'>Keshavan 2008</a>; <a href="./references#CD013337-bbs2-0261" title="Van OsJ , KapurS . Schizophrenia. Lancet2009;374(9690):635-45.">Van Os 2009</a>). It is also a heterogeneous disorder with psychopathology varying across patients and over the course of the illness (<a href="./references#CD013337-bbs2-0247" title="SeatonBE , GoldsteinG , AllenDN . Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning. Neuropsychology Review2001;11(1):45-67.">Seaton 2001</a>). The onset is typically in late adolescence or early adulthood and is marked by episodes of psychosis and severe functional disability (<a href="./references#CD013337-bbs2-0222" title="LiversedgeS , GilchristI , EverlingS . The Oxford Handbook of Eye Movements. OUP Oxford, 2011.">Liversedge 2011</a>). The complexity, phenotypic heterogeneity, and polygenic nature of the genetic risk for schizophrenia make it a challenge to treat and investigate, and the etiopathogenesis (the cause and development of a disease or abnormal condition) of schizophrenia is yet to be fully understood (<a href="./references#CD013337-bbs2-0210" title='KeshavanMS , NasrallahHA , TandonR . Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophrenia Research2011;127(1-3):3-13.'>Keshavan 2011</a>). The severity of the disability and lack of knowledge into its aetiology makes it the most disabling among all psychiatric disorders requiring a disproportionate share of mental health services (<a href="./references#CD013337-bbs2-0228" title="MueserKT , McGurkSR . Schizophrenia. Lancet2004;363(9426):2063-72.">Mueser 2004</a>); it is the costliest among severe mental disorders in terms of human suffering and expenditure incurred by society (<a href="./references#CD013337-bbs2-0261" title="Van OsJ , KapurS . Schizophrenia. Lancet2009;374(9690):635-45.">Van Os 2009</a>). The disability and cost to society are compounded by the common presence of comorbid obesity in this population, a problem that has been exacerbated more recently with the increased use of second‐generation antipsychotics, many of which are associated with the risk of weight gain and metabolic disturbances such as diabetes and metabolic syndrome (<a href="./references#CD013337-bbs2-0146" title="AllisonDB , MentoreJL , HeoM , ChandlerLP , CappelleriJC , InfanteMC , et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry1999;156(11):1686-9.">Allison 1999</a>; <a href="./references#CD013337-bbs2-0164" title="CaseyDE , HauptDW , NewcomerJW , HendersonDC , SernyakMJ , DavidsonM , et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry2004;65 Suppl 7:4-18.">Casey 2004</a>; <a href="./references#CD013337-bbs2-0176" title="De HertM , DetrauxJ , Van WinkelR , YuW , CorrellCU . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology2011;8(2):114-26.">De Hert 2011</a>; <a href="./references#CD013337-bbs2-0203" title="HomelP , CaseyD , AllisonDB . Changes in body mass index for individuals with and without schizophrenia. Schizophrenia Research2002;55:277-84.">Homel 2002</a>; <a href="./references#CD013337-bbs2-0235" title="RajkumarAP , HorsdalHT , WimberleyT , CohenD , MorsO , BorglumAD , et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. American Journal of Psychiatry2017;174(7):686-94. [PMID: 28103712]">Rajkumar 2017</a>). </p> <p>The World Health Organization (WHO) defines overweight and obesity as an "abnormal or excessive fat accumulation that may impair health". A person who has a body mass index (BMI) of more than 25 is overweight and those with a BMI of more than 30 are obese (<a href="./references#CD013337-bbs2-0267" title="World Health Organization. Obesity and overweight fact sheet. www.who.int/mediacentre/factsheets/fs311/en/ accessed before 22 July 2022.">WHO 2013</a>). The prevalence of obesity in people with schizophrenia has been reported to be anywhere from 1.5 times to 4 times higher than the general population (<a href="./references#CD013337-bbs2-0143" title="American Diabetes Association, the American Psychological Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care2004;27(2):596-601.">ADA/APA 2004</a>; <a href="./references#CD013337-bbs2-0167" title="CoodinS . Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry2001;46:549-55.">Coodin 2001</a>; <a href="./references#CD013337-bbs2-0195" title="GurpeguiM , Martínez-OrtegaJM , Gutiérrez-RojasL , RiveroJ , RojasC , JuradoD . Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Progress in Neuro-Psychopharmacology and Biological Psychiatry2012;37(1):169-75.">Gurpegui 2012</a>; <a href="./references#CD013337-bbs2-0254" title="SilverstoneT , SmithG , GoodallE . Prevalence of obesity in patients receiving depot antipsychotics. British Journal of Psychiatry1988;153:214-7.">Silverstone 1988</a>); the risk may be even higher for long‐term inpatients (<a href="./references#CD013337-bbs2-0242" title="RingenPA , FaerdenA , AntonsenB , FalkRS , MamenA , RognliEB , et al. Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments. Nordic Journal of Psychiatry2018;72(4):296-302. [PMID: 29523041]">Ringen 2018</a>). For people with schizophrenia, there is a marked increase in standardised mortality ratios for both natural and unnatural causes of death, and much of this increment may be attributed to the increased prevalence of coronary heart disease risk (<a href="./references#CD013337-bbs2-0166" title="CohnT , Prud'hommeD , StreinerD , KamehH , RemingtonG . Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry2004;49:753-60.">Cohn 2004</a>; <a href="./references#CD013337-bbs2-0190" title="GoffDC , SullivanLM , McEvoyJP , MeyerJM , NasrallahNA , DaumitGL , et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research2005;80:45-53.">Goff 2005</a>; <a href="./references#CD013337-bbs2-0198" title="HendersonDC , NguyenDD , CopelandPM , HaydenDL , BorbaCP , LouiePM , et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Journal of Clinical Psychiatry2005;66:1116-21.">Henderson 2005b</a>; <a href="./references#CD013337-bbs2-0223" title="MackinP , WatkinsonHM , YoungAH . Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia2005;48:215-21.">Mackin 2005</a>; <a href="./references#CD013337-bbs2-0244" title="SaariKM , LindemanSM , ViiloKM , IsohanniMK , JarvelinMR , LaurenLH , et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study. Journal of Clinical Psychiatry2005;66:559-63.">Saari 2005</a>; <a href="./references#CD013337-bbs2-0266" title="WestmanJ , ErikssonSV , GisslerM , HallgrenJ , PrietoML , BoboWV , et al. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiology and Psychiatric Sciences October 2018;27(5):519-527. [PMID: 28580898]">Westman 2017</a>), and related obesity in this population (<a href="./references#CD013337-bbs2-0152" title="AnnamalaiA , KosirU , TekC . Prevalence of obesity and diabetes in patients with schizophrenia. World Journal of Diabetes2017;8(8):390-6. [PMID: 28861176]">Annamalai 2017</a>; <a href="./references#CD013337-bbs2-0167" title="CoodinS . Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry2001;46:549-55.">Coodin 2001</a>; <a href="./references#CD013337-bbs2-0172" title="DaumitGL , ClarkJM , SteinwachsDM , GrahamCM , LehmanA , FordDE . Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. Journal of Nervous and Mental Disease2003;191:799-805.">Daumit 2003</a>; <a href="./references#CD013337-bbs2-0259" title="SusceMT , VillanuevaN , DiazFJ , deLeonJ . Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Journal of Clinical Psychiatry2005;66:167-73.">Susce 2005</a>). Obesity doubles the risk of all‐cause mortality, coronary heart disease, stroke and type 2 diabetes, increases the risk of some cancers, musculoskeletal problems and loss of function, and carries negative psychological consequences (<a href="./references#CD013337-bbs2-0181" title="Department of Health. At Least Five a Week. A report from the Chief Medical Officer. HMSO, London, 2004.">DoH 2004</a>). Being an obese or overweight adult is associated with increases in early mortality and large decreases in life expectancy, and these decreases are similar to those seen with smoking (<a href="./references#CD013337-bbs2-0233" title="PeetersA , BarendregtJJ , WillekensF , MackenbachJP , Al MamunA , BonneuxL , et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annual of Internal Medicine2003;138:24-32.">Peeters 2003</a>). The significance and recognition of this prevalence and its impact on premature mortality and morbidity has led to the development of consensus statements (<a href="./references#CD013337-bbs2-0143" title="American Diabetes Association, the American Psychological Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care2004;27(2):596-601.">ADA/APA 2004</a>; <a href="./references#CD013337-bbs2-0177" title="De NayerA , De HertM , ScheenA , Van GaalL , PeuskensJ . Belgian consensus on metabolic problems associated with atypical antipsychotics. International Journal of Psychiatry in Clinical Practice2005;9:130-7.">De Nayer 2005</a>), and guidelines (<a href="./references#CD013337-bbs2-0168" title="CooperSJ , ReynoldsGP , BarnesT , EnglandE , HaddadPM , HealdA , et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology (Oxford, England)2016;30(8):717-48. [PMID: 27147592]">Cooper 2016</a>), on its management. Despite this, evidence from a systematic review suggests that the all‐cause standardised mortality ratio between people with schizophrenia and the general population has risen steadily since the 1970s (<a href="./references#CD013337-bbs2-0245" title="SahaS , ChantD , McGrathJ . A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Archives of General Psychiatry2007;64:1123-31.">Saha 2007</a>). In stark contrast to the well‐recognised risk of metabolic comorbidity in schizophrenia, studies have repeatedly shown extremely low rates of intervention for these risk factors (<a href="./references#CD013337-bbs2-0176" title="De HertM , DetrauxJ , Van WinkelR , YuW , CorrellCU . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology2011;8(2):114-26.">De Hert 2011</a>; <a href="./references#CD013337-bbs2-0213" title="LappinJM , WijayaM , WatkinsA , MorellR , TeasdaleS , LedermanO , et al. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients. Schizophrenia Research2018;99:367-73. [PMID: 29486959]">Lappin 2018</a>). Extremely low rates of intervention for what would be considered 'modifiable' cardiovascular risk factors are also apparent in young, first‐episode populations (<a href="./references#CD013337-bbs2-0170" title="CorrellCU , RobinsonDG , SchoolerNR , BrunetteMF , MueserKT , RosenheckRA , et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry2014;71(12):1350-63. [PMID: 25321337]">Correll 2014</a>). In turn, a concurrent body of literature suggests that metabolic risk is accrued early on in illness (<a href="./references#CD013337-bbs2-0048" title="De HertM , KalnickaD , Van WinkelR , WampersM , HanssensL , Van EyckD , et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2006;67(12):1889-96. ">De Hert 2006</a>; <a href="./references#CD013337-bbs2-0263" title="WardMC , WhiteDT , DrussBG . A meta-review of lifestyle interventions for cardiovascular risk factors in the general medical population: lessons for individuals with serious mental illness. Journal of Clinical Psychiatry2015;76(4):e477-86. [PMID: 25919840]">Ward 2015</a>), later shaving off 15 to 20 years of life due to cardiovascular disease (<a href="./references#CD013337-bbs2-0202" title="HoangU , StewartR , GoldacreMJ . Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ (Clinical Research Ed.)2011;343:d5422. [PMID: 21914766]">Hoang 2011</a>; <a href="./references#CD013337-bbs2-0229" title="NewcomerJW , HennekensCH . Severe mental illness and risk of cardiovascular disease. JAMA2007;298(15):1794-6. [PMID: 17940236]">Newcomer 2007</a>). </p> <p>Beyond effects on cardiovascular morbidity and mortality, growing evidence in non‐psychiatric populations also suggests that obesity can be associated with structural brain changes, brain perfusion changes and cognitive deficits (<a href="./references#CD013337-bbs2-0206" title="JagustW . What can imaging reveal about obesity and the brain?Current Alzheimer Research2007;4(2):135-9.">Jagust 2007</a>; <a href="./references#CD013337-bbs2-0248" title="SellbomKS , GunstadJ . Cognitive function and decline in obesity. Journal of Alzheimer's Disease2012;30 Suppl 2:S89-95.">Sellbom 2012</a>), with observations supporting some similarities to those noted in schizophrenia (<a href="./references#CD013337-bbs2-0237" title="ReichenbergA , HarveyPD . Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychological Bulletin2007;133(5):833-58.">Reichenberg 2007</a>). The clinical implications of being overweight or obese on cognitive function in addition to the deficits observed in schizophrenia, remains a relatively unexplored area of research. Emerging evidence has linked cognitive impairment in schizophrenia to metabolic dysfunction (<a href="./references#CD013337-bbs2-0161" title="BoraE , AkdedeBB , AlptekinK . The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychological Medicine2017;47(6):1030-40. [PMID: 28032535]">Bora 2017</a>; <a href="./references#CD013337-bbs2-0187" title="FriedmanJI , WallensteinS , MoshierE , ParrellaM , WhiteL , BowlerS , et al. The effects of hypertension and body mass index on cognition in schizophrenia. American Journal of Psychiatry2010;167(19):1232-9.">Friedman 2010</a>; <a href="./references#CD013337-bbs2-0220" title="LindenmayerJP , KhanA , KaushikS , ThanjuA , PraveenR , HoffmanL , et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophrenia Research2012;142(1-3):171-6.">Lindenmayer 2012</a>), which might suggest that interventions to reduce obesity and cardio‐metabolic risk could have dual health benefits on cardiovascular outcomes and illness‐related functional disability. Quality of life is further reduced for people with schizophrenia with a high BMI (<a href="./references#CD013337-bbs2-0163" title="Bueno-AntequeraJ , Oviedo-CaroMA , Munguia-IzquierdoD . Relationship between objectively measured sedentary behavior and health outcomes in schizophrenia patients: the PsychiActive Project. Schizophrenia Research2018;197:87-92. [PMID: 29174336]">Bueno‐Antequera 2018</a>; <a href="./references#CD013337-bbs2-0185" title="FaulknerG , CohnT , RemingtonG , IrvingH . Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophrenia Research2007;90(1-3):174-8.">Faulkner 2007a</a>; <a href="./references#CD013337-bbs2-0212" title="KurzthalerI , FleischhackerWW . The clinical implications of weight gain in schizophrenia. Journal of Clinical Psychiatry2001;62 Suppl 7:32-7.">Kurzthaler 2001</a>; <a href="./references#CD013337-bbs2-0258" title="StrassnigM , BrarJS , GanguliR . Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophrenia Bulletin2003;29:393-7.">Strassnig 2003</a>), and those gaining weight (<a href="./references#CD013337-bbs2-0147" title="AllisonDB , MackellJA , McDonnellDD . The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services2003;54:565-7.">Allison 2003</a>). Furthermore, Weiden and colleagues reported a significant, positive association between obesity, subjective distress from weight gain and medication non‐compliance in a sample of people with schizophrenia (<a href="./references#CD013337-bbs2-0265" title="WeidenPJ , MackellJA , McDonnellDD . Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research2004;66:51-7.">Weiden 2004</a>). Many people with schizophrenia face the combined challenges of living with the illness, obesity and related illnesses. This combination is a major public health problem (<a href="./references#CD013337-bbs2-0163" title="Bueno-AntequeraJ , Oviedo-CaroMA , Munguia-IzquierdoD . Relationship between objectively measured sedentary behavior and health outcomes in schizophrenia patients: the PsychiActive Project. Schizophrenia Research2018;197:87-92. [PMID: 29174336]">Bueno‐Antequera 2018</a>; <a href="./references#CD013337-bbs2-0269" title="WirshingDA . Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry2004;65 Suppl 18:13-26.">Wirshing 2004</a>), and carries considerable cost to human life. Recognition of this has led to growing concern with how best to intervene (<a href="./references#CD013337-bbs2-0158" title="BirtJ . Management of weight gain associated with antipsychotics. Annals of Clinical Psychiatry2003;15:49-58.">Birt 2003</a>; <a href="./references#CD013337-bbs2-0163" title="Bueno-AntequeraJ , Oviedo-CaroMA , Munguia-IzquierdoD . Relationship between objectively measured sedentary behavior and health outcomes in schizophrenia patients: the PsychiActive Project. Schizophrenia Research2018;197:87-92. [PMID: 29174336]">Bueno‐Antequera 2018</a>; <a href="./references#CD013337-bbs2-0165" title="CatapanaL , CastleD . Obesity in schizophrenia: what can be done about it?Australasian Psychiatry2004;12:23-5.">Catapana 2004</a>; <a href="./references#CD013337-bbs2-0168" title="CooperSJ , ReynoldsGP , BarnesT , EnglandE , HaddadPM , HealdA , et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology (Oxford, England)2016;30(8):717-48. [PMID: 27147592]">Cooper 2016</a>; <a href="./references#CD013337-bbs2-0193" title="GreenA , PatelJ , GoismanR . Weight gain from novel antipsychotic drugs: need for action. General Hospital Psychiatry2000;22:224-35.">Green 2000</a>; <a href="./references#CD013337-bbs2-0215" title="Le FevrePD . Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism?Scottish Medical Journal2001;46:11-31.">Le Fevre 2001</a>; <a href="./references#CD013337-bbs2-0231" title="OsbornDP . The poor physical health of people with mental illness. Western Journal of Medicine2001;175:329-32.">Osborn 2001</a>). </p> </section> <section id="CD013337-sec-0012"> <h4 class="title">Mechanisms of weight gain in schizophrenia</h4> <p>To date, there is no consensus on what pharmacological factors may be involved in this weight gain, particularly regarding the newer antipsychotics. As reviewed elsewhere (<a href="./references#CD013337-bbs2-0150" title="AnanthJ , VenkateshR , BurgoyneK , GadasalliR , BinfordR , GunatilakeS . Atypical antipsychotic induced weight gain: pathophysiology and management. Annals of Clinical Psychiatry2004;16:75-85.">Ananth 2004</a>; <a href="./references#CD013337-bbs2-0207" title="JinH , MeyerJM , MudaliarS , JesteDV . Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophrenia Research2008;100(1-3):70-85.">Jin 2008</a>; <a href="./references#CD013337-bbs2-0239" title="ReynoldsGP , KirkSL . Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacology &amp; Therapeutics2010;125(1):169-79.">Reynolds 2010</a>; <a href="./references#CD013337-bbs2-0240" title="ReynoldsGP , McGowanOO . Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology (Oxford, England)2017;31(11):1430-6. [PMID: 28892404]">Reynolds 2017</a>), a range of potential weight gain‐inducing mechanisms such as dopaminergic blockage, increased appetite due to the interaction of antipsychotic medication with dopamine, serotonin, and histamine neuronal receptors, increased leptin, and increased systemic levels of various cytokines and soluble cytokine receptors could be implicated. Whether gender influences antipsychotic‐related weight gain susceptibility remains a topic of debate; while there are clinical data suggesting that women may be more susceptible to atypical antipsychotic‐associated weight gain (<a href="./references#CD013337-bbs2-0144" title="AichhornW , MarksteinerJ , WalchT , ZernigG , HinterhuberH , StuppaeckC , et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. Journal of Child and Adolescent Psychopharmacology2007;17(5):665-74.">Aichhorn 2007</a>; <a href="./references#CD013337-bbs2-0189" title="GebhardtS , HaberhausenM , Heinzel-GutenbrunnerM , GebhardtN , RemschmidtH , KriegJC , et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. Journal of Psychiatric Research2009;43:620-6.">Gebhardt 2009</a>), others have failed to demonstrate this (<a href="./references#CD013337-bbs2-0157" title="BassonBR , KinonBJ , TaylorCC , SzymanskiKA , GilmoreJA , TollefsonGD . Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Journal of Clinical Psychiatry2001;62:231-8.">Basson 2001</a>; <a href="./references#CD013337-bbs2-0236" title="RatzoniG , GothelfD , Brand-GothelfA , ReidmanJ , KikinzonL , GalG , et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry2002;41:337-43.">Ratzoni 2002</a>). The weight gain story may be further complicated through genetic or epigenetic mechanisms, or both, which may modulate risk. In this regard, among others, dopamine, serotonin, and leptin gene polymorphisms have emerged as genetic candidates for antipsychotic‐related cardio‐metabolic side effects (<a href="./references#CD013337-bbs2-0169" title="CorrellCU , LenczT , MalhotraAK . Antipsychotic drugs and obesity. Trends in Molecular Medicine2011;17(2):97-107.">Correll 2011</a>). In addition, it is important to note that obesity was commonly reported before antipsychotics were widely introduced (<a href="./references#CD013337-bbs2-0155" title="BaptistaT , KinNM , BeaulieuS , deBaptistaEA . Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry2002;35:205-19.">Baptista 2002</a>). Compared to the general population, people with schizophrenia also have a poor diet (<a href="./references#CD013337-bbs2-0179" title="DipasqualeS , ParianteCM , DazzanP , AgugliaE , McGuireP , MondelliV . The dietary pattern of patients with schizophrenia: a systematic review. Journal of Psychiatric Research2013;47:197-207.">Dipasquale 2013</a>; <a href="./references#CD013337-bbs2-0225" title="McCreadieR , MacdonaldE , BlacklockC , Tilak-SinghD , WilesD , HallidayJ , et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ1998;317:784-5.">McCreadie 1998</a>; <a href="./references#CD013337-bbs2-0258" title="StrassnigM , BrarJS , GanguliR . Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophrenia Bulletin2003;29:393-7.">Strassnig 2003</a>), and a physically inactive lifestyle (<a href="./references#CD013337-bbs2-0162" title="BrownS , BirtwhistleJ , RoeL , ThompsonC . The unhealthy lifestyle of people with schizophrenia. Psychological Medicine1999;29:697-701.">Brown 1999</a>; <a href="./references#CD013337-bbs2-0166" title="CohnT , Prud'hommeD , StreinerD , KamehH , RemingtonG . Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry2004;49:753-60.">Cohn 2004</a>; <a href="./references#CD013337-bbs2-0173" title="DaumitGL , GoldbergRW , AnthonyC , DickersonF , BrownCH , KreyenbuhlJ , et al. Physical activity patterns in adults with severe mental illness. Journal of Nervous and Mental Disease2005;193:641-6.">Daumit 2005</a>; <a href="./references#CD013337-bbs2-0260" title="VancampfortD , FirthJ , SchuchFB , RosenbaumS , MugishaJ , HallgrenM , et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry2017;16(3):308-15. [PMID: 28941119]">Vancampfort 2017</a>), and these lifestyle factors will contribute to weight gain. However, pharmacological intervention strategies may still treat or minimise weight gain associated with poor lifestyle. </p> </section> </section> <section id="CD013337-sec-0013"> <h3 class="title" id="CD013337-sec-0013">Description of the intervention</h3> <p>Pharmacological agents that have been approved for weight loss in the general population, and other medications that may suppress appetite, increase satiety, or increase thermogenesis have been studied to prevent weight gain in people with schizophrenia. These include metformin, topiramate, H2 antagonists such as famotidine and nizatidine, and antidepressants such as fluoxetine and reboxetine. Most clinical trials have been between six and 12 weeks long. Very few have been for 24 weeks or longer. However, clear evidence regarding the optimal duration of such interventions is lacking (<a href="./references#CD013337-bbs2-0168" title="CooperSJ , ReynoldsGP , BarnesT , EnglandE , HaddadPM , HealdA , et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology (Oxford, England)2016;30(8):717-48. [PMID: 27147592]">Cooper 2016</a>). </p> <p>Metformin is a biguanide and is a first‐line anti‐diabetic agent. It is usually prescribed in a dose ranging from 500 mg to 2500 mg and is usually administered in divided doses twice a day. Topiramate is an anticonvulsant that has recently been approved by the Food and Drug Administration (FDA) in combination with phentermine for weight loss. The dose ranges from 100 mg to 200 mg given in divided doses twice a day. Famotidine (20 mg to 40 mg once a day) and nizatidine (150 mg to 300 mg once a day) are both commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease as they block the histamine H2 receptor. Fluoxetine (20 mg once a day) and reboxetine (4 mg once a day) are antidepressants that have also been investigated for their weight loss promoting properties. Reboxetine is a norepinephrine reuptake inhibitor approved as an antidepressant in parts of Europe. Loss of appetite is a side effect of this medication prompting investigation as a weight loss agent. More recently, samidorphan, an opioid modulator that preferentially antagonises the μ‐opioid receptor, is being used for the prevention of olanzapine‐induced weight gain (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>). It is taken orally with a usual dose of 10 mg/day. Common side effects include nausea, sedation and dizziness. </p> </section> <section id="CD013337-sec-0014"> <h3 class="title" id="CD013337-sec-0014">How the intervention might work</h3> <p>Pharmacological interventions may operate on a range of potential mechanisms such as suppressing appetite, increasing satiety, or increasing thermogenesis by modifying central nervous system neurotransmission of norepinephrine, dopamine and serotonin. </p> <p>Antidiabetic agents are a class of drugs investigated for weight management. Metformin lowers liver glucose production and improves whole‐body insulin sensitivity. It is associated with weight loss in non‐psychiatrically ill populations, and may prevent continual weight gain while improving insulin resistance (<a href="./references#CD013337-bbs2-0204" title="HundalRS , InzucchiSE . Metformin: new understandings, new uses. Drugs2003;63(18):1879-94. [PMID: 12930161]">Hundal 2003</a>). Hence, it is commonly understood as a peripheral insulin sensitiser. Topiramate is an anticonvulsant, and weight loss is a common side effect of the drug. Its weight‐management properties come from its ability to reduce appetite, affect taste sensation, and control leptin and cortisol levels via GABA‐mediated mechanisms in the central nervous system (<a href="./references#CD013337-bbs2-0262" title="VelazquezA , ApovianCM . Updates on obesity pharmacotherapy. Annals of the New York Academy of Sciences2018;1411(1):106-19. [PMID: 29377198]">Velazquez 2018</a>). </p> <p>Another class of drugs used for weight loss includes agents that work on the monoamine system, and particularly the serotonin and norepinephrine systems. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used as an antidepressant. Early studies have shown serotonin blockade to be an effective anorectic strategy (<a href="./references#CD013337-bbs2-0191" title="GoldsteinDJ , Rampey AH Jr, EnasGG , PotvinJH , FludzinskiLA , LevineLR . Fluoxetine: a randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders1994;18(3):129-35. [PMID: 8186809]">Goldstein 1994</a>). Therefore, fluoxetine has been studied for weight gain attenuation seen with antipsychotic use. Reboxetine is a norepinephrine reuptake inhibitor approved as an antidepressant in parts of Europe. Loss of appetite is a side effect of this medication prompting investigation as a weight loss agent. </p> <p>The histaminergic system has also been a candidate for managing weight loss. Used in treatment of gastroesophageal reflux disease (GERD), famotidine, nizatidine and ranitidine are H2 receptor antagonists that work to decrease acid production, and that have associated weight‐reducing properties. With respect to H2 receptor antagonists, it is unclear whether the weight loss action is a direct result of gastric histamine receptor antagonism or if other factors play a role. Histamine is known to mediate leptin action and is involved in energy and feeding regulation (<a href="./references#CD013337-bbs2-0217" title="LettTA , WallaceTJ , ChowdhuryNI , TiwariAK , KennedyJL , MullerDJ . Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Molecular Psychiatry2012;17(3):242-66. [PMID: 21894153]">Lett 2012</a>). H2 receptor antagonists can therefore plausibly interact with these medicators to effect weight loss. Betahistine is a histamine enhancer with H1 agonistic/H3 antagonistic properties that has been associated with weight‐reducing properties. </p> <p>A combination of olanzapine and samidorphan is now available in the USA for the treatment of schizophrenia or bipolar disorder in adults. This agent offers the therapeutic efficacy of olanzapine while also mitigating olanzapine‐induced weight gain through opioid receptor antagonism; it is presently the only FDA‐approved drug for this specific indication. A recent evidence‐based review of the pharmacokinetics, safety, and efficacy of olanzapine plus samidorphan indicates that the effectiveness of the agent is equivalent to that of olanzapine, along with the advantage of lesser weight gain. </p> <p>Melatonin is a molecule with diverse physiological functions, which through its receptors may improve components of the metabolic syndrome and reduce obesity. As such, it is being explored for the attenuation of antipsychotic‐induced weight gain. </p> <p>Preventing weight gain avoids all the negative outcomes associated with weight gain and may help engender a healthy lifestyle. Furthermore, sustained changes in health behaviours as a result of such interventions may reduce risk of mortality and morbidity independent of any weight loss (<a href="./references#CD013337-bbs2-0264" title="WeiM , KampertJB , BarlowCE , NichamanMZ , GibbonsLW , PaffenbargerRS , et al. Relationship between low cardiorespiratory fitness and mortality in normal weight, overweight and obese men. JAMA1999;282:1547-53.">Wei 1999</a>). Indeed, prevention of weight gain has been an area of active enquiry and both older interventions such as metformin (<a href="./references#CD013337-bbs2-0178" title="deSilvaVA , SuraweeraC , RatnatungaSS , DayabandaraM , WanniarachchiN , HanwellaR . Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry2016;16(1):341. [PMID: 27716110]">de Silva 2016</a>), and newer molecules such as samidorphan may be useful in achieving this goal (<a href="./references#CD013337-bbs2-0253" title="SilvermanBL , MartinW , MemisogluA , DiPetrilloL , CorrellCU , KaneJM . A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophrenia Research2018;195:245-51. [PMID: 29158012]">Silverman 2018</a>). </p> </section> <section id="CD013337-sec-0015"> <h3 class="title" id="CD013337-sec-0015">Why it is important to do this review</h3> <p>In the seminal meta‐analysis highlighting atypical antipsychotic‐related weight gain, every antipsychotic medication except ziprasidone and molindone were associated with some degree of weight increase after just 10 weeks of treatment (<a href="./references#CD013337-bbs2-0146" title="AllisonDB , MentoreJL , HeoM , ChandlerLP , CappelleriJC , InfanteMC , et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry1999;156(11):1686-9.">Allison 1999</a>). The effects were greatest with olanzapine and clozapine, which increased body weight by approximately 4 kg to 4.5 kg, followed by risperidone (mean weight gain 2 kg). Notably, these data were assembled from chronic populations characterised by many years of exposure to medications and illness‐related effects. What has become clearer is that factors related to illness chronicity likely result in an underestimation of the impact of antipsychotics on weight gain, and an overestimation of differences between agents. Collectively, data involving both short‐term and long‐term evidence comparing olanzapine or risperidone in chronic patients to those experiencing a first episode, demonstrate a three to four times larger magnitude of weight gain in those early on in the illness (<a href="./references#CD013337-bbs2-0149" title="Alvarez-JimenezM , Gonzalez-BlanchC , Crespo-FacorroB , HetrickS , Rodriguez-SanchezJM , Perez-IglesiasR , et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs2008;22(7):547-62.">Alvarez‐Jimenez 2008</a>). Furthermore, no antipsychotic medication appears to be devoid of weight gain risk in people with little prior antipsychotic exposure. For example, one 12‐week cohort study enrolling antipsychotic‐naive youth assigned to aripiprazole, quetiapine or olanzapine, demonstrated substantial weight gain not only with olanzapine (average 8.5 kg), but also with risperidone, quetiapine and aripiprazole (average 4.4 kg; <a href="./references#CD013337-bbs2-0041" title="CorrellCU , ManuP , OlshanskiyV , NapolitanoB , KaneJM , MalhotraAK . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA2009;302(16):1765-73. ">Correll 2009</a>). These findings have since been replicated, including in a recent meta‐analysis (<a href="./references#CD013337-bbs2-0154" title="BakM , FransenA , JanssenJ , Van OsJ , DrukkerM . Almost all antipsychotics result in weight gain: a meta-analysis. PLOS One2014;9(4):e94112. [PMID: 24763306]">Bak 2014</a>). Interestingly, data in previously medication‐unexposed individuals also suggests that agents classified as being metabolically neutral may exhibit a more delayed onset of weight gain, with treatments differing by pattern, and not always the final amount of weight increase (<a href="./references#CD013337-bbs2-0186" title="FindlingRL , JohnsonJL , McClellanJ , FrazierJA , VitielloB , HamerRM , et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. Journal of the American Academy of Child and Adolescent Psychiatry2010;49(6):583-94.">Findling 2010</a>; <a href="./references#CD013337-bbs2-0234" title="Perez-IglesiasR , Crespo-FacorroB , Martinez-GarciaO , Ramirez-BonillaML , Alvarez-JimenezM , Pelayo-TeranJM , et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Research2008;99(1-3):13-22.">Perez‐Iglesias 2008</a>; <a href="./references#CD013337-bbs2-0271" title="ZipurskyRB , GuH , GreenAI , PerkinsDO , TohenMF , McEvoyJP , et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. British Journal of Psychiatry2005;187:537-43.">Zipursky 2005</a>). Moreover, results from a nationwide, register‐based analysis suggest that all antipsychotics contribute to the risk of diabetes, independently of class (<a href="./references#CD013337-bbs2-0235" title="RajkumarAP , HorsdalHT , WimberleyT , CohenD , MorsO , BorglumAD , et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. American Journal of Psychiatry2017;174(7):686-94. [PMID: 28103712]">Rajkumar 2017</a>). Obesity is also one of the most important risk factors for the development of dyslipidaemia, diabetes and cardiovascular diseases, leading to premature death (<a href="./references#CD013337-bbs2-0145" title="AlbertiKG , EckelRH , GrundySM , ZimmetPZ , CleemanJI , DonatoKA , et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation2009;120(16):1640-5. [PMID: 19805654]">Alberti 2009</a>). Taken together, these emerging data highlight the susceptibility, particularly of first‐episode patients, to antipsychotic‐related weight gain. This highlights the case for implementing early effective strategies to prevent or decrease metabolic risk accrual, which may occur early in the treatment of the illness (<a href="./references#CD013337-bbs2-0263" title="WardMC , WhiteDT , DrussBG . A meta-review of lifestyle interventions for cardiovascular risk factors in the general medical population: lessons for individuals with serious mental illness. Journal of Clinical Psychiatry2015;76(4):e477-86. [PMID: 25919840]">Ward 2015</a>). </p> <p>A previous Cochrane Review, published in 2007, covered both pharmacological and non‐pharmacological strategies for preventing weight gain in people with schizophrenia (<a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a>). We believe there is a sufficient volume of material to split <a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a> into separate reviews focusing on pharmacological and behavioural interventions independently. Furthermore, given the vast number of pharmacological interventions tried for prevention and treatment of weight gain, we have chosen to split the review on pharmacological interventions to focus on prevention of weight gain and reduction of weight gain in two separate reviews. The current review focuses on pharmacological interventions for the prevention of weight gain. While previous reviews have systematically analysed the role of metformin in preventing weight gain (<a href="./references#CD013337-bbs2-0178" title="deSilvaVA , SuraweeraC , RatnatungaSS , DayabandaraM , WanniarachchiN , HanwellaR . Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry2016;16(1):341. [PMID: 27716110]">de Silva 2016</a>), no systematic review examining all available pharmacological interventions in a preventive role has been published. This is important, as what we consider effective treatments for adult obesity produce modest weight loss (approximately 2 kg to 5 kg) compared to no treatment or usual care. While this degree of weight loss may have a meaningful impact, it is not sufficient to reverse the weight increases associated with antipsychotic treatment (e.g. average 8.5 kg increase in antipsychotic‐naive patients starting olanzapine; <a href="./references#CD013337-bbs2-0041" title="CorrellCU , ManuP , OlshanskiyV , NapolitanoB , KaneJM , MalhotraAK . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA2009;302(16):1765-73. ">Correll 2009</a>). In this regard, prevention strategies may represent the most useful strategy. We are interested in identifying and including all randomised controlled trials (RCTs) of pharmacological agents to prevent antipsychotic‐induced weight gain in all people with schizophrenia or schizophrenia‐like illnesses. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013337-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013337-sec-0016"></div> <p>To determine the effectiveness of pharmacological interventions for preventing antipsychotic‐induced weight gain in people with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013337-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013337-sec-0017"></div> <section id="CD013337-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013337-sec-0019"> <h4 class="title">Types of studies</h4> <p>We considered all relevant RCTs that met our inclusion criteria and reported useable data. We considered both open‐label and double‐blind studies, in which randomisation was implied; studies at high risk of bias for these categories were removed in a sensitivity analysis (see <a href="#CD013337-sec-0091">Sensitivity analysis</a>). We excluded quasi‐randomised studies, such as those that allocated intervention by alternate days of the week. </p> </section> <section id="CD013337-sec-0020"> <h4 class="title">Types of participants</h4> <p>People diagnosed with schizophrenia or schizophrenia‐like illnesses (such as schizoaffective disorder, schizophreniform disorder, and delusional disorder) using any diagnostic criteria irrespective of age, nationality or sex of participants. We included studies regardless of the length of the participant's illness, stage of illness, treatment setting, current clinical state, or symptom cluster. Diagnostic tools to determine diagnosis included the Diagnostic and Statistical Manual of Mental Health Disorders, 4th edition (DSM IV; <a href="./references#CD013337-bbs2-0153" title="American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association, 2000.">APA 2000</a>), the International Statistical Classification of Diseases (ICD‐10; <a href="./references#CD013337-bbs2-0268" title="World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems 10th Revision. icd.who.int/browse10/2016/en accessed before 25 July 2022.">WHO 2016</a>), and the Chinese Classificaton of Mental Disorders (CCMD‐3; <a href="./references#CD013337-bbs2-0171" title="Chinese Society of Psychiatry (CSP). Chinese Classification of Mental Disorders. web.archive.org/web/20061205213538/http://www.21jk.com/english/index.asp.">CSP 2003</a>). </p> </section> <section id="CD013337-sec-0021"> <h4 class="title">Types of interventions</h4> <section id="CD013337-sec-0022"> <h5 class="title">Pharmacological interventions for preventing weight gain</h5> <p>For people with schizophrenia, 'weight prevention' interventions are typically 'adjunctive' (add‐on) interventions that are co‐initiated with other routinely prescribed medications such as antipsychotics before any antipsychotic‐induced weight gain is experienced. For instance, co‐prescription of metformin at olanzapine initiation would be an example of an adjunctive agent prescribed for the purposes of preventing olanzapine‐induced weight gain. </p> <p>We considered all types of adjunctive pharmacological interventions for preventing weight gain. These can include those currently licensed for weight loss, an off‐label therapy, withdrawn from the market, or an isolated nutritive supplement. During article screening, a non‐prevention study could be identified if the adjunctive pharmacological intervention was being initiated in individuals that had already experienced significant antipsychotic‐induced weight gain (i.e. the agent was being prescribed for the purposes of treating weight gain, not preventing weight gain). Prevention studies were identified as those in which the pharmacological agent was prescribed around the same time as antipsychotic initiation. </p> </section> <section id="CD013337-sec-0023"> <h5 class="title">Standard care</h5> <p>We defined this as the care that all participants received in the study, which typically includes regular visits with their psychiatrist and continuing antipsychotic medications.  </p> </section> <section id="CD013337-sec-0024"> <h5 class="title">Non‐standard care: other behavioural interventions</h5> <p>We considered an intervention where an additional pharmacological intervention was combined with a behavioural intervention (i.e. diet or exercise, or both). We only considered interventions that compare such a combined intervention strategy with a behavioural intervention alone in order to assess the additive effect of using a pharmacological adjunct. </p> <p>In accordance with the above definitions, the planned or expected comparisons were as follows. </p> <p> <ol id="CD013337-list-0001"> <li> <p>Drug 1 plus standard care (e.g. antipsychotics, diet advice) versus placebo or no pharmacological weight gain prevention treatment plus standard care </p> </li> <li> <p>Drug 1 plus standard care (e.g. antipsychotics, diet advice) versus drug 2 (active control) plus standard care </p> </li> <li> <p>Drug 1 plus non‐standard care (e.g. behavioral intervention) versus placebo or no pharmacological weight gain prevention treatment plus non‐standard care </p> </li> <li> <p>Drug 1 plus non‐standard care (e.g. behavioral intervention) versus drug 2 (active control) plus non‐standard care </p> </li> </ol> </p> </section> </section> <section id="CD013337-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>We aimed to report binary outcomes recording clear and clinically meaningful degrees of change (e.g. global impression of much improved, or more than 50% improvement on a rating scale* ‐ as defined within the studies) before any others. Thereafter, we will list other binary outcomes and then those that are continuous. </p> <p>* For types of scales we extracted data from, please see (<a href="#CD013337-sec-0048">Data extraction and management</a>). </p> <section id="CD013337-sec-0026"> <h5 class="title">Primary outcomes</h5> <section id="CD013337-sec-0027"> <h6 class="title">1. Weight or BMI</h6> <p> <ol id="CD013337-list-0002"> <li> <p>Clinically important change in weight</p> </li> <li> <p>Average endpoint/change in weight</p> </li> <li> <p>Clinically important change in BMI</p> </li> <li> <p>Average endpoint/change in BMI</p> </li> </ol> </p> </section> <section id="CD013337-sec-0028"> <h6 class="title">2. Leaving the study early</h6> <p> <ol id="CD013337-list-0003"> <li> <p>For any reason</p> </li> </ol> </p> </section> <section id="CD013337-sec-0029"> <h6 class="title">4. Reports of nausea</h6> <p>The included studies very rarely reported the primary outcomes, 'clinically important change in weight' or 'clinically important change in BMI'. As such, we added 'average endpoint/change in weight' and 'average endpoint/change in BMI' as additional primary outcomes post‐hoc. We noted this change in the <a href="#CD013337-sec-0289">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD013337-sec-0030"> <h5 class="title">Secondary outcomes</h5> <section id="CD013337-sec-0031"> <h6 class="title">1. Weight (or another indicator of body mass (e.g. BMI, waist measurement, waist‐to‐hip ratio) </h6> <p> <ol id="CD013337-list-0004"> <li> <p>Any change in body weight</p> </li> <li> <p>Any change in BMI</p> </li> <li> <p>Clinically important change in waist circumference (as defined by individual studies)</p> </li> <li> <p>Any change in waist circumference</p> </li> <li> <p>Average endpoint/change in waist circumference</p> </li> <li> <p>Clinically important change in waist‐to‐hip ratio (as defined by individual studies)</p> </li> <li> <p>Any change in waist‐to‐hip ratio</p> </li> <li> <p>Average endpoint/change in waist‐to‐hip ratio</p> </li> <li> <p>Clinically important change in percentage body fat</p> </li> <li> <p>Any change in percentage body fat</p> </li> </ol> </p> <p>Similar to the primary outcomes, the included studies very rarely reported the secondary outcomes, 'clinically important change in waist circumference', 'any change in waist circumference', 'clinically important change in waist‐to‐hip ratio' or 'any change in waist‐to‐hip ratio'. As such, we added 'average endpoint/change in waist circumference' and 'average endpoint/change in waist‐to‐hip ratio' as additional secondary outcomes, post‐hoc. We noted this change in the <a href="#CD013337-sec-0289">Differences between protocol and review</a> section. </p> </section> <section id="CD013337-sec-0032"> <h6 class="title">2. Leaving the study early</h6> <p> <ol id="CD013337-list-0005"> <li> <p>For specific reason(s)</p> </li> </ol> </p> </section> <section id="CD013337-sec-0033"> <h6 class="title">3. Global state</h6> <p> <ol id="CD013337-list-0006"> <li> <p>Clinically important change in global state (as defined by individual studies)</p> </li> <li> <p>Any change in global state</p> </li> <li> <p>Average endpoint/change score on global state scale</p> </li> </ol> </p> </section> <section id="CD013337-sec-0034"> <h6 class="title">4. Mental state</h6> <p> <ol id="CD013337-list-0007"> <li> <p>Clinically important change in general mental state</p> </li> <li> <p>Any change in general mental state</p> </li> <li> <p>Average endpoint/change score on mental state scale</p> </li> </ol> </p> </section> <section id="CD013337-sec-0035"> <h6 class="title">5. Well‐being</h6> <p> <ol id="CD013337-list-0008"> <li> <p>Clinically important change in well‐being</p> </li> <li> <p>Any change in well‐being</p> </li> <li> <p>Average endpoint/change score on well‐being scale</p> </li> </ol> </p> </section> <section id="CD013337-sec-0036"> <h6 class="title">6. Quality of life</h6> <p> <ol id="CD013337-list-0009"> <li> <p>Clinically important change in quality of life</p> </li> <li> <p>Any change in quality of life</p> </li> <li> <p>Average endpoint/change score on quality‐of‐life scale</p> </li> </ol> </p> </section> <section id="CD013337-sec-0037"> <h6 class="title">7. Adverse effects/events ‐ general or specific</h6> <p> <ol id="CD013337-list-0010"> <li> <p>General</p> <ol id="CD013337-list-0011"> <li> <p>At least one adverse effect/event</p> </li> <li> <p>Average endpoint/change score on general adverse effect scale</p> </li> </ol> </li> <li> <p>Specific</p> <ol id="CD013337-list-0012"> <li> <p>Clinically important specific adverse effects (e.g. cardiovascular, gastrointestinal)</p> </li> <li> <p>Death ‐ suicide and natural causes</p> </li> </ol> </li> </ol> </p> </section> <section id="CD013337-sec-0038"> <h6 class="title">8. Physiological measures</h6> <p> <ol id="CD013337-list-0013"> <li> <p>Cardiovascular measures</p> </li> <li> <p>Laboratory measures</p> </li> </ol> </p> </section> <section id="CD013337-sec-0039"> <h6 class="title">9. Economic costs</h6> <p> <ol id="CD013337-list-0014"> <li> <p>Direct costs</p> </li> <li> <p>Indirect costs</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD013337-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013337-sec-0041"> <h4 class="title">Electronic searches</h4> <section id="CD013337-sec-0042"> <h5 class="title">Cochrane Schizophrenia Group's Register of Trials</h5> <p>On 16 June 2014, 5 August 2015, 4 September 2019, and 10 February 2021, the Information Specialist searched the register using the following search strategy: </p> <p>(*Metabolic Adverse Event* in Health Care Condition) AND (*Pharmacological Interventions* in Intervention) of STUDY </p> <p>In such a study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<a href="./references#CD013337-bbs2-0243" title="RobertsMT , ShokranehF , SunY , GroomM , AdamsCE . Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies. Evidence-Based Mental Health2021;24:62-9. [DOI: 10.1136/ebmental-2020-300151]">Roberts 2021</a>; <a href="./references#CD013337-bbs2-0249" title="ShokranehF , AdamsCE . Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis. BioImpacts2017;7(4):209-17. [DOI: 10.15171/bi.2017.25]">Shokraneh 2017</a>; <a href="./references#CD013337-bbs2-0252" title="ShokranehF , AdamsCE . Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis. Health Information and Libraries Journal2021. [DOI: 10.1111/hir.12366]">Shokraneh 2021</a>). This allows rapid and accurate searches that reduce waste in the next steps of systematic reviewing (<a href="./references#CD013337-bbs2-0250" title="ShokranehF , AdamsCE . Study-based registers reduce waste in systematic reviewing: discussion and case report. Systematic Reviews2019;8:129. [DOI: 10.1186/s13643-019-1035-3]">Shokraneh 2019</a>). </p> <p>Following Cochrane methods (<a href="./references#CD013337-bbs2-0214" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2/chapter-04. [DOI: 10.1002/9781119536604.ch4]">Lefebvre 2019</a>), this register is compiled by systematic searches of major resources (AMED, BIOSIS, CENTRAL, CINAHL, ClinicalTrials.Gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates, ProQuest Dissertations and Theses A&amp;I and its quarterly update, hand‐searches, grey literature, and conference proceedings (<a href="./references#CD013337-bbs2-0251" title="ShokranehF , AdamsCE . Cochrane Schizophrenia Group’s Study-Based Register of Randomized Controlled Trials: development and content analysis. Schizophrenia Bulletin Open2020;1:sgaa061. [DOI: 10.1093/schizbullopen/sgaa061]">Shokraneh 2020</a>; see <a href="http://schizophrenia.cochrane.org/register-trials" target="_blank">Cochrane Schizophrenia: Register of trials</a>). There are no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD013337-sec-0043"> <h4 class="title">Searching other resources</h4> <section id="CD013337-sec-0044"> <h5 class="title">Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD013337-sec-0045"> <h5 class="title">Personal contact</h5> <p>We contacted the first author of each potentially eligible study that we identified in the search for which we could not find published data. We noted the outcome of this contact in the <a href="./references#CD013337-sec-0292" title="">Characteristics of excluded studies</a> or <a href="./references#CD013337-sec-0291" title="">Characteristics of included studies</a>.  </p> </section> </section> </section> <section id="CD013337-sec-0046"> <h3 class="title" id="CD013337-sec-0046">Data collection and analysis</h3> <section id="CD013337-sec-0047"> <h4 class="title">Selection of studies</h4> <p>Review authors NS, SMA and ZA independently inspected citations from the searches and identified relevant abstracts; MH independently re‐inspected a random 20% sample of these abstracts to ensure reliability of selection. Where disputes arose, we acquired the full report for more detailed scrutiny. NS and ZA then obtained and inspected full reports of the abstracts or reports meeting the review criteria. SMA re‐inspected a random 20% of these full reports in order to ensure reliability of selection. When it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study concerned for clarification. </p> </section> <section id="CD013337-sec-0048"> <h4 class="title">Data extraction and management</h4> <section id="CD013337-sec-0049"> <h5 class="title">Extraction</h5> <p>Review authors NS, MD, ZA, and JL extracted data from all included studies. In addition, to ensure reliability, SMA independently extracted data from a random sample of these studies, comprising 10% of the total. We attempted to extract data presented only in graphs and figures whenever possible, but included them only if two review authors independently obtained the same result. If studies were multi‐centre, then where possible we extracted data relevant to each centre. We discussed any disagreement and documented our decisions. Where necessary, we attempted to contact study authors through an open‐ended request in order to obtain missing information or for clarification. </p> </section> <section id="CD013337-sec-0050"> <h5 class="title">Management</h5> <section id="CD013337-sec-0051"> <h6 class="title">Forms</h6> <p>We extracted data onto standard, predesigned, simple forms.</p> </section> <section id="CD013337-sec-0052"> <h6 class="title">Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ol id="CD013337-list-0015"> <li> <p>the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD013337-bbs2-0224" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249-52.">Marshall 2000</a>); </p> </li> <li> <p>the measuring instrument had not been written or modified by one of the study authors for that particular study; and </p> </li> <li> <p>the instrument was a global assessment of an area of functioning, not subscores, which are not, in themselves, validated or shown to be reliable. However there were exceptions, we included subscores from mental state scales that measure positive and negative symptoms of schizophrenia. </p> </li> </ol> </p> <p>Ideally, the measuring instrument was either:</p> <p> <ol id="CD013337-list-0016"> <li> <p>a self‐report; or</p> </li> <li> <p>completed by an independent rater or relative (not the therapist).</p> </li> </ol> </p> <p>We realise that this is not often reported clearly. We note whether this was the case or not in <a href="#CD013337-sec-0100">Description of studies</a>. </p> </section> <section id="CD013337-sec-0053"> <h6 class="title">Scales used</h6> <section id="CD013337-sec-0054"> <p><b>Global measures</b></p> <p> <ol id="CD013337-list-0017"> <li> <p><b>Clinical Global Impression Scale (CGI)</b> provides an assessment of an individual’s clinical status in light of the severity of their illness and level of clinical improvement (<a href="./references#CD013337-bbs2-0196" title="Guy William. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, 1976.">Guy 1976</a>). An individual is scored according to standardised criteria based on others with the same diagnosis. Assigned scores range on a 7‐point scale with lower scores indicating minimal clinical improvement or reduced illness severity, or both. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0055"> <p><b>Mental state</b></p> <p> <ol id="CD013337-list-0018"> <li> <p><b>Brief Psychiatric Rating Scale (BPRS)</b> provides an indication of an individual's psychological functioning in light of psychosis (<a href="./references#CD013337-bbs2-0232" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799-812.">Overall 1962</a>). This 18‐item scale (revised version ‐ the original contained 16 items) includes a 7‐point scale for each question (ranging from 0‐6 or 1‐7). Scores within this measure may vary from 0‐126 and reflect either the presence or absence of psychological abnormalities (ratings range from "not present" to "extremely severe"). In this scale, elevated scores evidence an increasingly disordered mental state. </p> </li> <li> <p><b>Positive and Negative Syndrome Scale (PANSS)</b> can be administered as a whole or as three separate components (1 ‐ severity of general psychopathology, 2 ‐ positive symptoms (PANSS‐P), 3 ‐ negative symptoms (PANSS‐N); <a href="./references#CD013337-bbs2-0208" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>). This scale is a 30‐item measure rating on a scale from 1‐7 (absent‐severe) with higher scores reflecting greater symptom severity. </p> </li> <li> <p><b>Scale for the Assessment of Negative Symptoms (SANS)</b> is used in patients with psychosis to assess the symptom severity of negative symptoms using a 6‐point scale, with lower scores being indicative of a reduced number of symptoms (<a href="./references#CD013337-bbs2-0151" title="AndreasenNC . The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry. Supplement1989;155(52):49-58.">Andreasen 1989</a>). Aspects of psychopathology measured by this scale include: affective blunting, alogia, avolition/apathy and anhedonia/asociality. </p> </li> <li> <p><b>Scale for the Assessment of Positive Symptoms (SAPS)</b> is used in patients with psychosis to assess the symptom severity of positive symptoms using a 6‐point scale, with lower scores being indicative of a reduced number of symptoms (<a href="./references#CD013337-bbs2-0151" title="AndreasenNC . The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry. Supplement1989;155(52):49-58.">Andreasen 1989</a>). Aspects of psychopathology measured by this scale include: hallucinations, delusions, disorganisation, and formal thought disorder. </p> </li> <li> <p><b>Hamilton Rating Scale for Depression (HAM‐D)</b> is a 17‐item scale that uses a 5‐point rating system for each question but in cases where it is especially difficult to categorise the individual, a 3‐point scale may be used (<a href="./references#CD013337-bbs2-0197" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23(1):56-62.">Hamilton 1960</a>). Here, lower scores reflect a less serious state of depression, whereas higher ones result for more intense depressive symptomology. The HAM‐D assesses various domains, including depressed mood, suicide, work and loss of interest, retardation, agitation, gastro‐intestinal symptoms, general somatic symptoms, hypochondria, loss of insight, and loss of weight. Interrater reliability is of particular value in this assessment given the difficulty of its administration; in this case, an individual will be scored based on the sum of both ratings. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0056"> <p><b>Adverse effects</b></p> <p> <ol id="CD013337-list-0019"> <li> <p><b>Barnes Akathisia Scale (BAS)</b> has three main components: reckless movements, agitation and distress ‐ all of which are assessed by the BAS in both objective and subjective domains (<a href="./references#CD013337-bbs2-0156" title="BarnesTR . A rating scale for drug-induced akathisia. British Journal of Psychiatry1989;154:672-6.">Barnes 1989</a>). This measure also includes a 5‐item global severity rating; otherwise, items are scored on a scale of 0 to 3, with higher ratings being indicative of severe akathisia. </p> </li> <li> <p><b>Simpson Angus Scale (SAS)</b> provides an assessment of drug‐induced Parkinsonism; a temporary movement disorder often prompted by the use of pharmacological agents (<a href="./references#CD013337-bbs2-0255" title="SimpsonGM , AngusJW . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;45(S212):11-9.">Simpson 1970</a>). This scale includes 10 items with a 0 to 4 rating system. A high score on this measure is indicative of a high degree of Parkinsonian symptoms. </p> </li> </ol> </p> </section> </section> <section id="CD013337-sec-0057"> <h6 class="title">Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data: change data can remove a component of between‐person variability from the analysis. However, calculation of change needs two assessments, baseline and endpoint, which can be difficult to obtain in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to use endpoint data primarily, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we prefer to use mean differences (MDs) rather than standardised mean differences (SMDs) throughout (<a href="./references#CD013337-bbs2-0175" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Deeks 2021</a>). </p> </section> <section id="CD013337-sec-0058"> <h6 class="title">Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant continuous data before inclusion. </p> <p>For endpoint data from studies including fewer than 200 participants:</p> <p> <ol id="CD013337-list-0020"> <li> <p>when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than one, it strongly suggested that the data were skewed and we excluded these data. If this ratio was higher than one but less than two, there was a suggestion that the data were skewed. We entered these data and tested whether their inclusion or exclusion would change the results substantially. If such data changed the results, we entered these as 'other data'. Finally, if the ratio was larger than two we included these data, because it is less likely that they were skewed (<a href="./references#CD013337-bbs2-0148" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200.">Altman 1996</a>; <a href="./references#CD013337-bbs2-0201" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Higgins 2021</a>). </p> </li> <li> <p>if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210 (<a href="./references#CD013337-bbs2-0208" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>)), we modified the calculation described above to take the scale starting point into account. In these cases skewed data were present if 2 SD &gt; (S − S min), where S is the mean score and 'S min' is the minimum score. </p> </li> </ol> </p> <p>Please note: we entered all relevant data from studies of more than 200 participants in the analysis irrespective of the above rules, because skewed data pose less of a problem in large studies. We also entered all relevant change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether or not data are skewed. </p> </section> <section id="CD013337-sec-0059"> <h6 class="title">Common measurement</h6> <p>To facilitate comparison between studies we aimed to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD013337-sec-0060"> <h6 class="title">Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This was done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS; <a href="./references#CD013337-bbs2-0232" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799-812.">Overall 1962</a>), or the PANSS (<a href="./references#CD013337-bbs2-0208" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD013337-bbs2-0218" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?Schizophrenia Research2005;79(2-3):231-8. [PMID: 15982856]">Leucht 2005a</a>; <a href="./references#CD013337-bbs2-0219" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366-71. [PMID: 16199797]">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD013337-sec-0061"> <h6 class="title">Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for pharmacological intervention for prevention of weight gain. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'not un‐improved') we reported data where the left of the line indicated an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD013337-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors NS, SMA and ZA worked independently to assess risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess study quality (<a href="./references#CD013337-bbs2-0200" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). This set of criteria is based on evidence of associations between potential overestimation of effect and the level of risk of bias of the article that may be due to aspects of sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting, or the way in which these 'domains' are reported. </p> <p>If the raters disagreed, we made the final rating by consensus. Where inadequate details of randomisation and other characteristics of studies are provided, we attempted to contact authors of the studies in order to obtain further information. We reported non‐concurrence in quality assessment, but if disputes arose regarding the category to which a study was to be allocated, we resolved this by discussion. </p> </section> <section id="CD013337-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <section id="CD013337-sec-0064"> <h5 class="title">Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI), as it has been shown that RR is more intuitive than odds ratios (<a href="./references#CD013337-bbs2-0160" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405-11. [PMID: 10667106]">Boissel 1999</a>); and that odds ratios tend to be interpreted as RRs by clinicians (<a href="./references#CD013337-bbs2-0174" title="DeeksJ . Issues in the selection for meta-analyses of binary data. In: 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.">Deeks 2000</a>). Although the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH), with their CIs, are intuitively attractive to clinicians, they are problematic to calculate and interpret in meta‐analyses (<a href="./references#CD013337-bbs2-0205" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27-30. [PMID: 19438480]">Hutton 2009</a>). For binary data presented in the summary of findings tables we calculated illustrative comparative risks where possible. </p> </section> <section id="CD013337-sec-0065"> <h5 class="title">Continuous data</h5> <p>For continuous outcomes we estimated MD between groups. We preferred not to calculate effect size measures (SMD). However if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD013337-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <section id="CD013337-sec-0067"> <h5 class="title">Cluster studies</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra‐class correlation in clustered studies, leading to a unit‐of‐analysis error whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated (<a href="./references#CD013337-bbs2-0180" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623-9.">Divine 1992</a>). This causes type I errors (<a href="./references#CD013337-bbs2-0159" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315(7108):600.">Bland 1997</a>; <a href="./references#CD013337-bbs2-0194" title="GullifordMC . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876-83.">Gulliford 1999</a>). </p> <p>Had we found any studies where clustering was incorporated into the analysis, we would have presented these data as if from a non‐cluster randomised study, but would have adjusted for the clustering effect. We did not identify any cluster‐RCTs to include in this review. </p> </section> <section id="CD013337-sec-0068"> <h5 class="title">Cross‐over studies</h5> <p>A major concern of cross‐over studies is the carry‐over effect. This occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, participants can differ significantly from their initial state at entry to the second phase, despite a wash‐out phase. For the same reason, cross‐over studies are not appropriate if the condition of interest is unstable (<a href="./references#CD013337-bbs2-0183" title="ElbourneD , AltmanDG , HigginsJP , CurtinaF , WorthingtondHV , VaileA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). As both carry‐over and unstable conditions are very likely in severe mental illness, we decided to only use data from the first phase of cross‐over studies. We did not identify any cross‐over studies to include in this review. </p> </section> <section id="CD013337-sec-0069"> <h5 class="title">Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined within the two‐by‐two table. If data were continuous, we combined data following the formula in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013337-bbs2-0201" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Higgins 2021</a>). Where additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD013337-sec-0070"> <h4 class="title">Dealing with missing data</h4> <section id="CD013337-sec-0071"> <h5 class="title">Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD013337-bbs2-0270" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254-7.">Xia 2009</a>). We chose, for any particular outcome, not to reproduce data or use them within analyses should more than 50% of data be unaccounted for. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we chose to address this within the summary of findings tables by down‐rating certainty. Finally, we also downgraded certainty within the summary of findings tables if the loss was 25% to 50% in total. </p> </section> <section id="CD013337-sec-0072"> <h5 class="title">Binary data</h5> <p>Where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). Those leaving the study early are all assumed to have the same rates of negative outcome as those who completed. We used the rate of those who stayed in the study ‐ in that particular arm of the study ‐ and applied this also to those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the ITT analysis using the above assumptions. </p> </section> <section id="CD013337-sec-0073"> <h5 class="title">Continuous data</h5> <section id="CD013337-sec-0074"> <h6 class="title">Attrition</h6> <p>We used data where attrition for a continuous outcome was between 0% and 50%, and reported data only from people who completed the study to that point. </p> </section> <section id="CD013337-sec-0075"> <h6 class="title">Standard deviations</h6> <p>If SDs were not reported, we tried to obtain the missing values from the authors. If these were not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs available for group means, and either P value or t value available for differences in mean, we calculated SDs according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013337-bbs2-0201" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Higgins 2021</a>). When only the SE was reported, we calculated SDs by the formula SD = SE * √(n). The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> presents detailed formulae for estimating SDs from P, t or F values, CIs, ranges or other statistics (<a href="./references#CD013337-bbs2-0201" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Higgins 2021</a>). If these formulae did not apply, we calculated the SDs according to a validated imputation method which was based on the SDs of the other included studies (<a href="./references#CD013337-bbs2-0188" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7-10.">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would have been to exclude a given study’s outcome and thus lose information. Nevertheless, if this were to be the case, we decided we would examine the validity of the imputations in a sensitivity analysis that excludes imputed values. </p> </section> <section id="CD013337-sec-0076"> <h6 class="title">Assumptions about participants who left the studies early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the studies early or were lost to follow‐up. Some studies just present the results of study completers; others use the method of last observation carried forward (LOCF); while more recently, methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD013337-bbs2-0216" title="LeonAC , MallinckrodtCH , Chuang-SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001-5. [PMID: 16905632]">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences between groups in their reasons for doing so is often the core problem in randomised schizophrenia studies. We therefore did not exclude studies based on the statistical approach used. However, by preference we used the more sophisticated approaches, that is, we preferred to use MMRM or multiple‐imputation to LOCF, and we only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'Incomplete outcome data' of the risk of bias tool (<a href="./references#CD013337-bbs2-0200" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> </section> </section> <section id="CD013337-sec-0077"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD013337-sec-0078"> <h5 class="title">Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for participants who were clearly outliers or situations that we had not predicted would arise and, where found, discussed such situations or participant groups. </p> </section> <section id="CD013337-sec-0079"> <h5 class="title">Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise, and discussed any such methodological outliers. </p> </section> <section id="CD013337-sec-0080"> <h5 class="title">Statistical heterogeneity</h5> <section id="CD013337-sec-0081"> <h6 class="title">Visual inspection</h6> <p>We inspected graphs visually to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD013337-sec-0082"> <h6 class="title">Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² statistic (<a href="./references#CD013337-bbs2-0199" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), alongside the Chi² P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance. The importance of the observed value of the I² statistic depends on the magnitude and direction of effects as well as the strength of evidence for heterogeneity (e.g. P value from Chi² test, or a confidence interval for I² statistic). We interpreted an I² statistic estimate of 50% or more, accompanied by a statistically significant Chi² statistic, as evidence of substantial heterogeneity (<a href="./references#CD013337-bbs2-0175" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Deeks 2021</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD013337-sec-0087">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD013337-sec-0083"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD013337-bbs2-0182" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). These are described in section 10.1 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD013337-bbs2-0257" title="SterneJA , EggerM , Moher D editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Sterne 2011</a>). </p> <section id="CD013337-sec-0084"> <h5 class="title">Protocol versus full study</h5> <p>We tried to locate protocols of included RCTs. If the protocol was available, we compared outcomes in the protocol and in the published report. If the protocol was not available, we compared outcomes listed in the methods section of the study report with reported results. </p> </section> <section id="CD013337-sec-0085"> <h5 class="title">Funnel plot</h5> <p>We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> </section> <section id="CD013337-sec-0086"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies, even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose to use a random‐effects model for all analyses. </p> </section> <section id="CD013337-sec-0087"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD013337-sec-0088"> <h5 class="title">Subgroup analyses</h5> <section id="CD013337-sec-0089"> <h6 class="title">Primary outcomes</h6> <p>We only undertook subgroup analyses for the primary outcome 'average endpoint/change in weight'. Subgroup analyses were only done for comparisons in which we observed high heterogeneity and the studies could be divided into subgroups (decided on post‐hoc) to potentially explain and reduce the source of heterogeneity. </p> </section> </section> <section id="CD013337-sec-0090"> <h5 class="title">Investigation of heterogeneity</h5> <p>We reported if inconsistency was high. Firstly, we investigated whether data were entered correctly. Secondly, if data were correct, we inspected the graph visually and removed outlying studies successively to see if homogeneity was restored. When unanticipated clinical or methodological heterogeneity was obvious we simply stated hypotheses regarding these for future reviews or versions of this review. If homogeneity could not be achieved with the first two approaches, heterogeneity was left unresolved. </p> </section> </section> <section id="CD013337-sec-0091"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses where relevant, based on the evidence found for each intervention comparison. Sensitivity analyses were only done for primary outcomes related to weight (e.g. average endpoint/change in body weight). If there were substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed below, we did not add data from the lower‐quality studies to the results of the higher‐quality studies, but presented these data within a subcategory. If their inclusion did not result in a substantive difference, they were kept in the analyses. </p> <section id="CD013337-sec-0092"> <h5 class="title">Implication of randomisation</h5> <p>If studies were described in some way as to imply randomisation, we compared data from the studies that were randomised with those where randomisation was implied. </p> </section> <section id="CD013337-sec-0093"> <h5 class="title">Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD013337-sec-0070">Dealing with missing data</a>), we compared the findings when we used our assumption with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD013337-sec-0094"> <h5 class="title">Assumptions for lost continuous data</h5> <p>Where assumptions have to be made regarding missing SDs (see <a href="#CD013337-sec-0070">Dealing with missing data</a>), we compared the findings when we used our assumption with data that were not imputed. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD013337-sec-0095"> <h5 class="title">Risk of bias</h5> <p>We analysed the effects of excluding studies that were at high risk of bias across one or more of the domains (see <a href="#CD013337-sec-0062">Assessment of risk of bias in included studies</a>). </p> </section> <section id="CD013337-sec-0096"> <h5 class="title">Imputed values</h5> <p>We also undertook a sensitivity analysis to assess the effects of including data from studies where we used imputed values for ICC in calculating the design effect in cluster‐RCTs. </p> </section> <section id="CD013337-sec-0097"> <h5 class="title">Fixed‐effect and random‐effects models</h5> <p>We synthesised data using a random‐effects model; however, we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether this altered the significance of the results. </p> </section> </section> <section id="CD013337-sec-0098"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to interpret findings (<a href="./references#CD013337-bbs2-0246" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook (accessed March 2021).">Schünemann 2021</a>); and used <a href="./references#CD013337-bbs2-0192" title="GRADEpro GDT. Version accessed December 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> to export data from our review to create summary of findings tables. These tables provide outcome‐specific information concerning the overall certainty of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the summary of findings tables. </p> <p> <ol id="CD013337-list-0021"> <li> <p>Weight: clinically important change in weight</p> </li> <li> <p>Weight: average endpoint/change in weight (post‐hoc)</p> </li> <li> <p>Weight: clinically important change in BMI</p> </li> <li> <p>Weight: average endpoint/change in BMI (post‐hoc)</p> </li> <li> <p>Leaving the study early: for any reason</p> </li> <li> <p>Compliance with treatment</p> </li> <li> <p>Reports of nausea</p> </li> </ol> </p> <p>Given the sparse data available for the prespecified primary outcomes, we added post‐hoc primary and secondary outcomes and reported them in the summary of findings tables. This change in protocol was made post‐hoc and is described in <a href="#CD013337-sec-0025">Types of outcome measures</a> and <a href="#CD013337-sec-0289">Differences between protocol and review</a>. </p> <p> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013337-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013337-sec-0099"></div> <section id="CD013337-sec-0100"> <h3 class="title">Description of studies</h3> <p>A brief overview of the included and excluded studies is presented below. For substantive descriptions of studies see <a href="./references#CD013337-sec-0291" title="">Characteristics of included studies</a>; <a href="./references#CD013337-sec-0292" title="">Characteristics of excluded studies</a>; and <a href="./references#CD013337-sec-0294" title="">Characteristics of ongoing studies</a>. Additional information on studies awaiting assessment is presented below. </p> <section id="CD013337-sec-0101"> <h4 class="title">Results of the search</h4> <p>Database searching identified a total of 991 records (on 16 June 2014, 5 August 2015, 4 September 2019 and 10 February 2021). After screening titles and abstracts for inclusion in the review, we selected 142 studies for full‐text assessment. From this, we excluded 121 full‐text articles, with reasons (<a href="./references#CD013337-sec-0292" title="">Characteristics of excluded studies</a>). Two studies are awaiting classification and two are ongoing. We included 17 studies in the quantitative meta‐analysis of this review.  </p> <p>Please see also <a href="#CD013337-fig-0001">Figure 1</a> for details (<a href="./references#CD013337-bbs2-0227" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Medicine 6;7:e1000097.">Moher 2009</a>). </p> <div class="figure" id="CD013337-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013337-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013337-sec-0102"> <h4 class="title">Included studies</h4> <section id="CD013337-sec-0103"> <h5 class="title">Design and duration</h5> <p>All studies were randomised. Fourteen interventions were double‐blind, two were open‐label (<a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>), and one had unclear blinding (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>). The duration of the studies ranged between 6 weeks (<a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>), and 24 weeks (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>). The average duration was approximately 12 weeks. Hence, we were able to provide information on outcomes over the short term and were not able to measure any outcome measure over the medium or long term. </p> </section> <section id="CD013337-sec-0104"> <h5 class="title">Participants</h5> <p>Most studies included people diagnosed with schizophrenia, schizoaffective disorder or schizophreniform psychosis, while one study included patients with bipolar disorder and major depressive disorder as well (<a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>). The majority of studies employed DSM IV criteria for diagnosis (<a href="./references#CD013337-bbs2-0153" title="American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association, 2000.">APA 2000</a>), while others (<a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>), used ICD‐10 (<a href="./references#CD013337-bbs2-0268" title="World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems 10th Revision. icd.who.int/browse10/2016/en accessed before 25 July 2022.">WHO 2016</a>), and <a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a> used CCMD‐3 (<a href="./references#CD013337-bbs2-0171" title="Chinese Society of Psychiatry (CSP). Chinese Classification of Mental Disorders. web.archive.org/web/20061205213538/http://www.21jk.com/english/index.asp.">CSP 2003</a>). </p> <p>The current review comprises an analysis of 1388 individuals. Only one study was conducted in children, with a mean age of 10.9 years; all other studies were conducted in adults aged between 18‐65 with a median age of 26.53 years. We pooled the study conducted in children together with the adult studies, despite known differences in treatment effect sizes between these populations; however, we expected the direction of effects to be the same. There were 737 male participants and 372 female participants, but gender was not specified for 251 individuals. When data were provided, the mean weight and BMI were 58.7 kg (in 14 studies) and 22.11 kg/m<sup>2</sup> (in 13 studies), respectively. Nine studies indicated that they were conducted in antipsychotic naive or first episode patients (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>). </p> </section> <section id="CD013337-sec-0105"> <h5 class="title">Setting</h5> <p>Studies included in the meta‐analysis involved either inpatients or outpatients, or both. Eleven studies reported this characteristic (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>); there were 319 inpatients and 99 outpatients. The setting of the remaining studies is unclear. </p> </section> <section id="CD013337-sec-0106"> <h5 class="title">Study size</h5> <p>Most studies were small (63 participants) and ranged between 14 and 561 participants.</p> </section> <section id="CD013337-sec-0107"> <h5 class="title">Interventions</h5> <p>All 17 studies evaluated adjunctive pharmacotherapy for weight maintenance or prevention of weight gain. </p> <section id="CD013337-sec-0108"> <h6 class="title">Pharmacological Interventions</h6> <p>The included studies used the following medications and drug classes: topiramate (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>), metformin (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), monoamine modulators such as reboxetine (<a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>), and fluoxetine (<a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>), H2 antagonists such as nizatidine (<a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>), famotidine (<a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>), and ranitidine (<a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a>), reboxetine plus betahistine, samidorphan (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>), and melatonin (<a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>). </p> <p>For the comparisons in this review, we grouped together medications that use a similar mechanism of action. </p> </section> <section id="CD013337-sec-0109"> <h6 class="title">Standard care</h6> <p>In all studies, standard care included treatment with antipsychotic medication. Other components of standard care were not explicitly outlined in all studies. </p> <p><b><i>Non‐standard care: other behavioural interventions</i> </b> </p> <p>None of the included studies looked at a combined pharmacological plus behavioural intervention. </p> </section> </section> <section id="CD013337-sec-0110"> <h5 class="title">Outcomes</h5> <p>All the included studies provided data for weight‐related outcomes. However, in some instances, they did not report adequate details of our primary and secondary outcomes or reported them in ways that made them unusable for the purpose of this review. For such studies, we emailed authors to provide us with more data. If we did not receive a response, we excluded the study for those outcomes (see <a href="./references#CD013337-sec-0292" title="">Characteristics of excluded studies</a>). Some studies failed to report appropriate measures of central tendency and deviation (e.g. mean and standard deviation or standard error or 95% CI). For such studies, we used the Review Manager 5 Calculator (<a href="./references#CD013337-bbs2-0238" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). However, caution is needed as the values may not be a complete reflection of the actual values.  </p> <p>We divided all outcomes into short term (less than six months), medium term (seven to 12 months) and long term (over one year). </p> <section id="CD013337-sec-0111"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0112"> <p><b>Weight or BMI</b></p> <p>Most studies reported endpoint data for weight or another indicator of body mass such as BMI. Three studies reported only change data (<a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), while four studies reported both change and end‐point measures (<a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> <p>Other less commonly reported measures included waist circumference, waist‐to‐hip ratio and hip circumference. </p> </section> <section id="CD013337-sec-0113"> <p><b>Leaving the study early</b></p> <p>Most of the studies made note of individuals who withdrew from the study early.</p> </section> <section id="CD013337-sec-0114"> <p><b>Compliance with treatment</b></p> <p>None of the included studies reported compliance with treatment. No study mentioned how they confirmed compliance, and no study reported adherence to medication during follow‐up. Given the lack of reporting data, we were unable to include this measure in the meta‐analysis. </p> </section> <section id="CD013337-sec-0115"> <p><b>Reports of nausea</b></p> <p>Only five studies reported the frequency of nausea (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>). </p> </section> </section> <section id="CD013337-sec-0116"> <h6 class="title">Secondary outcomes</h6> <p>Details of only those scales that provided usable data are shown below. Reasons for exclusion of data are given above under 'Outcomes'. </p> <section id="CD013337-sec-0117"> <p><b>Global measures</b></p> <p> <ol id="CD013337-list-0022"> <li> <p><b>Clinical Global Impression Scale (CGI):</b> five studies reported data using this instrument (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> </li> </ol> </p> <p><i>Mental state</i> </p> <p> <ol id="CD013337-list-0023"> <li> <p><b>Brief Psychiatric Rating Scale (BPRS):</b> two studies reported data using this instrument (<a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>). </p> </li> <li> <p><b>Positive and Negative Syndrome Scale (PANSS):</b> Four studies reported data using this instrument (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>). </p> </li> <li> <p><b>Scale for the Assessment of Negative Symptoms (SANS):</b> five studies reported data using this instrument (<a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> </li> <li> <p><b>Hamilton Rating Scale for Depression (HAM‐D):</b> four studies reported data using this instrument (<a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> </li> </ol> </p> <p><i>Adverse effects</i> </p> <p> <ol id="CD013337-list-0024"> <li> <p><b>Barnes Akathisia Scale (BAS):</b> four studies reported data using this scale (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> </li> <li> <p><b>Simpson Angus Scale (SAS):</b> five studies reported data using this scale (<a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0118"> <p><b>Other outcome measures</b></p> <p> <ol id="CD013337-list-0025"> <li> <p>Cardiovascular measures: three studies reported blood pressure data (<a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). </p> </li> <li> <p>Laboratory measures: investigating metabolic‐related laboratory measures was of importance in this review as they serve as additional indicators of drug action. However, only a limited number of studies reported on laboratory parameters. Some reported measures were fasting glucose (<a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), lipids (high‐density, low‐density and very low‐density lipoproteins, total cholesterol and triglycerides; <a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), fasting insulin (<a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), insulin resistance (<a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), leptin (<a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>), and haemoglobin (HbA1c) (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>). </p> </li> <li> <p>Unusable data: studies reported a large amount of data presented in a way not useable for this review. A fair number of studies provided their results only in graph form; additionally, many studies did not appropriately indicate measures of deviation and central tendency (e.g. mean and standard deviation or standard error or 95% CI), which rendered their results unusable within our review. These are stated in the <a href="./references#CD013337-sec-0291" title="">Characteristics of included studies</a> tables. </p> </li> <li> <p>Missing outcomes: no studies reported on the primary outcomes, 'clinically important change in BMI' or 'compliance with treatment'. None of the studies provided a description of how they confirmed compliance, and none of the studies reported on adherence to medication during follow‐up. Therefore, we were unable to include this measure in the meta‐analysis. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD013337-sec-0119"> <h4 class="title">Excluded studies</h4> <p>We excluded 121 studies from the review for the following reasons:</p> <p> <ol id="CD013337-list-0026"> <li> <p>108 studies used an ineligible intervention (<a href="./references#CD013337-bbs2-0018" title="AdamsDH , KinonBJ , BayganiS , MillenBA , VelonaI , Kollack-WalkerS , et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry2013;13:Art ID 143. ">Adams 2013</a>; <a href="./references#CD013337-bbs2-0019" title="AgahiM , AkashehN , AhmadvandA , AkbariH , IzadpanahF . Effect of melatonin in reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical trial. Diabetes and Metabolic Syndrome2018;12(1):9-15. IRCT2016051027832N1. Effect of melatonin in side effects of second-generation antipsychotic medications. https://trialsearch.who.int/?TrialID=IRCT2016051027832N1 (first received 27 September 2016). ">Agahi 2017</a>; <a href="./references#CD013337-bbs2-0020" title="AgarwalSM , Cost-DookhanK , PandaR , MacKenzieN , TreenQC , CaravaggioF , et al. Metformin in schizophrenia spectrum disorders and early co-morbid prediabetes/diabetes: a double-blind randomized control trial. Neuropsychopharmacology2019;44 Suppl 1:110-1. ">Agarwal 2019</a>; <a href="./references#CD013337-bbs2-0021" title="AssuncaoSS , RuschelSI , RosaLD , CamposJA , AlvesMJ , BraccoOL , et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Revista Brasileira de Psiquiatria (Sao Paulo, Brazil : 1999)2006;28(4):270-6. [CSZG: 13955]NCT00486005. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. https://clinicaltrials.gov/ct2/show/NCT00486005 (first received 13 June 2007). [CSZG: 14930]">Assuncao 2006</a>; <a href="./references#CD013337-bbs2-0022" title="AtmacaM , KulogluM , TezcanE , UstundagB . Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Human Psychopharmacology2003;18(6):457-61. [CSZG: 9841]">Atmaca 2003</a>; <a href="./references#CD013337-bbs2-0023" title="AtmacaM , KulogluM , TezcanE , UstundagB , KilicN . Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human Psychopharmacology2004;19(1):37-40. [CSZG: 10031]">Atmaca 2004</a>; <a href="./references#CD013337-bbs2-0024" title="BallMP , WarrenKR , FeldmanS , McMahonRP , KellyDL , BuchananRW . Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clinical Schizophrenia &amp; Related Psychoses2011;5(1):17-25. [CSZG: 22862]NCT00176436. Double-blind study of atomoxetine for weight management in patients taking olanzapine or clozapine. https://clinicaltrials.gov/ct2/show/NCT00176436 (first received 15 September 2005). [CSZG: 14590]">Ball 2011</a>; <a href="./references#CD013337-bbs2-0025" title="BaptistaT , RangelN , FernandezV , CarrizoE , El FakihY , UzcateguiE , et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophrenia Research2007;93(1-3):99-108. [CSZG: 15343]">Baptista 2007</a>; <a href="./references#CD013337-bbs2-0026" title="BaptistaT , UzcateguiE , RangelN , El FakihY , GaleazziT , BeaulieuS , et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Research2008;159(1-2):250-3. [CSZG: 16155]UzcateguiE , EIFakihY , RangelN , GaleazziT , BaptistaT . Metformin plus sibutramine in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study. In: 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA. 2007. [CSZG: 18966]">Baptista 2008</a>; <a href="./references#CD013337-bbs2-0027" title="BaptistaT , RangelN , El FakihY , UzcateguiE , GaleazziT , BeaulieuS , et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry2009;42(1):14-9. [CSZG: 18197]">Baptista 2009</a>; <a href="./references#CD013337-bbs2-0028" title="BarakN . Betahistine safely mitigates olanzapine adverse: role of histamine receptors in weight gain and somnolence. In: 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA. 2010. ">Barak 2010</a>; <a href="./references#CD013337-bbs2-0029" title="BarakN , BeckY , AlbeckJH . A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. Journal of Clinical Psychopharmacology2016;36:253-6. ">Barak 2016</a>; <a href="./references#CD013337-bbs2-0030" title="BiedermannF , FleischhackerWW , KemmlerG , EbenbichlerCF , LechleitnerM , HoferA . Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. International Clinical Psychopharmacology2014;29(3):181-4. [CSZG: 29185]BiedermannF , LechleitnerM , HoferA , HuberR , Futhmu NE-, EbenbichlerC , et al. Sibutramine in the treatment of antipsychotic-induces weight gain: a randomized, placebo-controlled double-blind study. Schizophrenia Research2010;117(2-3):260-1. [CSZG: 20590]">Biedermann 2014</a>; <a href="./references#CD013337-bbs2-0031" title="BorbaCP , FanX , CopelandPM , PaivaA , FreudenreichO , HendersonDC . Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. Journal of Clinical Psychopharmacology2011;31(5):653-8. [CSZG: 23238] [DOI: 10.1097/JCP.0b013e31822bb573]">Borba 2011</a>; <a href="./references#CD013337-bbs2-0032" title="BorovickaMC , FullerMA , KonickiPE , WhiteJC , SteeleVM , JaskiwGE . Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Journal of Clinical Psychiatry2002;63(4):345-8. [CSZG: 8392]">Borovicka 2002</a>; <a href="./references#CD013337-bbs2-0033" title="BusheC , Poole-HoffmannV , LipkovichI . Metabolic comparisons from a 6-month randomized trial of olanzapine and quetiapine in schizophrenia. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. San Diego, CA, USA: Elsevier Science Inc, 2007:255. BusheC , SniadeckiJ , BradleyAJ , Poole HoffmannV . Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. Journal of Psychopharmacology2010;24(7):1001-9. ">Bushe 2010</a>; <a href="./references#CD013337-bbs2-0034" title="BustilloJR , LaurielloJ , HammondR , KeithS . Treatment of weight-gain with fluoxetine in olanzapine-treated schizophrenic outpatients. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7573]BustilloJR , LaurielloJ , ParkerK , HammondR , RowlandL , BogenschutzM , et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology2003;28(3):527-9. [CSZG: 18501]LaurielloJ , BustilloJ , HammondR , BogenshutzM , KeithSJ . Treatment of weight-gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Schizophrenia Research2001;49(1-2):236. [CSZG: 9530]">Bustillo 2003</a>; <a href="./references#CD013337-bbs2-0035" title='BaptistaT , CarrizoE , FernandezV , SandiaI , ConnellL , PrietoD , et al. Metformin for body weight and metabolic control in patients with schizophrenia during long-term clozapine administration. In: 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA. 2009. [CSZG: 19068]BaptistaTJ , FernandezE , CarrizoE , FernandezV , SandiaI , PrietoD , et al. Polimorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. In: 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA. 2010. [CSZG: 21597]CarrizoE , FernandezV , ConnellL , SandiaI , PrietoD , MogollonJ , et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophrenia Research2009;113(1):19-26. [CSZG: 18699]CarrizoE , FernandezV , SandiaI , PrietoD , MogollonJ , ConnelL , et al. Corrigendum to "Extended release metfomin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study" Schizophr. Res. 113 (1) (2009) 19-26 (DOI:10.1016/j.schres.2009.05.007). Schizophrenia Research2009;115(1):96. [CSZG: 19023]FernandezE , CarrizoE , FernandezV , ConnellL , SandiaI , PrietoD , et al. Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. Schizophrenia Research2010;121(1-3):213-7. [CSZG: 20827]'>Carrizo 2009</a>; <a href="./references#CD013337-bbs2-0036" title="ChangJS , LeeNY , AhnYM , KimYS . The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic systems and metabolic profiles of patients with refractory schizophrenia. Journal of Clinical Psychopharmacology2012;32(2):282-4. ">Chang 2012</a>; <a href="./references#CD013337-bbs2-0037" title="ChenJX , WuSY , LinR , ChenHE . Metformin combined behavioral intervention therapy of clozapine in the treatment of schizophrenia in patients with body weight, blood glucose, blood lipids. Sichuan Mental Health2010;23(04):198-202. ">Chen 2010</a>; <a href="./references#CD013337-bbs2-0038" title="ChenCH , HuangMC , KaoCF , LinSK , KuoPH , ChiuCC , et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2013;74:e424-30. [CSZG: 28657]NCT01300637. Effects of adjunctive metformin on metabolic profiles in clozapine-treated schizophrenic patients. https://clinicaltrials.gov/ct2/show/NCT01300637 (first received 21 February 2011). [CSZG: 22667]">Chen 2013</a>; <a href="./references#CD013337-bbs2-0039" title="ChenPY , LuML , HuangMC , KaoCF , KuoPH , ChiuCC , et al. The relationships of obesity-related genetic variants with metabolic profiles and response to metformin in clozapine-treated patients with schizophrenia. Journal of Clinical Psychopharmacology2015;35(5):574-8. ">Chen 2015</a>; <a href="./references#CD013337-bbs2-0040" title="ChiuCC , LuML , HuangMC , ChenPY , LinYK , LinSK , et al. Effects of low dose metformin on metabolic traits in clozapine-treated schizophrenia patients: an exploratory twelve-week randomized, double-blind, placebo-controlled study. PloS One2016;11(12):e0168347. NCT02751307. Adjunctive low-dose metformin in patients with schizophrenia and metabolic abnormalities. https://clinicaltrials.gov/ct2/show/NCT02751307 (first received 26 April 2016). ">Chiu 2016</a>; <a href="./references#CD013337-bbs2-0043" title="CorrellCU , SikichL , ReevesG , JohnsonJ , KeetonC , SpanosM , et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry2020;19(1):69-80. ">Correll 2020b</a>; <a href="./references#CD013337-bbs2-0045" title="DaiS , ZhuL , XiaoY . The effects of metformin on obesity, glucose and lipid metabolism caused by antipsychotic drugs in schizophrenia patients [Er jiǎ shuāng guā duì kàng jīng shén bìng yào suǒ zhì jīng shén fēn liè zhèng huàn zhě féi pàng jí táng zhī dài xiè de yǐng xiǎng]. Cháng Zhì Yī Xué Yuàn Xué Bào2014;24(6):409-10. ">Dai 2014</a>; <a href="./references#CD013337-bbs2-0046" title="DanilovDS . The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova2014;114(3):34-40. ">Danilov 2014</a>; <a href="./references#CD013337-bbs2-0047" title='DeberdtW , CavazzoniPA , TrzaskomaQ , BymasterFP , WinokurA , FlorisM , et al. Amantadine for weight gain in olanzapine-treated patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9779]DeberdtW , TrzaskomaQ , CarlsonC , BymasterF , WinokurA , FlorisM . Amantadine for weight gain in olanzapine-treated patients. In: Thematic conference of the World Psychiatric Association on "Treatments in psychiatry: an update"; 2004 Nov 10-13; Florence, Italy. 2004. [CSZG: 17055]DeberdtW , TrzaskomaQ , CarlsonC , BymasterF , WinokurA , FlorisM . Amantadine for weight gain in olanzapine-treated patients. Schizophrenia Research2004;67(1):182. [CSZG: 11293]DeberdtW , WinokurA , CavazzoniPA , TrzaskomaQN , CarlsonCD , BymasterFP , et al. Amantadine for weight gain associated with olanzapine treatment. European Neuropsychopharmacology2005;15(1):13-21. [CSZG: 11432]'>Deberdt 2005</a>; <a href="./references#CD013337-bbs2-0049" title="Anonymous. Corrigendum. Journal of Psychopharmacology (Oxford, England)2017;31(4):515. deSilvaVA , DayabandaraM , WijesundaraH , HenegamaT , GunewardenaH , SuraweeraC , et al. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: a double blind, randomized, placebo controlled study. Journal of Psychopharmacology (Oxford, England)2015;29(12):1255-61. PintoEF , GeorgeB , KariaS , AndradeC . Metformin for antipsychotic-induced weight gain: statistical curiosities. Journal of Psychopharmacology (Oxford, England)2017;31(4):514. ">de Silva 2015</a>; <a href="./references#CD013337-bbs2-0050" title="DeutschS , SchwartzB , RosseR , MastropaoloJ , MarvelC , DrapalskiA . Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clinical Neuropharmacology2003;26(4):199-206. ">Deutsch 2003</a>; <a href="./references#CD013337-bbs2-0051" title="DingG , YuG , ZhangJ , LiangS , LiuL , HuangP , et al. The therapeutic effects of ling gui zhu gan tang mixture in 50 psychotic patients with obesity induced by the psychoactive drugs. Journal of Traditional Chinese Medicine / Chung i Tsa Chih Ying Wen Pan2005;25(1):25-8. ">Ding 2005</a>; <a href="./references#CD013337-bbs2-0053" title="ErikssonR , BrobergBV , IshoyPL , BakN , AndersenUB , JorgensenNR , et al. Effects of the glucagon-like peptide-1 receptor agonist exenatide on bone status in obese, non-diabetic, antipsychotic-treated schizophrenia spectrum patients. Schizophrenia Bulletin2019;45 Suppl 2:S198-9. ">Eriksson 2019</a>; <a href="./references#CD013337-bbs2-0054" title="FadaiF , MousaviB , BeigiN , FarhangS , HashempourS , ShahhameiN , et al. Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study. Pharmacopsychiatry2014;47:156-61. [CSZG: 29063]">Fadai 2014</a>; <a href="./references#CD013337-bbs2-0056" title="FanX , BorbaCP , CopelandP , HaydenD , FreudenreichO , GoffDC , et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatrica Scandinavica2013;127(3):217-26. [CSZG: 28759]NCT00345033. Aripiprazole for clozapine associated medical morbidity. https://clinicaltrials.gov/ct2/show/NCT00345033 (first received 27 June 2006). [CSZG: 14696]">Fan 2013</a>; <a href="./references#CD013337-bbs2-0057" title="CTRI/2013/02/003397. Efficacy of aripiprazole adjunctive treatment on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with clozapine. A randomized, double-blind, placebo-controlled trial. https://trialsearch.who.int/?TrialID=CTRI/2013/02/003397 (first received 14 February 2013). [CSZG: 28076]FleischhackerW , HeikkinenME , OlieJP , DewaeleP , McQuadeR , HennickenD , et al. Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine. European Neuropsychopharmacology2008;18:S447. [CSZG: 17328]FleischhackerWW , HeikkinenME , OlieJP , DewaeleP , McQuadeR , HennickenD , et al. Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response to clozapine. World Psychiatry2009;8 Suppl 1:PO1.31. FleischhackerWW , HeikkinenME , OlieJP , LandsbergW , DewaeleP , McQuadeR , et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. European Psychiatry2008;23 Suppl 2:S114-S5. [CSZG: 19932]FleischhackerWW , HeikkinenME , Olie J-P, LandsbergW , DewaeleP , McQuadeRD , et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2010;13(8):1115-25. [CSZG: 21393]NCT00300846. A multicenter, comparative, randomized, double-blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00300846 (first recieved 10 March 2006). [CSZG: 14603]">Fleischhacker 2010</a>; <a href="./references#CD013337-bbs2-0058" title="GhanizadehA , NiksereshtMS , SahraianA . The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophrenia Research2013;147:110-5. ">Ghanizadeh 2013</a>; <a href="./references#CD013337-bbs2-0059" title="GoodallE , OxtobyC , RichardsR , WatkinsonG , BrownD , SilverstoneT . A clinical trial of the efficacy and acceptability of D-fenluramine in the treatment on neuroleptic-induced obesity. British Journal of Psychiatry1988;153:208-13. ">Goodall 1988</a>; <a href="./references#CD013337-bbs2-0060" title="GrahamKA , GuH , LiebermanJA , HarpJB , PerkinsDO . Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. American Journal of Psychiatry2005;162(9):1744-6. [CSZG: 12392]GrahamKA , PerkinsDO , GuH , LiebermanJ , HarpJ . Double blind placebo controlled investigation of amantadine for weight loss in subjects who have gained weight during treatment with olanzapine. Schizophrenia Research2004;67(1):184. [CSZG: 11296]NCT00287352. Double blind placebo controlled investigation of amantadine for retarding weight gain in first episode adult psychotic subjects beginning therapy with olanzapine. https://clinicaltrials.gov/ct2/show/NCT00287352 (first received 6 February 2006). [CSZG: 27923]">Graham 2005</a>; <a href="./references#CD013337-bbs2-0062" title="HebraniP , ManteghiA , BehdaniF , HessamiE , RezayatK , MarvastM , et al. Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. Journal of Research in Medical Sciences2014;20(4):364-71. [CSZG: 29861]">Hebrani 2015</a>; <a href="./references#CD013337-bbs2-0063" title="HeikkinenH , OutakoskiJ , MerilaeinenV , TuomiA , HuttunenMO . Molindone and weight loss. Journal of Clinical Psychiatry1993;54(4):160-1. ">Heikkinen 1993</a>; <a href="./references#CD013337-bbs2-0064" title="HendersonDC , CopelandPM , DaleyTB , BorbaCP , CatherC , NguyenDD , et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. American Journal of Psychiatry2005;162(5):954-62. [CSZG: 11470]HendersonDC , DaleyTB , LouieP . A placebo-controlled trial of sibutramine added to patients with olanzapine-induced weight gain. World Journal of Biological Psychiatry2004;5 Suppl 1:152. [CSZG: 18867]HendersonDC , NguyenD , DaleyTB , LouieP , BurbaC , CopelandP . Double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. In: 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA. 2004. [CSZG: 10884]">Henderson 2005a</a>; <a href="./references#CD013337-bbs2-0065" title="HendersonDC , FanX , CopelandPM , BorbaCP , DaleyTB , NguyenDD , et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatrica Scandinavica2007;115(2):101-5. [CSZG: 14460]">Henderson 2007</a>; <a href="./references#CD013337-bbs2-0066" title="HendersonDC , FanX , SharmaB , CopelandPM , BorbaCP , BoxillR , et al. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatrica Scandinavica2009;119:457-65. [DOI: 10.1111/j.1600-0447.2008.01325.x]NCT00337350. A double-blind, placebo-controlled trial of rosiglitazone for clozapine induced glucose metabolism impairment: Bergman's minimal model analysis. https://clinicaltrials.gov/ct2/show/NCT00337350 (first received 15 June 2006). ">Henderson 2009a</a>; <a href="./references#CD013337-bbs2-0068" title="HendersonDC , FreudenreichO , BorbaCP , WangX , CopelandPM , MacklinE , et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophrenia Research2011;130(1-3):53-6. [CSZG: 23071] [PMID: 21565464]">Henderson 2011</a>; <a href="./references#CD013337-bbs2-0070" title="Holka-PokorskaJ , RadzioR , JaremaM , WichniakA . The stabilizing effect of dehydroepiandosterone on clinical paramters of metabolic syndrome in patients with schizophrenia treated with olanzapine- a randomized, double-blind trial. Psychiatriapolska2015;49(2):363-76. [CSZG: 29862]">Holka‐Pokorska 2015</a>; <a href="./references#CD013337-bbs2-0071" title="Hu X，OuyangZ . Efficacy of metformin on serum homocysteine level in schizophrenia patients with olanzapine － induced weight gain [Er jiǎ shuāng guā duì ào dàn píng zhì tǐ zhì liáng zēng jiā de jīng shén fēn liè zhèng huàn zhě xuè qīng tóng xíng bàn guāng ān suān shuǐ píng de yǐng xiǎng]. China Journal of Health Psychology2013;21(11):1610-11. ">Hu 2013</a>; <a href="./references#CD013337-bbs2-0072" title="IRCT20191223045870N1. Betahistine and weight- related and metabolic measures in schizophrenic patients treated with olanzapin or risperidone. https://www.irct.ir/trial/44644 (first received 13 March 2020). ">IRCT20191223045870N1</a>; <a href="./references#CD013337-bbs2-0073" title="EbdrupBH , BrobergBV , IshoyPL , BakN , AndersenUB , JorgensenNR , et al. Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism2018;20(5):1327-8. ErikssonR , BrobergBV , IshoyPL , BakN , AndersenUB , JorgensenNR , et al. Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density. Frontiers in Psychiatry2018;9:781. ErikssonR , BrobergBV , Lau IshoyP , BakN , AndersenUB , JorgensenNR , et al. Effects of the glucagon-like peptide-1 receptor agonist exenatide on bone status in obese, non-diabetic, antipsychotic-treated schizophrenia spectrum patients. Schizophrenia Bulletin2019;45:S198-9. IshoyPL , FagerlundB , BrobergBV , BakN , KnopFK , GlenthojBY , et al. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatrica Scandinavica2017;136(1):52-62. IshoyPL , FagerlundB , BrobergBV , BakN , KnopFK , GlenthojBY , et al. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotictreated, obese patients with schizophrenia. Dansk Psykiatrisk Selskabs Arsmode; 2-4 February 2017; Kolding, Denmark2017. IshoyPL , KnopFK , BrobergBV , BaandrupL , FagerlundB , JorgensenNR , et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open2014;4(1):e004158. IshoyPL , KnopFK , BrobergBV , BakN , AndersenUB , JorgensenNR , et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Dansk Psykiatrisk Selskabs Arsmode; 2-4 February 2017; Kolding, Denmark2017. IshoyPL , KnopFK , BrobergBV , BakN , AndersenUB , JorgensenNR , et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism2017;19(2):162-71. IshoyPL , KnopFK , BrobergBV , BakN , AndersenUB , JorgensenNR , et al. GLP-1 receptor agonist treatment in schizophrenia patients with obesity. Schizophrenia Bulletin2017;43:S168. IshoyPL , KnopFK , BrobergBV , BakN , AndersenUB , JorgensenNR , et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist: an investigator initiated prospective, randomized, placebo-controlled, double-blinded intervention study (the TAO study). Neuropsychopharmacology2016;41:S402. NCT01794429. Treatment of antipsychotic-associated obesity with a GLP-1 analogue. https://clinicaltrials.gov/ct2/show/NCT01794429 (first received 18 February 2013). ">Ishoy 2017</a>; <a href="./references#CD013337-bbs2-0074" title="JamilianH , ShayganfardM . The effects of topiramate on weight gain in patients with schizophrenia: a double-blind randomized placebo-controlled clinical trial. Journal of Pioneering Medical Sciences2018;8(2):55-9. ">Jamilian 2018</a>; <a href="./references#CD013337-bbs2-0075" title="BallonJS , HamerRM , CatellierDJ , StewartD , LavangeL , GoldenL , et al. Metformin and impaired glucose tolerance in overweight persons with schizophrenia. Schizophrenia Bulletin2011;37 Suppl 1:24. [CSZG: 22829]JarskogLF , HamerRM , CatellierDJ , StewartDD , LavangeL , RayN , et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. American Journal of Psychiatry2013;170(9):1032-40. [CSZG: 28631]LiebermanJ , JarskogLF , HamerR , CatellierD , StewartD , LaVangeL , et al. Metformin for obesity and metabolic abnormalities in schizophrenia. In: 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida. 2010. [CSZG: 23686]LiebermanJ , JarskogLF , HamerR , CatellierD , StewartD , LaVangeL , et al. Metformin for obesity and metabolic abnormalities in schizophrenia. Neuropsychopharmacology2010;35:S225-S6. [CSZG: 24447]NCT00816907. The use of metformin in the treatment of antipsychotic-induced weight gain in schizophrenia (The METS Study). https://clinicaltrials.gov/ct2/show/NCT00816907 (first received 5 January 2009). [CSZG: 17385]StroupS . Effect of metformin on weight in patients with schizophrenia with impaired fasting glucose. Neuropsychopharmacology2013;38:S41. [CSZG: 28468]">Jarskog 2013</a>; <a href="./references#CD013337-bbs2-0076" title="JarskogL , StroupTS . Metformin and 5-HT2C agonist lorcaserin for weight loss in schizophrenia. Biological Psychiatry2018;83(9 Suppl 1):S105-6. NCT02796144. Metformin and lorcaserin for weight loss in schizophrenia. https://clinicaltrials.gov/. ">Jarskog 2018</a>; <a href="./references#CD013337-bbs2-0077" title="JiangYW , JiangWH , MaLH , ZhangTX , HanJJ , LiL . Efficacy of behavioral intervention adjunctive to rosuvastatin for antipsychotic-induced metabolic syndrome. Chinese Journal of Psychiatry2017;50:295-301. ">Jiang 2017</a>; <a href="./references#CD013337-bbs2-0078" title="ChukhinE , TakalaP , HakkoH , RaidmaM , PutkonenH , RasanenP , et al. In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation. International Clinical Psychopharmacology2013;28(2):67-70. [CSZG: 28739]ISRCTN65731856. Orlistat therapy in clozapine- and olanzapine-treated patients who are overweight or obese. https://www.isrctn.com/ISRCTN65731856 (first received 25 May 2006). [CSZG: 15377]JoffeG , RasaoeoPK . A double-blind, placebo controlled, randomized, 16-week trial of orlistat in the prevention and management of clozapine and olanzapine-induced weight gain in 80 patients with psychotic. Stanley Foundation Research Programs2002. JoffeG , TakalaP , TchoukhineE , HakkoH , RaidmaM , PutkonenH , et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2008;69(5):706-11. [CSZG: 16446]TchoukhineE , TakalaP , HakkoH , RaidmaM , PutkonenH , RasanenP , et al. Orlistat in clozapine- or olanzapine- treated patients with overweight or obesity: a 16-week open label extension phase and both phases of a randomized controlled trial. Journal of Clinical Psychiatry2011;72(3):326-30. [CSZG: 22994] [ISRCTN65731856]">Joffe 2008</a>; <a href="./references#CD013337-bbs2-0079" title="KangD , JingZ , LiR , HeiG , ShaoT , LiL , et al. Effect of betahistine and metformin on antipsychotic-induced weight gain: an analysis of two clinical trials. Frontiers in Psychiatry2018;9:620. MaayanL . Betahistine for schizophrenia. Stanley Foundation Research Programs2009. NCT00709202. To examine the effect of betahistine on antipsychotic induced weight gain in adolescents. https://clinicaltrials.gov/ct2/show/NCT00709202 (first received 3 July 2008). Vaz-LealFJ . Metformin plus a lifestyle intervention was more effective than either alone for antipsychotic-induced weight gain: commentary. Evidence-Based Medicine2008;13(5):146. WuRR , JinH , GaoK , ShaoP , ChanPK , OuJJO , et al. Metformin for treatment of atypical antipsychotic-induced weight gain and endocrinological side effects in patients with first episode schizophrenia: results from randomized, double blind, placebo-controlled study. Schizophrenia Research2012;136:S77. Wu R-R, Zhao J-P, JinH , ShaoP , Fang M-S, Guo X-F, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA2008;299(2):185-93. ZhuY , WangY , WangB . Efficacy of behavioral intervention therapy and metformin in the treatment of atypical antipsychotics-induced metabolic syndrome. Archives of Psychiatry2009;22(3):195-7. [CSZG: 19242]">Kang 2018</a>; <a href="./references#CD013337-bbs2-0080" title="KellyDL , GorelickDA , ConleyRR , BoggsDL , LinthicumJ , LiuF , et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia. Journal of Clinical Psychopharmacology2011;31(1):86-90. [CSZG: 22623] [DOI: 10.1097/JCP.0b013e318204825b]">Kelly 2011</a>; <a href="./references#CD013337-bbs2-0081" title="KhanMF , HaqSU , MuradK , NazarZ . Effect of metformin in reduction of anti-psychotic medication induced weight gain in schizophrenia. Journal of Postgraduate Medical Institute2020;34(1):41-4. ">Khan 2020</a>; <a href="./references#CD013337-bbs2-0082" title="KimSI , SungYM , PaikKW , YunKW , KimYC , LimW . The efficacy of topiramate for weight loss and psychiatric symptom severity in overweight or obese patients maintained on atypical antipsychotics. In: 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA. 2007. ">Kim 2007</a>; <a href="./references#CD013337-bbs2-0083" title="KimNW , SongYM , KimE , ChoHS , CheonKA , KimSJ , et al. Adjunctive alpha-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study. International Clinical Psychopharmacology2016;31(5):265-74. ">Kim 2016</a>; <a href="./references#CD013337-bbs2-0085" title="KleinDJ . Metformin treatment of weight gain associated with antipsychotic drug therapy. International Journal of Neuropsychopharmacology2008;11 Suppl 1:32. ">Klein 2008</a>; <a href="./references#CD013337-bbs2-0086" title="KoYH , JoeSH , JungIK , KimSH . Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clinical Neuropharmacology2005;28(4):169-75. [CSZG: 18128]">Ko 2005</a>; <a href="./references#CD013337-bbs2-0087" title="KwonJS , Choi J-S, Bahk W-M, KimCY , KimCH , ShinYC , et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry2006;67(4):547-53. NCT00485823. Assessment of a weight management program for weight gain in patients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00485823 (first received 13 June 2007). NCT00485823. The assessment of a weight management program for treatment-emergent weight gain in patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder during olanzapine therapy. https://clinicaltrials.gov/ct2/show/NCT00485823 (first received 13 June 2007). ">Kwon 2006</a>; <a href="./references#CD013337-bbs2-0088" title="LarsenJR , VedtofteL , HolstJJ , OturaiP , KjaerA , CorellCU , et al. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open2014;4(3):e004227. LarsenJR , VedtofteL , JakobsenMS , JespersenHR , JakobsenMI , SvenssonCK , et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry2017;74(7):719-28. SvenssonCK , LarsenJR , VedtofteL , JakobsenMS , JespersenHR , JakobsenMI , et al. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatrica Scandinavica2019;139(1):26-36. VedtofteL , LarsenJR , JakobsenMS , JespersenHR , JakobsenMI , SvenssonCK , et al. The GLP-1 analog liraglutide improves glucose tolerance and reduces body weight in schizophrenia spectrum disorder patients treated with clozapine or olanzapine. Diabetes2017;66 Suppl 1:A33-4. ">Larsen 2017</a>; <a href="./references#CD013337-bbs2-0089" title="LiJ , LiX , LiuE , CopelandP , FreudenreichO , GoffDC , et al. No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. Schizophrenia Research2013;146(1-3):40-5. [CSZG: 28091]NCT00575666. Intranasal insulin treatment in patients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00575666 (first received 18 December 2007). [CSZG: 15650]">Li 2013</a>; <a href="./references#CD013337-bbs2-0090" title="ChiCTR1900024422. Effects and mechanism of T-cell subgroup imbalance on antipsychotic drug-induced obesity. http://www.chictr.org.cn/showprojen.aspx?proj=34285 (first received 7 October 2017). LiX , YuanX , KangY , PangL , LiuY , ZhuQ , et al. A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: a randomized controlled trial. Journal of Psychiatric Research2020;126:81-91. ">Li 2020</a>; <a href="./references#CD013337-bbs2-0091" title="Liú JB, WúJH . Chlorpromazine, clozapine, risperidone on glucose metabolism in patients with first-episode schizophrenia, the effects of blood lipids and weight [Dàn píng lì péi tóng duì shǒu fā jīng shén fēn liè zhèng huàn zhě táng dài xiè xuè zhī hé tǐ zhòng de yǐng xiǎng]. Chinese Journal of Nervous and Mental Diseases2004;30(4):293-5. ">Liu 2004</a>; <a href="./references#CD013337-bbs2-0092" title="Lu M-L, Lane H-Y, Lin S-K, Chen K-P, Chang W-H. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Journal of Clinical Psychiatry2004;65(6):766-71. ">Lu 2004</a>; <a href="./references#CD013337-bbs2-0093" title="LyuX , DuJ , ZhanG , WuY , SuH , ZhuY , et al. Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Frontiers in Pharmacology2018;9:181. NCT02736474. Naltrexone and bupropion combination on obese, smoking patients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT02736474 (first received 13 April 2016). ">Lyu 2018</a>; <a href="./references#CD013337-bbs2-0094" title="LarsenJR , VedtofteL , JakobsenMS , JespersenHR , JakobsenMI , SvenssonCK , et al. The GLP-1 analog liraglutide improves glucose tolerance and reduces body weight in schizophrenia spectrum disorder patients treated with clozapine or olanzapine. Acta Neuropsychiatrica2017;29:12-3. MaagensenH , LarsenJR , JorgensenNR , Fink-JensenA , VilsbollT . Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial. Psychiatry Research2021;296:113670. ">Maagensen 2021</a>; <a href="./references#CD013337-bbs2-0095" title="MartinWF , CorrellCU , WeidenPJ , JiangY , PathakS , DiPetrilloL , et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. American Journal of Psychiatry2019;176(6):457-67. ">Martin 2019</a>; <a href="./references#CD013337-bbs2-0097" title="CTRI-2014-07-004740. Efficacy of ranitidine in olanzapine induced weight gain: a dose response study. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=7044&amp;EncHid=&amp;modid=&amp;compid=%27,%277044det%27 (first received 15 July 2014). MehtaVS , RamD . Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study. Early Intervention in Psychiatry2014;10(6):522-7. MehtaVS , RamD . Role of ranitidine in negative symptoms of schizophrenia--an open label study. Asian Journal of Psychiatry2014;12:150-4. ">Mehta 2014</a>; <a href="./references#CD013337-bbs2-0098" title="ModellW , HussarAE . Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients. Journal of American Medical Assosiation1965;193(4):95-8. [CSZG: 11096]">Modell 1965</a>; <a href="./references#CD013337-bbs2-0099" title="MillarH , FelterC , LandsbergW . The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170). Journal of Psychopharmacology (Oxford, England)2008;22(5):A17. MuscatelloMR , BrunoA , PandolfoG , MicoU , ScimecaG , Di NardoF , et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophrenia Research2011;123(1-3):93-9. [DOI: 10.1016/j.schres.2010.12.011]">Muscatello 2011a</a>; <a href="./references#CD013337-bbs2-0100" title="MuscatelloMR , BrunoA , MicoU , BellinghieriPM , ScimecaG , CacciolaM , et al. Topiramate augumentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Journal of Psychopharmacology2011;25(5):667-74. [DOI: 10.1177/0269881110372548]">Muscatello 2011b</a>; <a href="./references#CD013337-bbs2-0101" title="NCT00044187. The assessment of sibutramine for the treatment of olanzapine-associated weight gain in subjects with schizophrenia, schizophreniform disorder, schizoaffective disorder, and bipolar I disorder. https://clinicaltrials.gov/ct2/show/NCT00044187 (first received 23 August 2002). ">NCT00044187</a>; <a href="./references#CD013337-bbs2-0102" title="NCT00114595. A double-blind, randomised, parallel-group comparison of ethyl-eicosapentaenoic acid (ethyl-epa) versus placebo as add-on medication in patients with established tardive dyskinesia. https://clinicaltrials.gov/show/NCT00114595 (first received 23 June 2005). ">NCT00114595</a>; <a href="./references#CD013337-bbs2-0103" title="NCT00320723. Nicotine replacement therapy added to cognitive behavioral therapy for smoking cessation in patients with major mental illness. https://clinicaltrials.gov/show/NCT00320723 (first received 3 May 2006). ">NCT00320723</a>; <a href="./references#CD013337-bbs2-0105" title="NCT00512070. Melatonin metabolism abnormality in patients with schizophrenia or schizoaffective disorder treated with olanzapine and melatonin dose finding for the correction of the metabolic abnormality. https://clinicaltrials.gov/show/NCT00512070 (first received 7 August 2007). ">NCT00512070</a>; <a href="./references#CD013337-bbs2-0106" title="NCT00672464. Cardio risk of acute schizophrenia olanzapine Duke (CRASOD). https://clinicaltrials.gov/show/NCT00672464 (first received 5 May 2008). ">NCT00672464</a>; <a href="./references#CD013337-bbs2-0107" title="NCT01491490. A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003:GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated with olanzapine or other antipsychotic(s) treatment in subjects with schizophrenia or other non-affective psychosis. https://clinicaltrials.gov/ct2/show/NCT01491490 (first received 14 December 2011). ">NCT01491490</a>; <a href="./references#CD013337-bbs2-0108" title="NCT03132571. A pilot study of naltrexone – bupropion combination versus placebo combined with bupropion for weight loss in comorbid schizophrenia. https://clinicaltrials.gov/ct2/show/NCT03132571 (first received 28 April 2017). ">NCT03132571</a>; <a href="./references#CD013337-bbs2-0109" title="PengPJ , HoPS , TsaiCK , HuangSY , LiangCS . A pilot study of randomized, head-to-head of metformin versus topiramate in obese people with schizophrenia. Clinical Neuropharmacology2016;39(6):306-10. ">Peng 2016</a>; <a href="./references#CD013337-bbs2-0110" title="PierreJM , PeloianJH , WirshingDA , WirshingWC , MarderSR . A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. Journal of Clinical Psychiatry2007;68(5):705-10. ">Pierre 2007</a>; <a href="./references#CD013337-bbs2-0111" title="PanQ , ChenF , OuyangH . Metformin addition therapy attenuates serum levels of leptin in schizophrenia with olanzapine-induced weight gain [èr jiǎ shuāng guā duì ào dàn píng zhì tǐ zhòng zēng jiā de jīng shén fēn liè zhèng huàn zhě xuè qīng shòu sù shuǐ píng de yǐng xiǎng]. China Journal of Health Psychology2014;22(6):826-8. ">Qi 2014</a>; <a href="./references#CD013337-bbs2-0112" title="RadulovicL , WeidenPJ , AllisonDB , CamilleC . Sibutramine treatment of obesity in schizophrenia. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. ">Radulovic 2002</a>; <a href="./references#CD013337-bbs2-0113" title="RanjbarF , GhanepourA , Sadeghi-BazarganiH , AsadloM , AlizadehA . The effect of ranitidine on olanzapine-induced weight gain. Biomedical Research International2013;2013:639391. ">Ranjbar 2013</a>; <a href="./references#CD013337-bbs2-0114" title="ReevesGM , KeetonC , CorrellCU , JohnsonJL , HamerRM , SikichL , et al. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child and Adolescent Psychiatry and Mental Health2013;7(1):31. ">Reeves 2013</a>; <a href="./references#CD013337-bbs2-0115" title="DavidM , SimmonsA , JiangY , GrahamC , SilvermanB . A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophrenia, schizophreniform, or bipolar I disorder. European Neuropsychopharmacology2017;27 Suppl 4:S954. EUCTR2017-000497-11-AT. Study to evaluate the efficacy of ALKS 3831 on body weight in young adults who have been recently diagnosed with schizophrenia, schizophreniform or bipolar I disorder. https://www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2017-000497-11-AT (first received 2017). NCT03187769. Study to evaluate the efficacy of ALKS 3831 on body weight in young adults who have been recently diagnosed with schizophrenia, schizophreniform, or bipolar I disorder. https://clinicaltrials.gov/ct2/show/NCT03187769 (first received 15 June 2017). SimmonsA , McDonnellD , JiangY , GrahamC , SilvermanB . A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophreniform, schizophrenia, or bipolar I disorder. Schizophrenia Bulletin2018;44 Suppl 1:S413-4. ">Simmons 2018</a>; <a href="./references#CD013337-bbs2-0116" title="ACTRN12615000524594. A pilot study on the effect of once weekly exenatide compared to treatment as usual for weight loss and glycaemic control in schizophrenia patients with obesity and diabetes. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368512 (first received 9 May 2015). MayfieldK , SiskindD , WinckelK , HollingworthS , KiselyS , RussellAW . Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. BJ Psych Open2015;1(1):67-73. SiskindD , RussellA , GambleC , WinckelK , HollingworthS , KiselyS . RCT of exenatide for clozapine-associated obesity. Schizophrenia Bulletin2017;43:S130. SiskindD , RussellA , GambleC , WinckelK , HollingworthS , KiselyS . Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial. Schizophrenia Bulletin2018;44 Suppl 1:S178. SiskindD . Treatment of clozapine-associated obesity and diabetes with exenatide (codex) in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51 Suppl 1:68. SiskindDJ , RussellAW , GambleC , WinckelK , MayfieldK , HollingworthS , et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes, Obesity and Metabolism2018;20(4):1050-5. ">Siskind 2018</a>; <a href="./references#CD013337-bbs2-0117" title="SiskindD , RussellA , GambleC , BakerA , CosgroveP , BurtonL , et al. Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX). Journal of Psychiatric Research2020;124:9-12. SiskindD , RussellA , KiselyS . 12-month follow up of metabolic measures following a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (Codex). Schizophrenia Bulletin2020;46:S248. ">Siskind 2020</a>; <a href="./references#CD013337-bbs2-0118" title="SmithRC , JinH , LiC , BarkN , ShekharA , DwivediS , et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophrenia Research2013;143(1):18-24. ">Smith 2013</a>; <a href="./references#CD013337-bbs2-0119" title="SmithRC , MaayanL , WuR , YoussefM , JingZ , SershenH , et al. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology2018;235(12):3545-58. ">Smith 2018</a>; <a href="./references#CD013337-bbs2-0120" title="StrousRD , StryjerR , MaayanR , GalG , ViglinD , KatzE , et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology2007;32(2):96-105. [PMID: 17208382]">Strous 2007</a>; <a href="./references#CD013337-bbs2-0121" title="SulejmanpasicG , BiseS , PepicF , ToskicA . Adjunctive treatment of aripiprazole to olanzapine for weight reduction in patients with schizophrenia. European Neuropsychopharmacology2019;29:S90. SulejmanpasicG , BiseS , ToskicA , PepicF . Olanzapine augmented with aripiprazole in treatment-resistant schizophrenia. European Neuropsychopharmacology2019;29:S89-S90. ">Sulejmanpasic 2019</a>; <a href="./references#CD013337-bbs2-0122" title="TalaeiA , FaridhosseiniF , KazemiH , Fayyazi BordbarMR , Rezaei ArdaniA . Effect of topiramate on drug associated weight gain of patients with schizophrenia and bipolar I disorders: a dose ranging randomized trial. Turkish Journal of Psychiatry [Turk psikiyatri dergisi]2016;27(2):84-91. ">Talaei 2016</a>; <a href="./references#CD013337-bbs2-0123" title="TavakoliE , RezaeiO , FadaiF . A comparison on composition of celery, dill and green tea as three medicinal plants with placebo to treat schizophrenic patients' metabolic syndrome. Afinidad2014;80(573):1118-23. ">Tavakoli 2014</a>; <a href="./references#CD013337-bbs2-0124" title="TaveiraTH , WuWC , TschibeluE , BorsookD , SimonsonDC , YamamotoR , et al. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. Journal of Psychopharmacology (Oxford, England)2014;28(4):395-400. ">Taveira 2014</a>; <a href="./references#CD013337-bbs2-0125" title="TekC , RatliffJ , ReutenauerE , GanguliR , O'MalleySS . A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. Journal of Clinical Psychopharmacology2014;34(5):608-12. TekC , RatliffJC , ReutenauerEL , PalmeseLB , TonizzoKM , O'MalleySS . Low-dose naltrexone for antipsychotic-induced weight gain in women with schizophrenia. Obesity2011;19 Suppl 1:S181. TekC , RatliffJC , ReutenauerEL , PalmeseLB , TonizzoKM , O'MalleySS . Naltrexone for antipsychotic-induced weight gain in women with schizophrenia. Biological Psychiatry2011;69(9 Suppl):283. ">Tek 2014</a>; <a href="./references#CD013337-bbs2-0126" title="TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia [Dissertation]. Helsinki, Finland: Medical Faculty of the University of Helsinki, 2013. ">Terevnikov 2013</a>; <a href="./references#CD013337-bbs2-0127" title="TiihonenJ , HalonenP , WahlbeckK , Repo-TiihonenE , HyvarinenS , EronenM , et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychiatry2005;66(8):1012-15. ">Tiihonen 2005</a>; <a href="./references#CD013337-bbs2-0128" title="WangXL . Metformin with life style intervention in treatment of clozapine - induced metabolic disorders. Chinese General Practice2009;12(5B):840-2. ">Wang 2009</a>; <a href="./references#CD013337-bbs2-0129" title="WangSS , WangCF , ZhangK , CaoCB , GuDH , YuZH . Propofol and etomidate mect combined low-dose aripiprazole in the treatment of schizophrenia control study of 160 cases. Medical Journal of Chinese People's Health2010;22(3):252-5, 257. ">Wang 2010</a>; <a href="./references#CD013337-bbs2-0130" title="WangM , Tong J-h, ZhuG , Liang G-M, Yan H-f, Wang X-Z. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophrenia Research2012;138(1):54-7. [CSZG: 23834]">Wang 2012</a>; <a href="./references#CD013337-bbs2-0131" title="WangL , ChenY , SuiYC , TanXQ , ZhouZ , LiN , et al. Metformin attenuates liver fat content: finding from schizophrenia patients with olanzapine-induced weight gain. Clinical Psychopharmacology and Neuroscience2020;18(1):67-74. ">Wang 2020a</a>; <a href="./references#CD013337-bbs2-0133" title="WeberM , WyneK . A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research2006;83(1):95-101. ">Weber 2006</a>; <a href="./references#CD013337-bbs2-0134" title="WeinerE , BallMP , BuchholzBA , GoldJM , EvinsAE , McMahonRP , et al. Buproprion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. Journal of Clinical Psychiatry2012;73(1):95-101. [NCT00176449]">Weiner 2012</a>; <a href="./references#CD013337-bbs2-0135" title="EUCTR2017-004064-35-GB. Liraglutide and the management of overweight and obesity in people with schizophrenia. https://www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2017-004064-35-GB (first received 2017). ISRCTN61129760. Liraglutide and the management of overweight and obesity in people with schizophrenia. https://www.isrctn.com/ISRCTN61129760 (first received 29 November 2017). WhicherCA , PriceHC , PhiriP , RathodS , Barnard-KellyK , NgiangaK , et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double-blind placebo-controlled trial. Diabetes, Obesity and Metabolism2021;26(6):1262-71. WhicherCA , PriceHC , PhiriP , RathodS , Barnard-KellyK , ReidyC , et al. Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial. Trials2019;20(1):633. WhicherCA , PriceHC , RathodS , PhiriP , BarnardK , ThorneK , et al. Trial design for 'liraglutide and the management of overweight and obesity in people with severe mental illness: A pilot study' in southern health NHS foundation trust. Diabetic Medicine2019;36 Suppl 1:51. ">Whicher 2021</a>; <a href="./references#CD013337-bbs2-0136" title="WuRR , JinH , GaoK , TwamleyEW , OuJJ , ShaoP , et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry2012;169(8):813-21. [CSZG: 24499]">Wu 2012</a>; <a href="./references#CD013337-bbs2-0137" title="YagciogluAE , AkdedeBB , TurgutTI , TumukluM , YaziciK , AlptekinK , et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry2005;66(1):63-72. ">Yagcioglu 2005</a>; <a href="./references#CD013337-bbs2-0138" title="Yoon B-H, Bahk W-M, BaeA , Kim M-K, Jon D-I, MinKJ . Effects of 3-months trial of zonisamide and weight management program in obese schizophrenic inpatients. International Journal of Neuropsychopharmacology2008;11 Suppl 1:150. ">Yoon 2008</a>); </p> </li> <li> <p>six studies study were non‐randomised studies or reviews (<a href="./references#CD013337-bbs2-0041" title="CorrellCU , ManuP , OlshanskiyV , NapolitanoB , KaneJM , MalhotraAK . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA2009;302(16):1765-73. ">Correll 2009</a>; <a href="./references#CD013337-bbs2-0042" title="CorrellCU , SikichL , ReevesG , RiddleM . Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?American Journal of Psychiatry2013;170(9):947-52. ">Correll 2013</a>; <a href="./references#CD013337-bbs2-0048" title="De HertM , KalnickaD , Van WinkelR , WampersM , HanssensL , Van EyckD , et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2006;67(12):1889-96. ">De Hert 2006</a>; <a href="./references#CD013337-bbs2-0061" title="HadleyS . Metformin for schizophrenia. Stanley Foundation Research Programs2009. ">Hadley 2009</a>; <a href="./references#CD013337-bbs2-0067" title="HendersonDC , FanX , CopelandPM , SharmaB , BorbaCP , BoxillR , et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology2009;29(2):165-9. NCT00351936. A placebo-controlled, cross-over trial of aripiprazole added to obese olanzapine-treated patients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00351936 (first received 13 July 2006). ">Henderson 2009b</a>; <a href="./references#CD013337-bbs2-0069" title="HoffmannV , CaseM , JacobsonJ . Algorithms including amantadine, metformin and zonisamide for mitigation of weight gain during olanzapine treatment in outpatients with schizophrenia. In: 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA. 2009. HoffmannVP , CaseM , JacobsonJG . Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. Journal of Clinical Psychiatry2012;73(2):216-23. NCT00401973. The assessment of the safety, efficacy, and practicality of an algorithm including amantadine, metformin and zonisamide for the prevention of olanzapine-associated weight gain in outpatients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00401973 (first received 22 November 2006). ">Hoffmann 2012</a>); </p> </li> <li> <p>four studies included an ineligible population (<a href="./references#CD013337-bbs2-0052" title="EggerC , MuehlbacherM , SchatzM , NickelM . Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. Journal of Clinical Psychopharmacology2007;5:475-8. ">Egger 2007</a>; <a href="./references#CD013337-bbs2-0055" title="FaghihiT , JahedA , Mahmoudi-GharaeiJ , SharifiV , AkhondzadehS , PadidehG . Role of omega-3-fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: A randomized double-blind placebo-controlled trial. DARU, Journal of Pharmaceutical Sciences2012;20:43. [DOI: 10.1186/2008-2231-20-43]">Faghihi 2012</a>; <a href="./references#CD013337-bbs2-0084" title="CottinghamEM , MorrisonJA , KleinDJ , BartonBA . A randomized, double-blind placebo-controlled trial of metformin (glucophage®) for weight-gain associated with atypical antipsychotics in children and adolescents. In: 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KleinDJ , CottinghamEM , SorterM , BartonBA , MorrisonJA . A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry2006;163(12):2072-9. ">Klein 2006</a>; <a href="./references#CD013337-bbs2-0096" title="McElroySL , WinstanleyE , MoriN , MartensB , McCoyJ , MoellerD , et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. Journal of Clinical Psychopharmacology2012;32(2):165-72. [DOI: 10.1097/JCP.0b013e3182488758]">McElroy 2012</a>); </p> </li> <li> <p>one study terminated early with no published data (<a href="./references#CD013337-bbs2-0044" title="CTRI/2013/05/003685. A clinical trial to study the effects of metformin in prevention of olanzapine induced weight gain, type 2 diabetes mellitus and lipid abnormalities in patients with schizophrenia. https://trialsearch.who.int/?TrialID=CTRI/2013/05/003685 (first received 27 May 2013). ">CTRI/2013/05/003685 2013</a>); </p> </li> <li> <p>one study did not report eligible outcomes (<a href="./references#CD013337-bbs2-0104" title="NCT00425815. A placebo-controlled trial of org 24448 (ampakine) added to atypical antipsychotics in patients with schizophrenia. https://clinicaltrials.gov/ct2/show/NCT00425815 (first received 23 January 2007). ">NCT00425815</a>); and </p> </li> <li> <p>one study did not have a proper comparator group (<a href="./references#CD013337-bbs2-0132" title="WangC , ShiW , XuJ , HuangC , ZhuJ . Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial. Annals of General Psychiatry2020;19:68. ">Wang 2020b</a>). </p> </li> </ol> </p> <p>These reasons are also presented in <a href="./references#CD013337-sec-0292" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD013337-sec-0120"> <h4 class="title">Studies awaiting assessment</h4> <p>We were unable to find abstracts or full publications for two studies, and there was no available contact information to gain access to these publications to determine eligibility (<a href="./references#CD013337-bbs2-0139" title="GinsbergDL . Add-on sibutramine for olanzapine-induced weight gain. Primary Psychiatry2004;11(7):24. ">Ginsberg 2004</a>; <a href="./references#CD013337-bbs2-0140" title="MondalH , PaulS , GuhaP . Role of metformin versus topiramate in preventing olanzapine associated weight gain and metabolic syndrome. Indian Journal of Pharmacology2014;1:S21. ">Mondal 2014</a>).  </p> </section> <section id="CD013337-sec-0121"> <h4 class="title">Ongoing studies</h4> <p>Two studies identified as being potentially eligible are still ongoing (<a href="./references#CD013337-bbs2-0141" title="NCT04524403. Study evaluating the safety, efficacy, and pharmacokinetics of miricorilant in obese adult patients with schizophrenia while taking antipsychotic medications (GRATITUDE II). https://clinicaltrials.gov/show/NCT04524403 (first received 24 August 2020). ">NCT04524403</a>; <a href="./references#CD013337-bbs2-0142" title="De BoerN , GuloksuzS , Van BaalC , WillebrandsL , DeenikJ , VinkersCH , et al. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle In Antipsychotic users (MELIA) trial. BMC Psychiatry2021;21(1):4. ">NL8440</a>).   </p> </section> </section> <section id="CD013337-sec-0122"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias, please refer to <a href="#CD013337-fig-0002">Figure 2</a> and <a href="#CD013337-fig-0003">Figure 3</a>. Full details of judgements are seen in the ’Risk of bias’ tables. </p> <div class="figure" id="CD013337-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013337-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD013337-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD013337-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD013337-sec-0123"> <h4 class="title">Allocation</h4> <p>All included studies were reported as randomised. Nine studies clearly mentioned their random sequence generation procedure; five studies used a computer‐generated randomisation code (<a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), three studies used a table of random numbers (<a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>), and one study used a block randomisation procedure (<a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>). The remaining studies did not provide any details on their randomisation methods (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>). </p> <p>Concealment of allocation has repeatedly been shown to be of key importance in excluding selection biases. Only three of the included studies explicitly mentioned the procedure followed to conceal allocation (<a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>), so we judged them to be at low risk of bias. We deemed six studies to be at high risk of selection bias due to a combined lack of reporting on details relating to randomisation, allocation concealment, and blinding (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>). We rated the remaining eight studies as unclear risk for allocation concealment as the study did not provide enough details on this point to make a judgement (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a>). </p> </section> <section id="CD013337-sec-0124"> <h4 class="title">Blinding</h4> <p>Thirteen studies included in this review were double‐blind, two were open‐label (<a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>), and one had unclear blinding procedures (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>). However, most of the studies did not report any test of blinding, and we therefore rated them as unclear for performance bias (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>). The two open‐label studies were deemed high risk of bias while all remaining studies were deemed to be low risk. </p> <p>We judged 10 studies to be at low risk of detection bias as most outcomes (weight and other metabolic parameters) were objective in nature and unlikely to be biased by blinding. However, the remaining studies did not explicitly state their methods of blinding outcome assessments, so it wasn't clear that detection bias was absent. In these instances, we judged them to be at unclear risk of bias for this domain (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>). </p> </section> <section id="CD013337-sec-0125"> <h4 class="title">Incomplete outcome data</h4> <p>We did not include studies where more than 50% of data were missing. We judged 12 studies to have low risk of attrition bias as they had a small dropout rate that was fairly distributed between groups, and they stated methods on how missing data were imputed. One study was found to have a high risk of bias because of the high rates of dropout and only 62% of the sample being included in the analyses (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>). However, a sensitivity analysis excluding this study from the analysis did not change the findings significantly. Hence, we included it in the review. We judged the remaining four studies as unclear in this domain because of the lack of information on number of dropouts in the study or the analysis methods accounting for missing data (<a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>; <a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>; <a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a>). </p> <p>Inclusion and exclusion of studies that performed an ITT or LOCF analysis did not change the results of the review significantly. Hence, we judged attrition bias to be low for all comparisons. </p> </section> <section id="CD013337-sec-0126"> <h4 class="title">Selective reporting</h4> <p>We deemed risk of bias due to selective reporting to be low in 10 studies. These studies reported all prespecified outcomes in their study protocol or comprehensive methods section. We judged the remaining seven studies as unclear because there was no clinical trial protocol available, and a lack of information on other outcomes that may have been measured (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>; <a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>; <a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>). </p> </section> <section id="CD013337-sec-0127"> <h4 class="title">Other potential sources of bias</h4> <p>Due to the comprehensive nature of the bias categorisation, we deemed most studies as low risk in this category. We rated only one study as unclear in this category because it was translated from Chinese and therefore language constraints made it difficult to assess any other biases (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>). </p> <p>All of the included studies had a duration of six months or less, thus, care needs to be taken in interpreting the long‐term effects of the treatment. However, we were unable to judge publication bias since the number of studies was 10 or fewer in each of the comparisons. </p> </section> </section> <section id="CD013337-sec-0128"> <h3 class="title" id="CD013337-sec-0128">Effects of interventions</h3> <p>See: <a href="./full#CD013337-tbl-0001"><b>Summary of findings 1</b> Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</a>; <a href="./full#CD013337-tbl-0002"><b>Summary of findings 2</b> H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia</a>; <a href="./full#CD013337-tbl-0003"><b>Summary of findings 3</b> Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia</a>; <a href="./full#CD013337-tbl-0004"><b>Summary of findings 4</b> Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</a> </p> <section id="CD013337-sec-0129"> <h4 class="title">Quantitative synthesis</h4> <section id="CD013337-sec-0130"> <h5 class="title">Metformin versus placebo or no treatment</h5> <p>See <a href="./full#CD013337-tbl-0001">summary of findings Table 1</a>. </p> <p>Five studies compared metformin with standard care (<a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a>; <a href="./references#CD013337-bbs2-0002" title="BaptistaT , MartinezJ , LacruzA , RangelN , BeaulieuS , SerranoA , et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2006;51(3):192-6. [CSZG: 12656]BaptistaT , SandiaI , LacruzA , RangelN , deMendozaS , BeaulieuS , et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. International Clinical Psychopharmacology2007;22:69-76. ">Baptista 2006</a>; <a href="./references#CD013337-bbs2-0014" title="NCT00682448. Metformin for the prevention of the metabolic side-effects of zyprexa. http://clinicaltrials.gov/show/NCT00682448 (first received 22 May 2008). RadoJ , vonAmmon CavanaughS . A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology2016;36:163-8. ">Rado 2016</a>; <a href="./references#CD013337-bbs2-0016" title="VishnupriyaR , EzhilramyaJ , MeenakshiB . Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study. International Journal of Pharmacy and Pharmaceutical Sciences2016;8:200-6. ">Vishnupriya 2016</a>; <a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>). </p> <p>The following primary outcomes were not reported in any of the studies included in this comparison: 'clinically important change in weight', 'clinically important change in BMI' and 'compliance with treatment'. The following secondary outcomes were also not reported in any of the studies included in this comparison: 'global state', 'well‐being', 'quality of life', 'adverse effects/events ‐ general or specific', or 'economic costs'. </p> <section id="CD013337-sec-0131"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0132"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0027"> <li> <p>Clinically important change in weight: no data to report</p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): metformin may prevent weight gain (MD −4.03 kg, 95% CI −5.78 to −2.28; I<sup>2</sup> = 0%; 4 studies, 131 participants; <a href="./references#CD013337-fig-0004" title="">Analysis 1.1</a>); however, the certainty of evidence for this outcome is low. </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc)</p> </li> <li> <p>Metformin may be effective in preventing increases in BMI (MD −1.63 kg/m<sup>2</sup>, 95% CI −2.96 to −0.29; I<sup>2</sup> = 90.25%; 5 studies, 227 participants; <a href="./references#CD013337-fig-0005" title="">Analysis 1.2</a>); however, the certainty of evidence for this outcome is low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0133"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0028"> <li> <p>For any reason: there was no difference between groups in terms of individuals leaving the study (RR 1.02, 95% CI 0.25 to 4.13; I<sup>2</sup> = 0%; 4 studies, 137 participants; <a href="./references#CD013337-fig-0007" title="">Analysis 1.4</a>); however, certainty of evidence for this outcome is very low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0134"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0135"> <p><b>Reports of nausea</b></p> <p>Metformin does not appear to cause more nausea than placebo (RR 2.38, 95% CI 0.28 to 19.95; I<sup>2</sup> = 40%; 2 studies, 69 participants; <a href="./references#CD013337-fig-0008" title="">Analysis 1.5</a>). The certainty of this outcome is very low, however, given the small number of studies reporting this adverse event. </p> </section> </section> <section id="CD013337-sec-0136"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0137"> <p><b>Weight: average endpoint/change in waist circumference (post‐hoc)</b></p> <p>Metformin does not appear to have an effect on waist circumference (MD −1.13 cm, 95% CI −4.28 to 2.02; I<sup>2</sup> = 98%; 5 studies, 232 participants; <a href="./references#CD013337-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD013337-sec-0138"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0029"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0139"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0140"> <p><b>Mental state</b></p> <p>No effect was observed on the following mental state outcome measures: SANS (MD −0.05, 95% CI −1.38 to 1.28; 1 study, 37 participants), SAPS (MD 0.09, 95% CI −0.67 to 0.85; 1 study, 37 participants) and BPRS (MD −1.80, 95% CI −6.50 to 2.90; 1 study, 37 participants; <a href="./references#CD013337-fig-0009" title="">Analysis 1.6</a>). However, given that only one study reported on each of these outcomes, the certainty of evidence is very low and the effect is uncertain. </p> </section> <section id="CD013337-sec-0141"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0142"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0143"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0144"> <p><b>Physiological: laboratory measures</b></p> <p>In the studies that reported these parameters, it does not appear that metformin has an effect on laboratory measures including fasting blood glucose, HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, insulin, and insulin resistance (<a href="./references#CD013337-fig-0010" title="">Analysis 1.7</a>). This finding is uncertain, however, given the small number of studies that reported this measure. </p> </section> <section id="CD013337-sec-0145"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> <section id="CD013337-sec-0146"> <h5 class="title">H2 antagonists versus placebo</h5> <p>See <a href="./full#CD013337-tbl-0002">summary of findings Table 2</a>. </p> <p>We included three RCTs in this comparison, one examined two doses of nizatidine (<a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>), one examined famotidine (<a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>), and one examined ranitidine (<a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a>). None of the studies included in this comparison reported the primary outcomes: 'clinically important change in weight', 'clinically important change in BMI' and 'compliance with treatment'. The following secondary outcomes were also not reported in any of the studies included in this comparison: 'weight (or other indicator of body mass)', 'leaving the study early for specific reasons', 'global state', 'well‐being', 'quality of life', 'physiological measures' or 'economic costs'. </p> <section id="CD013337-sec-0147"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0148"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0030"> <li> <p>Clinically important change in weight: no data to report</p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): H2 antagonists may be effective in preventing weight gain (MD −1.32 kg, 95% CI −2.09 to −0.56; I<sup>2</sup> = 0%; 3 studies, 248 participants; <a href="./references#CD013337-fig-0011" title="">Analysis 2.1</a>); however, the certainty of evidence for this outcome is low. </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc): H2 antagonists may be effective in preventing any increases in BMI (MD −0.66 kg/m2, 95% CI −0.99 to −0.33; I<sup>2</sup> = 0%; 2 studies, 79 participants; <a href="./references#CD013337-fig-0012" title="">Analysis 2.2</a>); however, given the small number of studies in the comparison, the certainty of evidence for this outcome is very low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0149"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0031"> <li> <p>For any reason: there was no difference between groups in terms of individuals leaving the study (RR 1.07, 95% CI 0.72 to 1.57; I<sup>2</sup> = 0%; 2 studies, 189 participants; <a href="./references#CD013337-fig-0013" title="">Analysis 2.3</a>); however, the certainty of evidence for this outcome is low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0150"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0151"> <p><b>Reports of nausea</b></p> <p>There was no report of increased incidence of nausea in the intervention groups compared with placebo (RR 1.13, 95% CI 0.34 to 3.68; 1 study, 175 participants; <a href="./references#CD013337-fig-0014" title="">Analysis 2.4</a>); however, the effect is uncertain as the certainty of evidence is low. </p> </section> </section> <section id="CD013337-sec-0152"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0153"> <p><b>Weight (or other indicator of body mass)</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0154"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0032"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0155"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0156"> <p><b>Mental state</b></p> <p>There was no evidence of effect of H2 antagonists on mental state, as reported by various mental state scales: CGI (MD 0.10, 95% CI −0.74 to 0.94; 1 study, 14 participants), SANS (MD −1.90, 95% CI −4.97 to 1.17; 1 study, 14 participants), SAPS (MD −0.10, 95% CI −4.09 to 3.89; 1 study, 14 participants) (<a href="./references#CD013337-fig-0016" title="">Analysis 2.6</a>) and BPRS (MD 2.32, 95% CI −0.89 to 5.53; 1 study, 169 participants; <a href="./references#CD013337-fig-0015" title="">Analysis 2.5</a>). However, the effect of these agents on mental state is uncertain as the certainty of evidence is very low. </p> </section> <section id="CD013337-sec-0157"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0158"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0159"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>There was no report of increased incidence of any adverse effects in the intervention groups compared with placebo. However, the effect is uncertain as the certainty of evidence is very low. </p> <p> <ol id="CD013337-list-0033"> <li> <p>Headache (RR 1.06, 95% CI 0.28 to 4.08; 1 study, 175 participants; <a href="./references#CD013337-fig-0017" title="">Analysis 2.7</a>) </p> </li> <li> <p>Dry mouth (RR 3.60, 95% CI 0.67 to 19.38; 1 study, 175 participants; <a href="./references#CD013337-fig-0018" title="">Analysis 2.8</a>) </p> </li> <li> <p>Anxiety (RR 1.04, 95% CI 0.37 to 2.90; 1 study, 175 participants; <a href="./references#CD013337-fig-0019" title="">Analysis 2.9</a>); </p> </li> <li> <p>Depression (RR 3.69, 95% CI 0.68 to 19.97; 1 study, 175 participants; <a href="./references#CD013337-fig-0020" title="">Analysis 2.10</a> ); </p> </li> <li> <p>Dizziness (RR 0.61, 95% CI 0.21 to 1.73; 1 study, 175 participants; <a href="./references#CD013337-fig-0021" title="">Analysis 2.11</a>); </p> </li> <li> <p>Increased appetite (OR 0.47, 95% CI 0.19 to 1.16; 1 study, 175 participants; <a href="./references#CD013337-fig-0022" title="">Analysis 2.12</a>); </p> </li> <li> <p>Somnolence (RR 0.72, 95% CI 0.47 to 1.10; I<sup>2</sup> = 0%; 2 studies, 189 participants; <a href="./references#CD013337-fig-0023" title="">Analysis 2.13</a>); </p> </li> <li> <p>SAS (MD −0.48, 95% CI −1.86 to 0.90; I<sup>2</sup> = 50%; 2 studies, 183 participants; <a href="./references#CD013337-fig-0024" title="">Analysis 2.14</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0160"> <p><b>Physiological: laboratory measures</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0161"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> <section id="CD013337-sec-0162"> <h5 class="title">Monoamine modulators versus placebo</h5> <p>See <a href="./full#CD013337-tbl-0003">summary of findings Table 3</a>. </p> <p>We included three RCTs in this comparison, two examined reboxetine alone (<a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>), and one examined fluoxetine (<a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>). None of these studies reported the primary outcomes, 'clinically important change in weight', 'clinically important change in BMI' and 'compliance with treatment'. The following secondary outcomes were also not reported in any of the studies included in this comparison: 'weight (or other indicator of body mass)', 'leaving the study early for specific reasons', 'global state', 'well‐being', 'quality of life', 'physiological measures' or 'economic costs'. </p> <section id="CD013337-sec-0163"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0164"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0034"> <li> <p>Clinically important change in weight: no data to report</p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): these monoamine modulators may have an effect on preventing increases in body weight (MD −1.89 kg, 95% CI −3.31 to −0.47; I<sup>2</sup> = 12%; 3 studies, 103 participants; <a href="./references#CD013337-fig-0025" title="">Analysis 3.1</a>); however, the certainty of evidence for this outcome is low. </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc): these monoamine modulators may have an effect on preventing increases in BMI (MD −0.66 kg/m2, 95% CI −1.05 to −0.26; I<sup>2</sup> = 0%; 3 studies, 103 participants; <a href="./references#CD013337-fig-0026" title="">Analysis 3.2</a>); however, the certainty of evidence for this outcome is low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0165"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0035"> <li> <p>For any reason: there was no difference between groups in terms of individuals leaving the study (RR 1.05, 95% CI 0.56 to 1.94; I<sup>2</sup> = 0%; 3 studies, 103 participants; <a href="./references#CD013337-fig-0027" title="">Analysis 3.3</a>); however, the certainty of evidence for this outcome is low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0166"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0167"> <p><b>Reports of nausea</b></p> <p>No data to report</p> </section> </section> <section id="CD013337-sec-0168"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0169"> <p><b>Weight (or other indicator of body mass)</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0170"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0036"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0171"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0172"> <p><b>Mental state</b></p> <p>Monoamine modulators showed improvements in the HAM‐D scale (MD −2.12, 95% CI −4.22 to −0.01; I<sup>2</sup> = 37%; 2 studies, 79 participants; <a href="./references#CD013337-fig-0031" title="">Analysis 3.7</a>), but there were no between‐group differences in other  mental state scores such as the  SANS (MD −0.14, 95% CI −1.98 to 1.71; I<sup>2</sup> = 0%; 3 studies, 103 participants; <a href="./references#CD013337-fig-0028" title="">Analysis 3.4</a>), SAPS (MD 0.09, 95% CI −2.01 to 2.19; I<sup>2</sup> = 54%; 3 studies, 103 participants; <a href="./references#CD013337-fig-0029" title="">Analysis 3.5</a>), or CGI (MD 0.13, 95% CI −0.28 to 0.54; I<sup>2</sup> = 0%; 2 studies, 79 participants; <a href="./references#CD013337-fig-0030" title="">Analysis 3.6</a>). </p> </section> <section id="CD013337-sec-0173"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0174"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0175"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>Only one study reported the following adverse effects.</p> <p> <ol id="CD013337-list-0037"> <li> <p>Change in BAS score (MD −0.18, 95% CI −0.65 to 0.29; 1 study, 59 participants)</p> </li> <li> <p>Change in SAS score (MD 0.26, 95% CI −1.00 to 1.52; 1 study, 59 participants)</p> </li> <li> <p>Increased appetite (MD −0.68, 95% CI −1.19 to −0.17; 1 study, 59 participants)</p> </li> </ol> </p> <p>It is difficult to draw firm conclusions given the very low certainty of the evidence (<a href="./references#CD013337-fig-0032" title="">Analysis 3.8</a>). </p> </section> <section id="CD013337-sec-0176"> <p><b>Physiological: laboratory measures</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0177"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> <section id="CD013337-sec-0178"> <h5 class="title">Topiramate versus placebo or no treatment</h5> <p>See <a href="./full#CD013337-tbl-0004">summary of findings Table 4</a>. </p> <p>We included three RCTs in this comparison (<a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>). We deemed the overall certainty of evidence to be very low for all outcomes. </p> <p>None of the studies in this comparison reported the primary outcomes, 'clinically important change in weight', 'clinically important change in BMI' and 'compliance with treatment'. </p> <p>The following secondary outcomes were also not reported in any of the studies included in this comparison: 'weight (or other indicator of body mass)', 'leaving the study early for specific reasons', 'global state', 'well‐being', 'quality of life', or 'economic costs'. </p> <section id="CD013337-sec-0179"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0180"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0038"> <li> <p>Clinically important change in weight: no data to report</p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): topiramate did not show a significant effect in preventing weight gain (MD −4.82 kg, 95% CI −9.99 to 0.35; I<sup>2</sup> = 74%; 3 studies, 168 participants; <a href="./references#CD013337-fig-0033" title="">Analysis 4.1</a>), however, the certainty of evidence for this outcome is very low. </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc): topiramate may prevent increases in BMI (MD −2.68 kg/m2, 95% CI −4.10 to −1.26; I<sup>2</sup> = 0%; 2 studies, 120 participants; <a href="./references#CD013337-fig-0034" title="">Analysis 4.2</a>), however, the certainty of evidence for this outcome is very low. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0181"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0039"> <li> <p>For any reason: there was no difference between groups in terms of individuals leaving the study (RR 1.09, 95% CI 0.85 to 1.41; I<sup>2</sup> = 0%; 2 studies, 132 participants; <a href="./references#CD013337-fig-0035" title="">Analysis 4.3</a>) but it is difficult to draw firm conclusions given the low certainty of the evidence. </p> </li> </ol> </p> </section> <section id="CD013337-sec-0182"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0183"> <p><b>Reports of nausea</b></p> <p>The rates of gastrointestinal and neurological adverse effects were not different between groups (<a href="./references#CD013337-fig-0036" title="">Analysis 4.4</a>); however, the certainty of evidence for this outcome is low. </p> </section> </section> <section id="CD013337-sec-0184"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0185"> <p><b>Weight (or other indicator of body mass)</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0186"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0040"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0187"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0188"> <p><b>Mental state</b></p> <p>Topiramate may slightly decrease PANSS total scores (MD −2.08, 95% CI −3.07 to −1.10; I<sup>2</sup> = 0%; 2 studies, 120 participants) and PANSS General Psychopathology Scale (MD −1.53, 95% CI −2.16 to −0.90; I<sup>2</sup> = 0%; 2 studies, 120 participants; <a href="./references#CD013337-fig-0037" title="">Analysis 4.5</a>). </p> </section> <section id="CD013337-sec-0189"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0190"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0191"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>There was no report of increased incidence of any adverse effects in the intervention groups compared to the placebo groups. However, the effect is uncertain as the certainty of the evidence is very low (<a href="./references#CD013337-fig-0038" title="">Analysis 4.6</a>). </p> </section> <section id="CD013337-sec-0192"> <p><b>Physiological measures</b></p> <p> <ol id="CD013337-list-0041"> <li> <p>Cardiovascular measures: participants in the topiramate arm had lower systolic (MD −4.62, 95% CI −8.14 to −1.10; 1 study, 67 participants) and diastolic (MD −3.47, 95% CI −6.12 to −0.82; 1 study, 67 participants) blood pressure compared to those in the placebo arm but the certainty of evidence is very low (<a href="./references#CD013337-fig-0039" title="">Analysis 4.7</a>). </p> </li> <li> <p>Laboratory measures: there was no difference between groups in terms of total cholesterol (MD −11.69, 95% CI −31.86 to 8.48; I<sup>2</sup> = 90%; 2 studies, 120 participants), LDL cholesterol (MD −7.99, 95% CI −21.82 to 5.84; I<sup>2</sup> = 80%; 2 studies, 120 participants), HDL cholesterol (MD 0.36, 95% CI −1.59 to 2.31; I<sup>2</sup> = 0%; 2 studies, 120 participants) and triglycerides (MD −5.12, 95% CI −18.70 to 8.46; I<sup>2</sup> = 52%; 2 studies, 120 participants). However, topiramate did appear to improve fasting blood glucose (MD −9.22, 95% CI −12.59 to −5.86; I<sup>2</sup> = 0%; 2 studies, 120 participants). Results in this comparison are uncertain as the certainty of the evidence is very low (<a href="./references#CD013337-fig-0040" title="">Analysis 4.8</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0193"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> <section id="CD013337-sec-0194"> <h5 class="title">Melatonin versus placebo</h5> <p>Only one study examined the use of melatonin for preventing antipsychotic induced weight gain in an eight‐week long intervention (<a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a>).This study did not report on the primary outcomes 'clinically important change in weight', 'clinically important change in BMI' and 'compliance with treatment'. The following secondary outcomes were also not reported in this study: 'leaving the study early for specific reasons', 'global state', 'well‐being', 'quality of life', or 'economic costs'. </p> <section id="CD013337-sec-0195"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0196"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0042"> <li> <p>Clinically important change in weight: no data to report</p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): melatonin was associated with significantly less weight gain (MD 3.20 kg, 95% CI −5.86 to −0.54; <a href="./references#CD013337-fig-0041" title="">Analysis 5.1</a>) compared to placebo. </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc): melatonin was associated with a significantly less increase in BMI (MD −1.10 kg/m<sup>2</sup>, 95% CI −1.99 to −0.21; <a href="./references#CD013337-fig-0042" title="">Analysis 5.2</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0197"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0043"> <li> <p>For any reason: there was no difference between groups in terms of individuals leaving the study. The study initially randomised 48 patients (24 to each group). Following dropouts, 36 participants (18 in each group) were included in the ITT analysis (<a href="./references#CD013337-fig-0046" title="">Analysis 5.6</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0198"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0199"> <p><b>Reports of nausea</b></p> <p>No data to report</p> </section> </section> <section id="CD013337-sec-0200"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0201"> <p><b>Weight (or other indicator of body mass)</b></p> <p>Average endpoint/change in weight, BMI, or other measures (post‐hoc): melatonin was associated with a significant decrease in waist circumference (MD −2.80 cm, 95% CI −5.43 to −0.17; <a href="./references#CD013337-fig-0043" title="">Analysis 5.3</a>). No significant effect on hip circumference, or waist‐to‐hip ratio was observed (<a href="./references#CD013337-fig-0044" title="">Analysis 5.4</a>; <a href="./references#CD013337-fig-0045" title="">Analysis 5.5</a>). </p> </section> <section id="CD013337-sec-0202"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0044"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0203"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0204"> <p><b>Mental state</b></p> <p>There seemed to be a positive effect of melatonin on mental state scores. PANSS total (MD −12.90, 95% CI −22.59 to −3.21) and general psychopathology (MD −7.50, 95% CI −12.65 to −2.35) scores were reduced significantly more in the melatonin group compared to placebo <a href="./references#CD013337-fig-0047" title="">Analysis 5.7</a>). </p> </section> <section id="CD013337-sec-0205"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0206"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0207"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0208"> <p><b>Physiological measures</b></p> <p> <ol id="CD013337-list-0045"> <li> <p>Cardiovascular measures: no data to report</p> </li> <li> <p>Laboratory measures: the melatonin group had lower total cholesterol at endpoint than the placebo group (MD −25.40, 95% CI −49.04 to −1.76). There were no significant differences between groups in terms of any of the other physiological laboratory outcomes. (<a href="./references#CD013337-fig-0048" title="">Analysis 5.8</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0209"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> <section id="CD013337-sec-0210"> <h5 class="title">Reboxetine plus betahistine versus placebo</h5> <p>Only one study examined the use of reboxetine plus betahistine for preventing antipsychotic‐induced weight gain in a six‐week‐long intervention (<a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a>). This study did not report on the primary outcomes 'clinically important change in weight', 'clinically important change in BMI' 'reports of nausea' and 'compliance with treatment'. The following secondary outcomes were also not reported in this study: 'weight (or other indicators of body mass', 'leaving the study early for specific reasons', 'global state', 'well‐being', 'quality of life', 'physiological measures', or 'economic costs'. </p> <section id="CD013337-sec-0211"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0212"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0046"> <li> <p>Clinically important change in weight: fewer participants in the reboxetine group reported more than 5% weight gain (RR 0.27, 95% CI 0.11 to 0.65; 43 participants; <a href="./references#CD013337-fig-0049" title="">Analysis 6.1</a>) and more than 7% weight gain (RR 0.24, 95% CI 0.07 to 0.83; 43 participants; <a href="./references#CD013337-fig-0050" title="">Analysis 6.2</a>) than the placebo group. </p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): participants in the reboxetine plus betahistine group experienced less weight gain than those in the placebo group (MD −2.75 kg, 95% CI −4.62 to −0.88; <a href="./references#CD013337-fig-0051" title="">Analysis 6.3</a>). </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc): there was also less increase in BMI in the reboxetine plus betahistine group versus the placebo group (MD −0.88 kg/m<sup>2</sup>, 95% CI −1.47 to −0.29; <a href="./references#CD013337-fig-0052" title="">Analysis 6.4</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0213"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0047"> <li> <p>For any reason: there was no difference between groups in terms of number of individuals who left the study. There were seven dropouts from 29 participants in the reboxetine plus betahistine group and four dropouts from 14 participants in the placebo group (RR 0.84, 95% CI 0.30 to 2.41; <a href="./references#CD013337-fig-0053" title="">Analysis 6.5</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0214"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0215"> <p><b>Reports of nausea</b></p> <p>No data to report</p> </section> </section> <section id="CD013337-sec-0216"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0217"> <p><b>Weight (or other indicator of body mass)</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0218"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0048"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0219"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0220"> <p><b>Mental state</b></p> <p>There were no significant differences between the reboxetine plus betahistine group and the placebo group in terms of mental state scores on the SANS, HAM‐D, SAPS and CGI (<a href="./references#CD013337-fig-0054" title="">Analysis 6.6</a>). </p> </section> <section id="CD013337-sec-0221"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0222"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0223"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>The groups did not differ in terms of neurological adverse effects, such as change in BAS (MD 0.06, 95% CI −0.21 to 0.33) or SAS (MD 0.55, 95% CI −0.28 to 1.38; <a href="./references#CD013337-fig-0055" title="">Analysis 6.7</a>). </p> </section> <section id="CD013337-sec-0224"> <p><b>Physiological measures</b></p> <p> <ol id="CD013337-list-0049"> <li> <p>Cardiovascular measures: no data to report</p> </li> <li> <p>Laboratory measures: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0225"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> <section id="CD013337-sec-0226"> <h5 class="title">Samidorphan plus olanzapine versus olanzapine alone</h5> <p>Only one study examined the use of samidorphan plus olanzapine versus olanzapine alone (<a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a>). This study did not report on the primary outcomes 'clinically important change in BMI', 'average endpoint/change in BMI', 'reports of nausea' and 'compliance with treatment'. The following secondary outcomes were also not reported in this study: 'leaving the study early for specific reasons', 'global state', 'well‐being', 'quality of life', or 'economic costs'. </p> <section id="CD013337-sec-0227"> <h6 class="title">Primary outcomes</h6> <section id="CD013337-sec-0228"> <p><b>Weight or BMI</b></p> <p> <ol id="CD013337-list-0050"> <li> <p>Clinically important change in weight: significantly lower proportions of participants in the olanzapine plus samidorphan group experienced 10% or higher weight gain (RR 0.59, 95% CI 0.43 to 0.81; <a href="./references#CD013337-fig-0056" title="">Analysis 7.1</a>) and 7% or higher weight gain (RR 0.64, 95% CI 0.51 to 0.82; <a href="./references#CD013337-fig-0057" title="">Analysis 7.2</a>) than in the olanzapine group. </p> </li> <li> <p>Average endpoint/change in weight (post‐hoc): there were no between‐group differences in body weight at endpoint (MD −2.35, 95% CI −4.80 to 0.10; <a href="./references#CD013337-fig-0058" title="">Analysis 7.3</a>). </p> </li> <li> <p>Clinically important change in BMI: no data to report</p> </li> <li> <p>Average endpoint/change in BMI (post‐hoc): no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0229"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0051"> <li> <p>For any reason: a total of 352 (64%) participants completed treatment, with similar completion rates in the two treatment groups (RR 0.98, 95% CI 0.79 to 1.23; <a href="./references#CD013337-fig-0060" title="">Analysis 7.5</a>). The most common reasons for discontinuation with olanzapine plus samidorphan and with olanzapine alone were adverse events (12.0% and 9.8%, respectively), withdrawal by participant (8.4% and 9.8%, respectively), and loss to follow‐up (8.0% and 9.4%, respectively). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0230"> <p><b>Compliance with treatment ‐ as defined by individual studies</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0231"> <p><b>Reports of nausea</b></p> <p>No data to report</p> </section> </section> <section id="CD013337-sec-0232"> <h6 class="title">Secondary outcomes</h6> <section id="CD013337-sec-0233"> <p><b>Weight (or other indicator of body mass)</b></p> <p>Average endpoint/change in waist circumference: participants in the samidorphan plus olanzapine group had less increase in waist circumference than the olanzapine group (MD −2.11, 95% CI −3.64 to −0.58; <a href="./references#CD013337-fig-0059" title="">Analysis 7.4</a>). </p> </section> <section id="CD013337-sec-0234"> <p><b>Leaving the study early</b></p> <p> <ol id="CD013337-list-0052"> <li> <p>For specific reasons: no data to report</p> </li> </ol> </p> </section> <section id="CD013337-sec-0235"> <p><b>Global state</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0236"> <p><b>Mental state</b></p> <p>The PANSS total score improved similarly in both groups (MD 1.20, 95% CI −0.81 to 3.21; <a href="./references#CD013337-fig-0061" title="">Analysis 7.6</a>). Reductions in CGI‐S score from baseline to week 24 were similar between the two treatment groups (MD 0.07, 95% CI −1.12 to 1.26; <a href="./references#CD013337-fig-0061" title="">Analysis 7.6</a>). </p> </section> <section id="CD013337-sec-0237"> <p><b>Well‐being</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0238"> <p><b>Quality of life</b></p> <p>No data to report</p> </section> <section id="CD013337-sec-0239"> <p><b>Adverse effects/events ‐ general or specific</b></p> <p>Adverse events were reported in 74.1% and 82.2% of the olanzapine plus samidorphan group and the olanzapine group, respectively, with no significant between‐group differences. The most commonly reported adverse event in the two groups was weight increase (24.8% and 36.2%, respectively), with significant between‐group differences. Somnolence (21.2% and 18.1%), dry mouth (12.8% and 8.0%), and increased appetite (10.9% and 12.3%) were other commonly reported adverse events but with no between‐group differences (<a href="./references#CD013337-fig-0063" title="">Analysis 7.8</a>). There were no clinically meaningful changes or differences observed in vital signs, ECG results, or movement disorder scale scores for participants in the two treatment groups. </p> </section> <section id="CD013337-sec-0240"> <p><b>Physiological measures</b></p> <p> <ol id="CD013337-list-0053"> <li> <p>Cardiovascular measures: no data to report</p> </li> <li> <p>Laboratory measures: there were no significant between‐group differences in terms of physiological laboratory measures such as fasting blood glucose, insulin, HbA1c, LDL‐C, HDL‐C, total cholesterol and triglycerides (<a href="./references#CD013337-fig-0062" title="">Analysis 7.7</a>). </p> </li> </ol> </p> </section> <section id="CD013337-sec-0241"> <p><b>Economic costs</b></p> <p>No data to report</p> </section> </section> </section> </section> <section id="CD013337-sec-0242"> <h4 class="title">Subgroup analyses and investigation of heterogeneity</h4> <p>No subgroup analyses were completed for the outcome average endpoint/change in weight for any of the comparisons. </p> </section> <section id="CD013337-sec-0243"> <h4 class="title">Sensitivity analyses</h4> <p>We only performed sensitivity analyses for the following weight outcomes, 'average endpoint/change in body weight' or 'average endpoint/change in BMI'. The following preplanned sensitivity analyses did not apply to our review: exclusion of studies with unclear randomisation methods, lost binary data, lost continuous data or imputed values. </p> <section id="CD013337-sec-0244"> <h5 class="title">Metformin versus placebo or no treatment</h5> <section id="CD013337-sec-0245"> <h6 class="title">Exclusion of studies with high risk of bias</h6> <p>We judged <a href="./references#CD013337-bbs2-0001" title="ArmanS , SadramelyMR , NadiM , KoleiniN . A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal2008;29(8):1130-4. [CSZG: 16966]FarshidfarF , KoleiniN , SadramelyM . Is metformin effective to prevent weight gain associated with risperidone?European Psychiatry2011;26 Suppl 1:1713. [CSZG: 22962]">Arman 2008</a> to be high risk of bias for allocation concealment (selection bias) and incomplete outcome data (attrition bias). Excluding this study did not change the overall results (MD −4.18 kg, 95% CI −5.95 to −2.42; I<sup>2</sup> = 0%, 3 studies, 99 participants; <a href="./references#CD013337-fig-0064" title="">Analysis 8.1</a>). </p> </section> <section id="CD013337-sec-0246"> <h6 class="title">Fixed‐effect model</h6> <p>When we applied a fixed‐effect model, the overall results did not change (MD −4.03 kg, 95% CI −5.78 to −2.28; I<sup>2</sup> = 0%; I<sup>2</sup> = 0%; 4 studies, 131 participants; <a href="./references#CD013337-fig-0065" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD013337-sec-0247"> <h5 class="title">H2 Antagonists versus placebo</h5> <section id="CD013337-sec-0248"> <h6 class="title">Fixed‐effect model</h6> <p>When we applied a fixed‐effect model, the overall results did not change (MD −1.32 kg, 95% CI −2.09 to −0.56; I<sup>2</sup> = 0%; 3 studies, 248 participants;<a href="./references#CD013337-fig-0066" title="">Analysis 8.3</a>). </p> </section> </section> <section id="CD013337-sec-0249"> <h5 class="title">Monoamine modulators versus placebo</h5> <section id="CD013337-sec-0250"> <h6 class="title">Fixed‐effect model</h6> <p>When we applied a fixed‐effect model, the overall results did not change (MD ‐1.84 kg, 95% CI ‐3.01 to ‐0.67; I<sup>2</sup> = 12%; 3 studies; 103 participants <a href="./references#CD013337-fig-0067" title="">Analysis 8.4</a>). </p> </section> </section> <section id="CD013337-sec-0251"> <h5 class="title">Topiramate versus placebo or no treatment</h5> <section id="CD013337-sec-0252"> <h6 class="title">Exclusion of studies with high risk of bias</h6> <p>We deemed <a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a> to be high risk of bias for allocation concealment (selection bias) and incomplete outcome data (attrition bias). After excluding this study, only two studies remained in the analysis (<a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>); this analysis shows that topiramate may be effective in preventing weight gain (MD −7.63 kg, 95% CI −12.01 to −3.25; I<sup>2</sup> = 0%; 2 studies; 120 participants; <a href="./references#CD013337-fig-0068" title="">Analysis 8.5</a>). </p> </section> <section id="CD013337-sec-0253"> <h6 class="title">Fixed‐effect model</h6> <p>When we applied a fixed‐effect model, the overall results did not change (MD −1.83 kg, 95% CI −3.03 to −0.63; I<sup>2</sup> = 74%; 3 studies; 168 participants; <a href="./references#CD013337-fig-0069" title="">Analysis 8.6</a>). </p> </section> </section> </section> <section id="CD013337-sec-0254"> <h4 class="title">Publication bias</h4> <p>Due to the small number of included studies we did not perform a funnel plot analysis.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013337-sec-0255" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013337-sec-0255"></div> <section id="CD013337-sec-0256"> <h3 class="title" id="CD013337-sec-0256">Summary of main results</h3> <section id="CD013337-sec-0257"> <h4 class="title">General summary</h4> <p>This review included 17 RCTs with 1388 participants that examined adjunctive pharmacological interventions for the prevention of antipsychotic‐induced weight gain in people with schizophrenia or schizophrenia‐like illnesses. All of the included studies were published between 2002 and 2020 and varied in duration (interventions ranged from six weeks to six months). </p> <p>This review found that pharmacological options may offer promise in preventing weight gain associated with antipsychotic use. Of the studied drugs, metformin may be slightly effective in preventing weight gain. We are uncertain about the other agents used in a preventative role because the certainty of evidence is very low. </p> <p>This review found the medications to have a favourable tolerability profile; none of the drugs studied had a higher number of dropouts in the active arm compared with the placebo arm or no treatment. Moreover, none of the agents had an associated negative impact on mental state. </p> <p>The pharmacological interventions with the most evidence and promise and the specifics of their effect on weight and other outcome measures are discussed below. </p> </section> <section id="CD013337-sec-0258"> <h4 class="title">Treatment effects</h4> <section id="CD013337-sec-0259"> <h5 class="title">Metformin verus placebo or no treatment</h5> <p>Used as a first‐line antidiabetic agent for more than five decades, metformin has a very good established safety and tolerability profile. As a preventative strategy, combined results from five studies involving 227 participants, show that co‐initiation of metformin treatment along with an antipsychotic may lead to less weight gain and reduction in BMI. There were no differences between metformin and placebo in terms of number of participants leaving the study early for any reason. for number of reports of nausea, or for any mental state outcomes. </p> <p>Interestingly, only one study included in this comparison was conducted in first‐episode or antipsychotic‐naive patients (<a href="./references#CD013337-bbs2-0017" title="Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction. American Journal of Psychiatry2008;165(4):540. [CSZG: 16163]Wu R-R, Zhao J-P, Guo X-F, He Y-Q, Fang M-S, Guo W-B, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry2008;165(3):352-8. [CSZG: 16115]">Wu 2008</a>). The effect of metformin on weight in this population appeared to be similar to that observed in more chronic populations. </p> <p>Our findings are in line with recent meta‐analyses and systematic reviews that have examined the utility of metformin in the prevention and treatment of antipsychotic‐induced weight gain (<a href="./references#CD013337-bbs2-0178" title="deSilvaVA , SuraweeraC , RatnatungaSS , DayabandaraM , WanniarachchiN , HanwellaR . Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry2016;16(1):341. [PMID: 27716110]">de Silva 2016</a>), or in the context of clozapine use alone (<a href="./references#CD013337-bbs2-0221" title="LiuZ , ZhengW , GaoS , QinZ , LiG , NingY . Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: a meta-analysis. Shanghai Archives of Psychiatry2015;27(6):331-40. [PMID: 27199524]">Liu 2015</a>; <a href="./references#CD013337-bbs2-0256" title="SiskindDJ , LeungJ , RussellAW , WysoczanskiD , KiselyS . Metformin for clozapine associated obesity: a systematic review and meta-analysis. PloS One2016;11(6):e0156208. [PMID: 27304831]">Siskind 2016</a>). </p> </section> <section id="CD013337-sec-0260"> <h5 class="title">H2 antagonists versus placebo</h5> <p>We included three RCTs that evaluated H2 antagonists as preventative agents. One examined two doses of nizatidine (<a href="./references#CD013337-bbs2-0003" title="BreierA , TanakaY , RoychowdhuryS , ClarkWS . Nizatidine may ameliorate weight gain during olanzapine treatment. European Neuropsychopharmacology2001;11(3):279. [CSZG: 7803]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [CSZG: 7996]BreierAF , TanakaY , RoychowdhuryS . Nizatidine ameliorates olanzapine treatment-related weight gain. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 8949]CavazzoniP , TanakaY , RoychowdhurySM , BreierA , AllisonDB . Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. European Neuropsychopharmacology2003;13:81-5. [CSZG: 11078]">Cavazzoni 2003</a>), one examined famotidine (<a href="./references#CD013337-bbs2-0011" title="PoyurovskyM , TalV , MaayanR , Gil-AdI , FuchsC , WeizmanA . The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology2004;14(4):332-6. [CSZG: 11020]">Poyurovsky 2004</a>), and one examined ranitidine (<a href="./references#CD013337-bbs2-0015" title="SunJ . Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders [Léi ní tì dīng fáng zhì ào dàn píng suǒ zhì tǐ zhòng zēng jiā jí táng dài xiè zhàng ài de yán jiū]. Chinese Journal of Nervous and Mental Disorders2007;33(9):560-2. ">Sun 2007</a>). Overall, this medication class may be slightly effective in mitigating the amount of weight gained during antipsychotic treatment. Additionally, there were no differences between H2 antagonists and placebo in terms of number of participants leaving the study early for any reason or for number of reports of nausea or other adverse effects. However, we need more studies with a greater sample size to fully understand the effects of these medications, as the current certainty of evidence is very low. </p> </section> <section id="CD013337-sec-0261"> <h5 class="title">Monoamine modulators versus placebo</h5> <p>We included three RCTs that evaluated monoamine modulators as preventative agents. Two examined reboxetine alone (<a href="./references#CD013337-bbs2-0010" title="PoyurovskyM , IsaacsI , FuchsC , SchneidmanM , FaragianS , WeizmanRW . Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. American Journal of Psychiatry2003;160(2):297-302. [CSZG: 9260]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International journal of neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]PoyurovskyM , IsaaksI , FuchsC , SchneidmanM , FaragianS , WeizmanR , et al. Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study. International Journal of Neuropsychopharmacology2002;5 Suppl 1:S171. [CSZG: 8358]">Poyurovsky 2003</a>; <a href="./references#CD013337-bbs2-0012" title="PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. In: 62nd Annual Scientific Meeting of the Society of Biological Psychiatry. 2007:129. [CSZG: 20279]PoyurovskyM , FuchsC , PashinianA , LeviA , FaragianS , MaayanR , et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology2007;192(3):441-8. [CSZG: 15289]PoyurovskyM , MaayanR , Gil-AdI , WeizmanA , WeizmanR . Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9811]">Poyurovsky 2007</a>), and one examined fluoxetine (<a href="./references#CD013337-bbs2-0009" title="PoyurovskyM , IsaaksI , PashnianA , FuchsC , SchneidmanM , FaragianS , et al. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients. European Neuropsychopharmacology2002;12 Suppl 3:S312. PoyurovskyM , PashinianA , Gil-AdI , MaayanR , SchneidmanM , FuchsC , et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. American Journal of Psychiatry2002;159(6):1058-60. [CSZG: 8582]">Poyurovsky 2002</a>). Overall, this class may be effective in preventing weight gain. There were no differences in the number of dropouts and frequency of adverse events. Important to note is that all studies were conducted in populations that were fairly antipsychotic‐naive or in their first episode of psychosis. </p> <p>Of the pharmacological agents studied in this review that act on monoamine systems to prevent weight gain in people with schizophrenia, the most evidence is available for reboxetine. Two RCTs studied reboxetine's role as an agent for controlling weight gain. The dose of reboxetine was 4 mg/day in both studies Reboxetine alone may be effective in preventing weight gain with antipsychotics. Reboxetine is a noradrenaline reuptake inhibitor approved for treating depression. The antidepressant properties were also evident in our review, where we found the active groups to score significantly lower on depression‐rating scales. These findings agree with a meta‐analysis of the effect of noradrenaline reuptake inhibitors such as reboxetine, atomoxetine and mazindol on various aspects of pathology in schizophrenia (<a href="./references#CD013337-bbs2-0211" title="KishiT , IwataN . Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials. Pharmacopsychiatry2015;48(1):30-6. [PMID: 25321187]">Kishi 2015</a>). Noradrenaline reuptake inhibitors were found to decrease depressive symptoms and lower weight, effects driven largely by the reboxetine studies. </p> </section> <section id="CD013337-sec-0262"> <h5 class="title">Topiramate versus placebo or no treatment</h5> <p>We included three RCTs that studied topiramate as a preventative agent for antipsychotic‐induced weight gain in a total of 175 participants (<a href="./references#CD013337-bbs2-0005" title="KimJ , YimS , NamJ . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. Elsevier Science Bv, 2006:86. KimJH , YimS , NamJ . A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia. In: 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006. KimJH , YimSJ , NamJH . A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophrenia Research2006;82(1):115-7. ">Kim 2006</a>; <a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>). There did not appear to be an effect of topiramate in preventing weight gain; however, two RCTs showed that topiramate (100 mg/d to 200 mg/d) may prevent increase in BMI following initiation of olanzapine, and may improve fasting blood glucose levels (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>). Both these studies were conducted in an antipsychotic‐naive or first‐episode population. There were no differences in the number of dropouts and reports of nausea. Only two of the included studies reported on physiological laboratory measures and mental state outcomes (<a href="./references#CD013337-bbs2-0006" title="LiuJJ . Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction. Contemporary Nurse (Specialist Edition)2011;23(06):665-7. ">Liu 2011</a>; <a href="./references#CD013337-bbs2-0008" title="NarulaPK , RehanHS , UnniKE , GuptaN . Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophrenia Research2010;118(1-3):218-23. [CSZG: 20722]">Narula 2010</a>); therefore, we judged the certainty of evidence for this comparison to be very low and the effects of topiramate on these outcomes are uncertain. Topiramate may also have favourable effects on psychopathology, as demonstrated by improved scores on the PANSS; however, results of the outcome are uncertain. </p> <p>Overall, this review is in line with a recent review of topiramate efficacy, which had less stringent inclusion criteria and included all RCTs that involved topiramate use in schizophrenia (<a href="./references#CD013337-bbs2-0230" title="OkuyamaY , OyaK , MatsunagaS , KishiT , IwataN . Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatric Disease and Treatment2016;12:3221-36. [PMID: 28008259]">Okuyama 2016</a>). They found topiramate to be effective, but significantly more participants were found to suffer from paraesthesia and concentration difficulties. These side effects were numerically more common in our review as well. However, while these are preliminary findings from small studies, more research needs to be conducted to better characterise its effects. Moreover, the cognitive effects of topiramate need to evaluated in this population. </p> </section> <section id="CD013337-sec-0263"> <h5 class="title">Other comparisons: melatonin versus placebo; reboxetine plus betahistine versus placebo; and olanzapine plus samidorphan versus olanzapine alone </h5> <p>We found only one study for each of the following interventions: melatonin versus placebo; reboxetine plus betahistine versus placebo; and olanzapine plus samidorphan versus olanzapine alone. Given the limited evidence, we cannot draw any conclusions for these interventions. We need more RCTs to determine the treatment effects with greater certainty. </p> <section id="CD013337-sec-0264"> <h6 class="title">Melatonin versus placebo</h6> <p><a href="./references#CD013337-bbs2-0007" title="IRCT201107187049N1. An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia. https://www.irct.ir/trial/7480 (first received 2011-09-10). ModabberniaA , HeidariP , SoleimaniR , SobhaniA , RoshanZA , TaslimiS , et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research2014;53(1):133-40. NCT01593774. Melatonin for prevention of metabolic side effects of olanzapine. https://clinicaltrials.gov/ct2/show/NCT01593774 (first received 8 May 2012). ">Modabbernia 2014</a> examined the effects of melatonin versus placebo in a group of first‐episode or antipsychotic‐naive patients. They found that melatonin may be effective in limiting weight gain and increase in BMI and waist circumference. There was also no significant difference between groups in terms of number of individuals discontinuing or leaving the study early. Melatonin appeared to have favourable effects on total cholesterol levels and PANSS scores. However, there were no significant differences between the two groups in terms of changes in other laboratory measures (e.g. cholesterol, insulin and blood sugar) or mental state scores. </p> </section> <section id="CD013337-sec-0265"> <h6 class="title">Reboxetine plus betahistine versus placebo</h6> <p><a href="./references#CD013337-bbs2-0013" title="PoyurovskyM , FuchsC , PashinianA , LeviA , WeizmanR , WeizmanA . Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology2013;226(3):615-22. [CSZG: 28732]">Poyurovsky 2013</a> combined 4 mg/d of reboxetine with 48 mg/d betahistine. Significantly fewer participants gained more than 5% and more than 7% of their bodyweight in the reboxetine plus betahistine group than in the placebo group. There was also less increase in body weight and BMI in the experimental than placebo group, with no significant differences in mental state outcomes and adverse events. Betahistine is a histamine enhancer with H1 agonistic/H3 antagonistic properties. Recent studies in people with schizophrenia (<a href="./references#CD013337-bbs2-0029" title="BarakN , BeckY , AlbeckJH . A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. Journal of Clinical Psychopharmacology2016;36:253-6. ">Barak 2016</a>; <a href="./references#CD013337-bbs2-0119" title="SmithRC , MaayanL , WuR , YoussefM , JingZ , SershenH , et al. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology2018;235(12):3545-58. ">Smith 2018</a>), have demonstrated betahistine to be well‐tolerated and effective in reducing weight gain following the initiation of olanzapine. Given olanzapine's strong action on the histaminergic receptors and their probable importance in relation to weight gain, betahistine seems like an interesting lead worth pursuing. </p> </section> <section id="CD013337-sec-0266"> <h6 class="title">Olanzapine plus samidorphan versus olanzapine alone</h6> <p><a href="./references#CD013337-bbs2-0004" title="CorrellCU , NewcomerJW , SilvermanB , DiPetrilloL , GrahamC , JiangY , et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. American Journal of Psychiatry2020;177(12):1168-78. ">Correll 2020a</a> compared the effectiveness of two doses of the combination agent olanzapine plus samidorphan (10 mg/10 mg and 20 mg/10 mg) with olanzapine alone. The chosen doses represent the lowest and highest approved maintenance dosages of olanzapine for schizophrenia treatment and the intended therapeutic fixed dosage of samidorphan that has been determined to have the most optimal weight and safety profile when combined with olanzapine. Samidorphan is an opioid receptor antagonist. This combination agent has recently gained popularity in the USA following its FDA approval for the treatment of schizophrenia and bipolar disorder in adults. Results from this single study indicated that participants gained less weight on olanzapine plus samidorphan compared to olanzapine alone. Furthermore, the risk of clinically significant weight gain (of ≥ 7% and ≥ 10%) was reduced by 50% relative to olanzapine. Mental state scores demonstrated similar improvements in both groups, and there was no significant difference between the groups in terms of number of reported adverse events. These findings are in line with an earlier study, <a href="./references#CD013337-bbs2-0095" title="MartinWF , CorrellCU , WeidenPJ , JiangY , PathakS , DiPetrilloL , et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. American Journal of Psychiatry2019;176(6):457-67. ">Martin 2019</a>, that studied the efficacy of olanzapine plus 5 mg of samidorphan to treat schizophrenia compared to olanzapine alone (the primary outcome of this study was to determine its therapeutic effect on primary symptoms of schizophrenia). </p> </section> </section> </section> <section id="CD013337-sec-0267"> <h4 class="title">Sensitivity analyses</h4> <p>The results of the outcome 'change in weight' were not much different in a series of pre‐planned sensitivity analyses in which we excluded studies with high risk of bias regarding blinding or incomplete outcome data, or when a fixed‐effect model instead of a random‐effects model was applied. Nevertheless, the statistical power of these analyses was low. </p> </section> </section> <section id="CD013337-sec-0268"> <h3 class="title" id="CD013337-sec-0268">Overall completeness and applicability of evidence</h3> <p>Extending the previous version of this review (<a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a>), we were able to include studies that involved people with schizophrenia from a wide range of settings including both inpatient and outpatients from North and South America, Europe, Asia, and Australia. The 15 years since the last version of the review was published has seen more studies being published overall; the number of studies that evaluated a pharmacological intervention for the prevention of antipsychotic‐induced weight gain has gone up to 17, compared to six in the previous review. Taken together, these studies provide enough information to answer the question we set out to answer. However, given the low number of studies for most of the interventions, the low to very low certainty of evidence limits our ability to draw substantive conclusions. Another limitation is that there were a few studies for which we were not able to obtain the full text and therefore could not include in the meta‐analysis. Furthermore, the broad geographical representativeness of the included studies (we were able to include studies from each of the continents except Africa), the variety of clinical settings and disease severity of the included participants increases the generalisability of the evidence with the obvious caveat that much more needs to be done before firm conclusions can be drawn about most of the agents studied in this review. </p> </section> <section id="CD013337-sec-0269"> <h3 class="title" id="CD013337-sec-0269">Quality of the evidence</h3> <p>In this review, we have summarised evidence from 17 double‐blind or open‐label RCTs that together studied 1388 individuals with schizophrenia and related disorders. However, many of the shortcomings of studies individually and in the field generally that were identified in the previous version of this review (<a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a>), still apply. For many of the pharmacological comparisons there was only a single study. Additionally, there was variability in the dosage of the interventions, study duration and follow‐up, and other essential aspects of methodology. Most studies did not describe adequate randomisation and blinding procedures, and not all studies included an ITT analysis. Many studies did not use structured scales to evaluate side effects and tolerability systematically. In addition, while clinical guidelines suggest that weight loss medications should only be used in combination with lifestyle counselling, the majority of pharmacological studies did not include, or did not describe, such a component. Finally, there was an absence of long‐term studies that would allow for evaluation of longer‐term effectiveness and safety of the interventions. </p> <p>We deemed the risk of bias to be high in a large number of the studies that contributed to this review as they did not describe essential elements of an RCT in the methods. As such, we downgraded the certainty of evidence for all outcomes by one level in most of the comparisons. Additionally, for most of the comparisons, we downgraded the certainty of the evidence one level further to 'low', since the total number of participants included in the comparisons was less than the number of participants generated by a conventional sample size calculation for a single, adequately powered study. For several outcomes, in most comparisons, we downgraded the certainty of evidence by one further level to 'very low' as the heterogeneity of the results was quite high making interpretation uncertain. For most agents analysed in the meta‐analysis, interpretation is limited by the small number of studies and small sample sizes. </p> </section> <section id="CD013337-sec-0270"> <h3 class="title" id="CD013337-sec-0270">Potential biases in the review process</h3> <p>For studies registered yet incomplete due to early termination or loss to follow‐up, we could not obtain any data. Hence, this review presents a potential bias towards published data. Contributing to this point is that our search was primarily based on the Cochrane Schizophrenia Register of Trials, which searches only published literature. Given the limited number of studies in each comparison, we could not complete funnel plot analyses to assess publication bias. Lastly, the majority of comparisons in this review are based on only one or two studies, thus, the results cannot indicate the true effect of the medication. Further studies on a number of agents giving positive results are warranted before we can draw firm conclusions. </p> </section> <section id="CD013337-sec-0271"> <h3 class="title" id="CD013337-sec-0271">Agreements and disagreements with other studies or reviews</h3> <p>Systematic reviews that have examined individual agents that are included in this meta‐analysis have been discussed under respective sections in the summary of main results, above. This section discusses other studies or reviews that have dealt with multiple agents for the purposes of preventing antipsychotic‐induced weight gain. Notably, to the best of our knowledge, only the previous version of this review (<a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a>), has been published that compares various pharmacological interventions in a preventative role. Despite the number of studies that have been published since examining many other pharmacological interventions, there has yet to be another review published comparing the most up‐to‐date literature. This emphasises the importance of this present review. </p> <p>In agreement with <a href="./references#CD013337-bbs2-0184" title="FaulknerG , CohnT , RemingtonG . Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005148. [DOI: 10.1002/14651858.CD005148.pub2]">Faulkner 2007</a>, which looked at only six RCTs for the prevention of weight gain in people with schizophrenia, we also found that there was a significant treatment effect of adjunctive pharmacological agents for achieving modest prevention of weight gain and that this can be achieved in a safe manner. The previous review asserted that reboxetine and topiramate were effective at weight prevention, although this must be interpreted with caution given only one study was available at the time for each agent. In contrast, however, the present review, which adds to and extends the previous pool of evidence, suggests that metformin may be the most effective in modestly preventing weight gain. The present review also reports on olanzapine plus samidorphan for the first time, which is a novel combination drug that has received recent FDA approval for the treatment of schizophrenia and bipolar disorder in the USA and aims to mitigate the amount of weight gain experienced with olanzapine. Only one study was available to be included in this review on this agent, thus the evidence is quite limited. Nonetheless, it suggests that there is another novel agent that may be effective in preventing the risk of clinically significant weight gain (of ≥ 7% and ≥ 10%) with olanzapine, an antipsychotic with one of the greatest metabolic liabilities. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013337-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013337-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013337-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD013337-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 1: Weight: average endpoint/change in body weight" data-id="CD013337-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 1: Weight: average endpoint/change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 2: Weight: average endpoint/change in body mass index" data-id="CD013337-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 2: Weight: average endpoint/change in body mass index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 3: Weight: average endpoint/change in waist circumference" data-id="CD013337-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 3: Weight: average endpoint/change in waist circumference </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 4: Leaving the study early: for any reason" data-id="CD013337-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 4: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 5: Reports of nausea" data-id="CD013337-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 5: Reports of nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 6: Mental state" data-id="CD013337-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 6: Mental state </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 7: Physiological: laboratory measures" data-id="CD013337-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 7: Physiological: laboratory measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 1: Weight: average endpoint/change in body weight" data-id="CD013337-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 1: Weight: average endpoint/change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 2: Weight: average endpoint/change in body mass index" data-id="CD013337-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 2: Weight: average endpoint/change in body mass index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 3: Leaving the study early: for any reason" data-id="CD013337-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 3: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 4: Reports of nausea" data-id="CD013337-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 4: Reports of nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 5: Mental state: BPRS (higher = worse)" data-id="CD013337-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 5: Mental state: BPRS (higher = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 6: Mental state: various scales" data-id="CD013337-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 6: Mental state: various scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 7: Adverse effect: headache" data-id="CD013337-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 7: Adverse effect: headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 8: Adverse effect: dry mouth" data-id="CD013337-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 8: Adverse effect: dry mouth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 9: Adverse effect: anxiety" data-id="CD013337-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 9: Adverse effect: anxiety</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 10: Adverse effect: depression" data-id="CD013337-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 10: Adverse effect: depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 11: Adverse effect: dizziness" data-id="CD013337-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 11: Adverse effect: dizziness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 12: Adverse effect: increased appetite" data-id="CD013337-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 12: Adverse effect: increased appetite </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 13: Adverse effect: somnolence" data-id="CD013337-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 13: Adverse effect: somnolence</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H2 antagonists versus placebo, Outcome 14: Adverse effect: SAS" data-id="CD013337-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: H2 antagonists versus placebo, Outcome 14: Adverse effect: SAS</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 1: Weight: average endpoint/change in body weight" data-id="CD013337-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 1: Weight: average endpoint/change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 2: Weight: average endpoint/change in body mass index (BMI)" data-id="CD013337-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 2: Weight: average endpoint/change in body mass index (BMI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 3: Leaving the study early: for any reason" data-id="CD013337-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 3: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 4: Mental state: SANS (higher = worse)" data-id="CD013337-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 4: Mental state: SANS (higher = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 5: Mental state: SAPS (higher = worse)" data-id="CD013337-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 5: Mental state: SAPS (higher = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 6: Mental state: CGI (higher = worse)" data-id="CD013337-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 6: Mental state: CGI (higher = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 7: Mental state: HAM‐D (higher = worse)" data-id="CD013337-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 7: Mental state: HAM‐D (higher = worse) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Monoamine modulators versus placebo, Outcome 8: Adverse effects" data-id="CD013337-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Monoamine modulators versus placebo, Outcome 8: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 1: Weight: average endpoint/change in body weight" data-id="CD013337-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 1: Weight: average endpoint/change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 2: Weight: average endpoint/change in body mass index" data-id="CD013337-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 2: Weight: average endpoint/change in body mass index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 3: Leaving the study early: for any reason" data-id="CD013337-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 3: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 4: Reports of nausea" data-id="CD013337-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 4: Reports of nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 5: Mental state" data-id="CD013337-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 5: Mental state </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 6: Adverse effects" data-id="CD013337-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 6: Adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 7: Physiological: cardiovascular measures" data-id="CD013337-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 7: Physiological: cardiovascular measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 8: Physiological: laboratory measures" data-id="CD013337-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Topiramate versus placebo/no‐pharmacological weight gain prevention treatment, Outcome 8: Physiological: laboratory measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 1: Weight: average endpoint/change in body weight" data-id="CD013337-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 1: Weight: average endpoint/change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 2: Weight: average endpoint/change in body mass index" data-id="CD013337-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 2: Weight: average endpoint/change in body mass index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 3: Weight: average endpoint/change in waist circumference" data-id="CD013337-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 3: Weight: average endpoint/change in waist circumference </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 4: Weight: average endpoint/change in hip circumference" data-id="CD013337-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 4: Weight: average endpoint/change in hip circumference </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 5: Weight: average endpoint/change in waist/hip ratio" data-id="CD013337-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 5: Weight: average endpoint/change in waist/hip ratio </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 6: Leaving the study early: for any reason" data-id="CD013337-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 6: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 7: Mental state" data-id="CD013337-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 7: Mental state</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Melatonin versus placebo, Outcome 8: Physiological: laboratory measures" data-id="CD013337-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Melatonin versus placebo, Outcome 8: Physiological: laboratory measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 1: Weight: clinically important change in weight &gt; 5%" data-id="CD013337-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 1: Weight: clinically important change in weight &gt; 5% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 2: Weight: clinically important change in weight &gt; 7%" data-id="CD013337-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 2: Weight: clinically important change in weight &gt; 7% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 3: Weight: average endpoint/change in body weight" data-id="CD013337-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 3: Weight: average endpoint/change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 4: Weight: average endpoint/change in body mass index" data-id="CD013337-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 4: Weight: average endpoint/change in body mass index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 5: Leaving the study early: for any reason" data-id="CD013337-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 5: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 6: Mental state" data-id="CD013337-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 6: Mental state</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Reboxetine + betahistine versus placebo, Outcome 7: Adverse events" data-id="CD013337-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Reboxetine + betahistine versus placebo, Outcome 7: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 1: Weight: clinically important change in weight &gt; 10%" data-id="CD013337-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 1: Weight: clinically important change in weight &gt; 10% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 2: Weight: clinically important change in weight &gt; 7%" data-id="CD013337-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 2: Weight: clinically important change in weight &gt; 7% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 3: Weight: average endpoint/change in body weight (kg)" data-id="CD013337-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 3: Weight: average endpoint/change in body weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 4: Weight: average endpoint/change in waist circumference" data-id="CD013337-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 4: Weight: average endpoint/change in waist circumference </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 5: Leaving the study early: for any reason" data-id="CD013337-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 5: Leaving the study early: for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 6: Mental state" data-id="CD013337-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 6: Mental state</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 7: Physiological: laboratory measures" data-id="CD013337-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 7: Physiological: laboratory measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 8: Adverse events" data-id="CD013337-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Olanzapine/samidorphan versus olanzapine only, Outcome 8: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analyses, Outcome 1: Metformin vs placebo excluding studies with high risk of bias: weight: change in body weight" data-id="CD013337-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analyses, Outcome 1: Metformin vs placebo excluding studies with high risk of bias: weight: change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analyses, Outcome 2: Metformin vs placebo, fixed‐effect model: weight, change in body weight" data-id="CD013337-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analyses, Outcome 2: Metformin vs placebo, fixed‐effect model: weight, change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analyses, Outcome 3: H2 antagonists vs placebo, fixed‐effect model: weight, change in body weight" data-id="CD013337-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analyses, Outcome 3: H2 antagonists vs placebo, fixed‐effect model: weight, change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analyses, Outcome 4: Monoamine modulators vs placebo, fixed‐effect model: weight, change in body weight" data-id="CD013337-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analyses, Outcome 4: Monoamine modulators vs placebo, fixed‐effect model: weight, change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analyses, Outcome 5: Topiramate vs placebo excluding studies with high risk of bias: weight, change in body weight" data-id="CD013337-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analyses, Outcome 5: Topiramate vs placebo excluding studies with high risk of bias: weight, change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013337-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/urn:x-wiley:14651858:media:CD013337:CD013337-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analyses, Outcome 6: Topiramate vs placebo, fixed‐effect model: weight: change in body weight" data-id="CD013337-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_t/tCD013337-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analyses, Outcome 6: Topiramate vs placebo, fixed‐effect model: weight: change in body weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/media/CDSR/CD013337/image_n/nCD013337-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD013337-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design for future studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomisation: random</p> <p>Allocation: concealed</p> <p>Blinding: double‐blind</p> <p>Duration: 12 months</p> <p>Setting: inpatients or outpatients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: patients with schizophrenia, or any schizophrenia‐like illness</p> <p>Gender: male and female</p> <p>Age: mean 30 years, range: 18‐65 (adult population)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological interventions for preventing weight gain including those currently licensed for weight loss, an off‐label therapy, withdrawn from the market, or an isolated nutritive supplement </p> <p>Samidorphan ‐ standalone + combination therapy with olanzapine</p> <p>Pharmacological adjunct plus behavioural intervention versus behavioural intervention alone </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically important change in weight (e.g. binary outcomes such as ≥ 7% weight loss)<br/>Clinically important change in BMI </p> <p>Waist‐to‐hip ratio</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Look at effects of factors such as stage of illness and ethnicity</p> <p>Dose effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>BMI:</b> body mass index </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design for future studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013337-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in weight ranged from 5.88 to 6.87</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.03 kg lower<br/>(5.78 lower to 2.28 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight</b> </p> <p>Average endpoint/change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI ranged from 1.93 to 2.26</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.63 lower<br/>(2.96 lower to 0.29 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.25 to 4.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(14 to 239) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.38<br/>(0.28 to 19.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/>(16 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The total number of participants included in the review is less than the number of participants required for a single, adequately powered study. Also, the confidence interval is extremely wide.<br/><sup>b</sup>We deemed one of the included studies in this outcome to have high risk of bias.<br/><sup>c</sup>Heterogeneity of the results was quite high making interpretation uncertain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013337-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> H2 antagonists<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with H2 antagonists</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in body weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in body weight ranged from 4.18 to 4.88</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.32 lower<br/>(2.09 lower to 0.56 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight</b>: clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI was 1.82</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.66 lower<br/>(0.99 lower to 0.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.72 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>189<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(247 to 539) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(0.34 to 3.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(23 to 245) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The risk of bias is uncertain for most studies included in this comparison.<br/><sup>b</sup>The total number of participants included in the review is less than the number of participants required for a single, adequately powered study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013337-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> monoamine modulators<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with monoamine modulators</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in body weight (kg) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in body weight ranged from 4.91 to 5.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.89 lower<br/>(3.31 lower to 0.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in BMI (kg/m<sup>2</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI ranged from 0.86 to 1.12</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.66 lower<br/>(1.05 lower to 0.26 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.56 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>115<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000<br/>(149 to 435) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The total number of participants included in the review is less than the number of participants required for a single, adequately powered study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013337-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with schizophrenia with antipsychotic‐induced weight gain<br/><b>Setting:</b> inpatients or outpatients<br/><b>Intervention:</b> topiramate<br/><b>Comparison:</b> placebo or no treatmentL </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topiramate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in weight (kg) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in weight was 4.02</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.82 lower<br/>(9.99 lower to 0.35 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Weight:</b> clinically important change in BMI (kg/m<sup>2)</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight:</b> average endpoint/change in BMI (kg/m<sup>2</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average endpoint/change in BMI was 22.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.68 lower<br/>(4.10 lower to 1.26 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early:</b> for any reason </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/>(0.85 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>132<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000<br/>(322 to 534) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Compliance with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Reports of nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/>(0.26 to 5.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(10 to 830) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BMI:</b> body mass index; <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The risk of bias is uncertain or high for most studies included in this comparison.<br/><sup>b</sup>The total number of participants included in the review is less than the number of participant required for a single, adequately powered study.<br/><sup>c</sup>The risk of bias is high for most studies included in this comparison. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/full#CD013337-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo/no‐pharmacological weight gain prevention treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Weight: average endpoint/change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.03 [‐5.78, ‐2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Weight: average endpoint/change in body mass index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐2.96, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Weight: average endpoint/change in waist circumference <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.13 [‐4.28, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.25, 4.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Reports of nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.28, 19.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mental state <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.63, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 SANS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐1.38, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 SAPS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.67, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 BPRS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐6.50, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Physiological: laboratory measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Fasting blood glucose (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.04 [‐28.27, 8.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 HDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [‐4.07, 8.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Insulin (mIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.82 [‐9.53, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Insulin resistance index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.62, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 LDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.54 [‐39.77, 32.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 Total cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.71 [‐30.35, 16.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.7 Triglycerides (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.18 [‐45.31, 10.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo/no‐pharmacological weight gain prevention treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">H2 antagonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Weight: average endpoint/change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.32 [‐2.09, ‐0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐2.68, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐3.01, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Famotidine 40 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐6.09, 10.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Ranitidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.58 [‐2.48, ‐0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Weight: average endpoint/change in body mass index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐0.99, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.72, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.64, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Famotidine 40 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Reports of nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.34, 3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.08, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.40, 8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Mental state: BPRS (higher = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [‐0.89, 5.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 dose= 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐2.22, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 dose= 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [‐2.22, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Mental state: various scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 CGI (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.74, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 SANS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐4.97, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 SAPS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐4.09, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse effect: headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.28, 4.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.11, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.47, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Adverse effect: dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [0.67, 19.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.81 [0.27, 86.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [0.39, 24.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse effect: anxiety <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.37, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.20, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.28, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Adverse effect: depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.69 [0.68, 19.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [0.32, 21.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.83 [0.40, 117.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Adverse effect: dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.21, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.11, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.16, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Adverse effect: increased appetite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.19, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.09, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.17, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Adverse effect: somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.47, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.30, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.37, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 Famotidine 40 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.36, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Adverse effect: SAS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐1.86, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐1.60, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐1.25, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Famotidine 40 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐3.84, ‐0.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">H2 antagonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Monoamine modulators versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Weight: average endpoint/change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.89 [‐3.31, ‐0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.07, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐7.56, 20.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Weight: average endpoint/change in body mass index (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐1.05, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.08, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐2.35, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.56, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.47, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.43, 9.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Mental state: SANS (higher = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐1.98, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐2.67, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [‐2.54, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Mental state: SAPS (higher = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐2.01, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.42 [‐8.87, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [‐0.36, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Mental state: CGI (higher = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.28, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.28, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Mental state: HAM‐D (higher = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐4.22, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐4.22, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Neurological: change in BAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.65, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Neurological: change in SAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐1.00, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 Gastrointestinal: increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.19, ‐0.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Monoamine modulators versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topiramate versus placebo/no‐pharmacological weight gain prevention treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Weight: average endpoint/change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.82 [‐9.99, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Weight: average endpoint/change in body mass index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.68 [‐4.10, ‐1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.85, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Reports of nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.26, 5.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Mental state <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Average score: PANSS general psychopathology scale (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.53 [‐2.16, ‐0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Average score: PANSS positive (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.02, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 Average score: PANSS negative (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.79, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.4 Average score: PANSS total (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.08 [‐3.07, ‐1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Gastrointestinal: constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.03, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Gastrointestinal: dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.27, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.3 Gastrointestinal: increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.10, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.4 Gastrointestinal: nausea/vomiting/diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.34, 28.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.5 Gastrointestinal: weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.07, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.6 Neurological: asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.37, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.7 Neurological: concentration/attention/memory difficulty</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.97 [1.17, 68.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.8 Neurological: dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.18, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.9 Neurological: fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.53, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.10 Neurological: insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.05, 5.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.11 Neurological: paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.21 [0.39, 134.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.12 Neurological: psychomotor slowing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.26 [0.52, 165.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.13 Neurological: somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.88, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Physiological: cardiovascular measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Cardiovascular measure: diastolic blood pressure [mm Hg]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.47 [‐6.12, ‐0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Cardiovascular measure: systolic blood pressure [mm Hg]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.62 [‐8.14, ‐1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Physiological: laboratory measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Fasting blood glucose (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.22 [‐12.59, ‐5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 HDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐1.59, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Insulin (ulU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐3.66, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.4 Insulin resistance Index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.10, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.5 LDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.99 [‐21.82, 5.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.6 Leptin (ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.84 [‐8.52, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.7 Total cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.69 [‐31.86, 8.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.8 Triglycerides (mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.12 [‐18.70, 8.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.9 VLDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐6.09, 3.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topiramate versus placebo/no‐pharmacological weight gain prevention treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Melatonin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Weight: average endpoint/change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Weight: average endpoint/change in body mass index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Weight: average endpoint/change in waist circumference <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Weight: average endpoint/change in hip circumference <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Weight: average endpoint/change in waist/hip ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Mental state <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Average score: PANSS general psychopathology scale (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 Average score: PANSS positive (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.3 Average score: PANSS negative (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.4 Average score: PANSS total (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Physiological: laboratory measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Fasting blood glucose (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 HDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.3 Insulin (ulU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.4 Insulin resistance index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.5 LDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.6 Total cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.7 Triglycerides (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Melatonin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Reboxetine + betahistine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Weight: clinically important change in weight &gt; 5% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Weight: clinically important change in weight &gt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Weight: average endpoint/change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Weight: average endpoint/change in body mass index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Mental state <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Average score: SAPS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 Average score: SANS (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.3 Average score: HAM‐D (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.4 Average score: CGI (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 Neurological: BAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 Neurological: SAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Reboxetine + betahistine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Olanzapine/samidorphan versus olanzapine only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Weight: clinically important change in weight &gt; 10% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Weight: clinically important change in weight &gt; 7% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Weight: average endpoint/change in body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Weight: average endpoint/change in waist circumference <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Leaving the study early: for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Mental state <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 Average score: PANSS total (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 Average score: CGI (higher = worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Physiological: laboratory measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 Fasting blood glucose (mg %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.2 HDL cholesterol (mg %)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.3 Insulin (ulU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.4 LDL cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.5 Total cholesterol (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.6 Triglycerides (mg /dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.7 HbA1c [%]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 Weight increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.2 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.3 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.4 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Olanzapine/samidorphan versus olanzapine only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013337-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Metformin vs placebo excluding studies with high risk of bias: weight: change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.18 [‐5.95, ‐2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Metformin vs placebo, fixed‐effect model: weight, change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.03 [‐5.78, ‐2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 H2 antagonists vs placebo, fixed‐effect model: weight, change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.32 [‐2.09, ‐0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Nizatidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐2.68, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Nizatidine 300 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐3.01, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.3 Famotidine 40 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐6.09, 10.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.4 Ranitidine 150 mg, twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.58 [‐2.48, ‐0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Monoamine modulators vs placebo, fixed‐effect model: weight, change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.84 [‐3.01, ‐0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Reboxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.07, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐7.56, 20.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Topiramate vs placebo excluding studies with high risk of bias: weight, change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.63 [‐12.01, ‐3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Topiramate vs placebo, fixed‐effect model: weight: change in body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.83 [‐3.03, ‐0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013337.pub2/references#CD013337-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013337.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013337-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013337-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013337-note-0021">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013337-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013337-note-0016">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013337-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013337-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD013337-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD013337-note-0022">Română</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013337-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013337\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013337\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013337\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013337\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013337\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013337.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013337.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013337.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013337.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013337.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724751813"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013337.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724751816"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013337.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6a772af61c00',t:'MTc0MDcyNDc1Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 